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Tuberculosis (TB) is still a major global public health concern. Of the 7 million 
incident TB cases recognized by the World Health Organization in 2018, 15% were 
extrapulmonary tuberculosis (EPTB) cases. Diagnosing EPTB remains a challenge 
despite continuing efforts and progress in the development of new TB diagnostic tools. 
Signs and symptoms of EPTB are often non-specific and similar in a range of other 
conditions. Laboratory confirmation of extrapulmonary disease is constrained by the 
difficulty of obtaining appropriate biological specimens, conventional diagnostic 
methods with low sensitivity and lack of an accurate, rapid, low-cost diagnostic test 
for EPTB. In addition, laboratory facilities are costly and often limited in low-resource 
settings. This may lead to diagnostic delay in initiating antituberculosis (anti-TB) 
treatment, on the other hand, starting empirical treatment, without laboratory 
confirmation, emphasises the need of close monitoring of treatment response.  
The overall aim of this thesis was to improve the diagnosis and management of EPTB 
cases in a low-resource setting. Keeping the primary objective in mind, the secondary 
aims were to implement and assess the performance of a new diagnostic test based on 
immunochemical detection of the Mycobacterium tuberculosis complex specific 
antigen MTP64 (MPT64 test), for diagnosing EPTB in the routine diagnostics at 
Mnazi Mmoja Hospital (MMH) in Zanzibar. Further, to evaluate the health care 
seeking pathways and the diagnostic delays experienced by presumptive EPTB 
patients, identify factors associated with longer diagnostic delay, and to assess the 
impact of anti-TB treatment on self-rated health among EPTB cases. Next, to describe 
the clinical presentation of EPTB, and follow the study participants during anti-TB 
treatment to assess clinical parameters, independent of laboratory investigations, 
which could aid in the monitoring of treatment response among EPTB cases. 
Presumptive EPTB patients of all ages were prospectively enrolled at MMH for 
thirteen months from august 2014. At inclusion, data were collected in a face-to face 
interview using the semi-structured study questionnaire, the results from a full physical 
examination were recorded and the adult patients initiating anti-TB treatment 
answered the EQ-5D-3L to evaluate the study participant`s self-rated health before 
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treatment. Further, a biological specimen was collected from the site of assumptive 
EPTB infection and subjected to the MPT64 test, GeneXpert® MTB/RIF assay and 
routine laboratory diagnostics. The included patients initiating anti-TB treatment were 
assessed after the intensive phase of treatment and at treatment completion. The adult 
study participants again reported their self-rated health using the EQ-5D-3L after 
completing anti-TB treatment. Utilizing a predefined composite reference standard, the 
patients were classified as TB (confirmed TB, probable TB or possible TB) or non-TB 
cases to assess the diagnostic tests performances and other variables.   
We included 132 patients (median age 27 years, interquartile range 8-41 years), who 
were defined in accordance with the composite reference standard as TB cases (n=64 
in paper I and III; n=69 in paper II) and non-TB cases (n=62 in paper I and III, n=63 in 
paper II). Six patients were classified as uncategorized cases in paper I and III. A 
higher proportion of positive test results was found for the MPT64 test in TB cases 
(45/69, 65%) as compared to ZN staining (8/69, 12%), culture (8/60, 13%) and the 
GeneXpert® MTB/RIF assay (6/38, 16%). The MPT64 test showed an overall 
sensitivity and specificity of 69% and 95%, respectively, with the best test 
performance demonstrated among TB lymphadenitis cases and in paediatric TB. Many 
EPTB cases experienced a delay exceeding two months from symptom onset until 
treatment was initiated, with health system delay as the main contributor to overall 
delay. The majority of adult TB cases described reduced work capacity with a median 
of 60 days due to the ongoing illness and using the EQ-5D instrument, a significantly 
improved self-perceived health status was noted after as compared to before anti-TB 
treatment. We further evaluated three clinical parameters, weight gain, clinical 
improvement and regression of objective findings during anti-TB treatment and found 
that most of the TB cases fulfilled ≥2 parameters after the intensive phase of anti-TB 
treatment.  
The MPT64 test is implementable in the routine diagnostic laboratory in this low-
resource setting and has the potential to improve the diagnosis of EPTB, especially for 
lymph node TB and paediatric TB in this and similar settings. With many EPTB 
patients experiencing long delays in the initiation of treatment together with the 
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reported reduced work capacity among the adult TB patients and improvement of self-
reported health status after treatment, reducing the diagnostic delay and timely 
initiation of appropriate treatment can have crucial impact on the economic loss and 
morbidity of the affected patients. We propose that a combination of only clinical 
parameters can be incorporated in a simple assessment tool to aid health care workers 
in low-resource settings to monitor treatment response among EPTB patients. The 
findings from this study can be used to improve EPTB patient management in the 
current setting, but larger and more studies in various routine diagnostic settings are 
needed to expand the knowledge base regarding the MPT64 test and further evaluate 
and validate various simple clinical parameters to be incorporated as the suggested 
easy treatment response assessment tool.   
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1.1 The continuous fight against the tuberculosis epidemic 
Tuberculosis (TB) infection continues to be a global public health concern and is 
among the top 10 leading causes of death worldwide and ranks above human 
immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) as a 
cause of death from a sole infectious agent, despite implementation of standard care 
and a global fall in TB incidence (2% per year) and mortality rates (3% per year) (1-3). 
With the announcement of the Directly Observed Treatment Short-course (DOTS) 
strategy by the World Health Organization (WHO) in 1994 the public sector TB 
programmes were strengthened to handle drug-susceptible TB disease, providing 
standardized short-course chemotherapy under direct and supportive observation to at 
least all sputum smear positive pulmonary TB (PTB) patients and monitoring 
programme performance (4). Building on the DOTS strategy, the WHO`s Stop TB 
Strategy launched in 2006 and the Stop TB Partnerships’ Global Plan to Stop TB 
2006-2015 addressed DOTS expansion, HIV/TB coinfection and drug-resistant TB, in 
addition to advocating the need for research (4). In the post-2015 global TB strategy, 
the global fight against TB was continued, with the United Nations Sustainable 
Development Goals and WHO`s End TB strategy sharing the common vision to end 
the worldwide TB epidemic (5).  
 “A world free of tuberculosis – zero deaths, disease and suffering due to 
tuberculosis”(5) 
The targets are to reduce the number of TB deaths by 95% and 90% reduction of TB 
incidence rate by year 2035, compared with 2015 numbers. In addition, no families 
should face catastrophic costs because of TB disease. The strategy is built on several 
pillars and components, included in these are early diagnosis and appropriate treatment 
of all people with TB, and developing and swift uptake of novel tools, strategies and 
interventions (5).  
18 
 
In 2018, the worldwide estimated number of new TB cases was 10 million (range, 9-
11.1 million), with 9% of the cases among persons living with HIV (2). The burden of 
HIV-associated active TB is highest in the WHO African region. Globally, 70% of the 
estimated new TB cases were notified (2). This points the fact, that even though 
millions of TB patients are diagnosed and receive successful treatment every year, still 
a substantial number of TB cases are either unnotified or undetected. Extrapulmonary 
TB (EPTB) patients have received less attention in international TB guidelines, global 
TB control strategies and public health research. In addition to PTB being the main 
form of the disease, the lower priority given to EPTB could be due to EPTB not being 
a significant contributor to the transmission of TB disease. Still, the contribution of 
EPTB to the morbidity (6) and TB-related mortality (7, 8) is significant and delay in 
the diagnosis could possibly cause more advanced disease, complications and sequelae 
and increased economic constrains for the affected patients and their families.   
Increased priority should be given to the timely and effective diagnosis, rapid initiation 
of specific antituberculosis (anti-TB) treatment and monitoring of adequate response to 
treatment in EPTB patients, in line with the End TB strategy. But, the diagnosis of 
EPTB is challenging due to unspecific and various clinical presentations, the difficulty 
of obtaining adequate specimens for laboratory investigations, the paucibacillary 
nature of the disease leading to decreased sensitivity of routine laboratory diagnostic 
tests (9, 10). Further, an accurate, low-cost and rapid diagnostic method for the 
diagnosis of EPTB is missing. All could contribute to a delay in the diagnosis and 
initiation of treatment. Anti-TB treatment is often initiated based on patient medical 
history and signs and symptoms suggestive of EPTB, without bacteriological 
confirmation. The international standards for TB care state that a specimen from the 
site of infection should be collected in all patients with presumptive EPTB and 
bacteriologically confirmation of TB disease as a basic principle still holds also among 
EPTB cases (3). There is a need to develop new methods for diagnosing EPTB that are 
feasible in low-resource settings. Studies are required to assess factors leading to 
diagnostic delay among EPTB patients. This would lead to identification of areas of 
intervention to increase case detection and early diagnosis and treatment of EPTB. 
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1.2 Epidemiology of extrapulmonary tuberculosis 
Even though primarily considered a pulmonary disease, TB can affect any organ in the 
body. The term EPTB describes occurrence of TB at other body sites than the lung (6). 
PTB is the major contributor to the transmission and burden of TB disease, but EPTB 
accounts for a considerable proportion of the total TB burden and was reported in 15% 
of the notified incident TB cases in 2018 (2). Involvement of extrapulmonary sites can 
appear in isolation or accompany PTB. There has been described a decreasing trend in 
the overall number of TB cases, but an increasing proportion of EPTB among the total 
notified TB patients (11, 12). In a low HIV prevalent population, at least 15-20% of 
the TB cases are extrapulmonary (3), but in settings with extensive diagnostic and 
reporting system the proportion of EPTB among the total TB cases is reported to be 
even higher (13, 14). In addition, in special subgroups, such as in 
immunocompromised patients and at younger ages there is a higher proportion of 
EPTB (15-18). Among TB/HIV coinfected patients the occurrence of extrapulmonary 
manifestations increases with declining CD4 cell counts (19), and has been reported to 
be present in 45-56% of patients with TB and HIV infection/AIDS (20, 21), and in 
70% of TB/HIV cases with CD4 cell count ≤ 100 cells/µL (19). Similarly, compared 
to more immunocompetent individuals, extrapulmonary disease is seen in a high 
proportion of patients receiving tumor necrosis factor-alpha (TNF-α) antagonists 
treatment (22). Other factors described to be associated with increased risk of EPTB 
compared to PTB is female gender, end-stage renal disease and ethnicity/geographic 
origin (16, 17, 23, 24). Extrapulmonary site of TB disease has been found associated 
with Asian or African origin compared with Western European origin (14, 23), and a 
study from the United States reported non-Hispanic blacks to have higher risk of 
EPTB than non-Hispanic whites (17).  
Despite availability of anti-TB treatment, unfavorable treatment outcome and mortality 
in EPTB is relatively high. Various studies have reported death rates between 4,5-29% 
among EPTB patients (7, 24-26), and treatment outcome described to be associated 
with HIV infection and site of EPTB disease (8, 26). 
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1.3 Pathophysiology of tuberculosis infection 
1.3.1 Microbiology and transmission of disease 
It is 138 years since Robert Koch presented his work on the successful isolation of the 
tubercle bacilli, the causative agent of TB (27). TB disease in humans is primarily 
caused by Mycobacterium tuberculosis (Mtb) (28). Mtb belongs to the  Mtb complex 
(MtbC) of organisms, and other species in the MtbC able to cause human disease are 
Mycobacterium africanum, Mycobacterium bovis (M.bovis), Mycobacterium microti, 
Mycobacterium canetti, Mycobacterium pinnipedii and Mycobacterium caprae (28-
31).  
Transmission of TB is almost entirely from person-to-person by the airborne route, 
when an individual inhales droplet nuclei containing tubercle bacilli expelled from a 
person with active pulmonary or respiratory tract TB (32). The risk of infection after 
exposure is depended on several factors, such as length, frequency and proximity to 
the infectious individual, the infectiousness of the TB diseased person, environmental 
factors and susceptibility of the exposed individual. An individual`s infectiousness is 
reflected in the amount of tubercle bacilli seen in sputum specimens, with smear 
positive PTB cases as the most potent sources (33), though smear negative PTB cases 
also play a part in the transmission of TB disease (34). TB can also be transmitted 
through zoonotic transmission, from animals to humans. Zoonotic TB, largely as a 
result of M.bovis from cattle, occurring through the ingestion of contaminated animal 
products, like untreated milk or meat, or potentially airborne transmission if close 
contact with infected animals, can be important in some settings (30).  
1.3.2 Outcomes of tuberculosis infection 
In the vast majority, primary TB infection occurs after droplet nuclei containing Mtb 
bacilli, small enough in size (1-5 µm), pass through the respiratory tract and reach the 
pulmonary alveoli of the new host (31). However, exposure to Mtb does not 
necessarily lead to infection as the pathogen can be eliminated due to either innate or 
adaptive immune response (35). The original focus of infection in the lungs, the Ghon 
focus, and the accompanying hilar lymphadenopathy form the primary (Ghon) 
complex (36). In most cases the primary infection is asymptomatic (37). The 
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progression of primary infection to active disease (primary TB) is mostly seen in 
children or immunocompromised adults, such as those with HIV co-infection. Primary 
TB results from local spread in the lung or hematogenous or lymphatic dissemination 
of the bacilli to various organs and tissues (32), and may result in pulmonary TB, 
miliary TB and EPTB such as pleuritis, lymphadenitis (mostly cervical), meningitis 
and pericarditis (32). The other outcomes of the primary infection are elimination of 
the bacilli by immune responses leading to clearance of the infection or containment of 
the infection leaving the bacilli in a quiescent stage, i.e. latent TB infection. Post-
primary TB occurring years after the initial infection is a result of either endogenous 
reactivation of persistent bacilli or due to exogenous reinfection. In post-primary TB, 
the disease process characteristically remains localized, and the lungs are usually 
affected with typical upper lobe involvement and comprehensive tissue destruction 
with cavitation (32). Still, any organ can be involved, with pleuritis and lymphadenitis 
as the most common extrapulmonary sites (32). Figure 1 gives a simple summary of 
the outcomes of Mtb infection. 
Figure 1.  Simplified schematic overview of the outcomes of Mycobacterium tuberculosis infection. 




Development of a cell-mediated, adaptive immune response to Mtb antigens in 
exposed individuals, detectable around 3-8 weeks after the initial infection (38), 
indicated by tuberculin skin test (TST) conversion or positive interferon-γ release 
assay (IGRA), is usually thought to represent Mtb infection (39, 40). Still, the relative 
number of individuals surely harbouring dormant Mtb after TST or IGRA conversion 
is unknown (41), since individuals with successful elimination of the pathogen might 
have positive TST or IGRA due to memory T cell responses (35). A widely quoted 
estimate that 1/3 of the world population is immune sensitized and thus potentially 
harbouring latent TB infection, could be an over-estimate of the infection pool (37, 
42). Among immunocompetent individuals the estimated lifetime risk of developing 
active TB disease following a single infection is ~10% (43-45), with the majority of 
active TB cases occurring within some years after the initial infection (37, 46). Even 
though there is a persistent risk of reactivation throughout a person’s lifetime, the risk 
of developing disease seems to decrease with time since infection (45, 47). The 
outcome of infection, the risk of progression to active disease or risk of reactivation of 
latent TB infection depends to a great extent on the host`s immune status. Several 
predisposing factors is associated with an increased risk of  active TB disease such as 
TNF-α antagonists treatment (48, 49), end-stage renal failure (50, 51), organ transplant 
recipients (50), diabetes (52, 53), underweight, under- and malnutrition (50, 54), 
smoking (55), malignancies (54) and silicosis (56, 57). However, HIV infection is the 
most potent risk factor for developing TB, with the risk over 20-times greater among 
HIV infected compared to HIV uninfected individuals (29).  
TB patients have traditionally, from a public health and clinical perspective, been 
categorized as having either latent TB infection (noninfectious, asymptomatic) or 
active TB disease (potentially infectious, symptomatic disease) (35, 58). Recent 
research demonstrates that the classical binary division of TB may be an 
oversimplification and that the transition from latent TB infection to active disease 
involves early, asymptomatic disease states, where microbiological evidence and/or 
radiological manifestations are the only signs of active TB disease (59, 60). It is thus 
proposed that TB infection can better be regarded as a continuous disease spectrum 
extending from elimination of infection by immune responses, to controlled infection 
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with persisting inactive bacilli, to subclinical disease with active bacterial replication, 
to fulminant and potentially life-threatening disease at the outermost extreme (35, 39, 
61).  
1.3.3 Immune response and granuloma formation  
The immune response to Mtb and the host-pathogen interactions, involving an 
interplay between the bacteria and the innate and adaptive immune system, are 
complex, multifactorial and to some extent incompletely defined. Entering the alveolar 
space, the innate immune system provides the first line of defense against Mtb (29), 
and the first host-pathogen interaction appears to be mediated through pattern 
recognition receptors located on phagocytic cells, leading to receptor-mediated 
phagocytosis of Mtb (62-64). Generation of adaptive immunity is important for control 
and containment of the infection. With Mtb being an intracellular pathogen protective 
immunity relies to a great extent on cell-mediated immune responses, with the CD4+ 
T-helper 1 cell in a prominent role (65, 66). Macrophages and DCs are crucial in 
initiating, stimulating and directing adaptive antigen-specific T cell immunity, with 
presentation of Mtb antigens and production of cytokines and costimulatory signals 
(67). DCs and macrophages present mycobacterial antigens loaded on major 
histocompatibility complex to T cells (65). Further, they secrete proinflammatory 
cytokines such as interleukin (IL) 1, IL-6, IL-12, TNF-α, recruiting cells to the site of 
infection, stimulate interferon gamma (INF-γ) producing cells and promote formation 
and maintenance of the granuloma (64, 65, 67). Effector T cells respond by secreting 
cytokines like TNF-α, INF-γ and IL-2. TNF-α and INF-γ in turn activate macrophages 
and increase their microbicidal capacity, recruit additional cells to the site of infection 
and maintain the granulomas cellular integrity (64, 68-70). IL-2 is mainly involved in 
T cell differentiation into memory and effector cells (71). Thus, some weeks after the 
infection, cell-mediated immunity develops, and effectively controls the infection (72). 
Progressive assembly of cells at the site of infection, into an organized, compact 
aggregate of macrophages, interspersed with lymphocytes, DCs and various other 
inflammatory cells, surrounded by a rim of fibroblasts, leads to the formation of the 
TB granuloma (73).  
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The granuloma formation is the histopathological hallmark of TB infection. At the 
early, initial stage, the granuloma is a cluster of mature macrophages, distinguished by 
higher number of organelles and increased cytoplasmic size (74, 75). Granuloma 
macrophages can go through additional morphological changes and differentiate into 
specialized cells, such as foam cells (identified by lipid accumulation in the 
cytoplasm), some will fuse to produce multinucleated giant cells or transform to 
epithelioid macrophages (epitheloid histiocytes) (74-77). Epitheloid macrophages are 
elongated, slender, large cells, where interlocking pseudopods associate and closely 
pack adjacent cells (76). When adaptive immunity develops, the granuloma evolves 
into a more intact, organized structure, with a lymphocytic cuff surrounding the 
macrophage-rich center (78). The macrophage cell death by necrosis leads to the 
accumulation of necrotic material creating a morphological pattern, caseous necrosis, 
which is most commonly seen in TB granulomas (74, 79). HIV coinfection leads to 
numeric or functional depletion of Mtb-specific CD4+ T cells, resulting in diminished 
cell-mediated immune responses, impairment of the lymphocyte-macrophage immune 
axis and ability to form competent granulomas (29). With increasing 





Figure 2. Structure and cellular constituents of the tuberculous granuloma. Ramakrishnan L. 
Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol. 2012;12(5):352-66 (74). Reprinted with 
permission from Macmillan Publishers Limited, Nature Reviews Immunology.  
 
1.4 Clinical presentation of extrapulmonary tuberculosis 
TB is one of the diseases referred to as “The Great Imitator” as it can resemble various 
other disease presentations (81). EPTB cases can present unspecific constitutional 
symptoms like weight loss, fever, night sweats, reduced appetite and general malaise, 
in addition to specific signs and symptoms according to the site of infection (6). Still, 
the signs and symptoms in EPTB are often insidious and nonspecific. TB 
lymphadenitis and TB pleuritis are predominantly reported as the most common sites 
of EPTB infection (12, 82, 83), both among HIV negative and HIV positive patients 
(6). However, in some settings bone and joint TB and genitourinary TB have been 
described as the most frequent sites (17, 84), thus suggesting that sites of EPTB may 
differ according to population and geographic location (85). Concomitant PTB is a 




Figure 3. Distribution of sites of extrapulmonary tuberculosis disease. Data derived and adapted from 
references (16, 18, 82, 83, 85, 87-89).  
 
In lymph node TB, peripheral lymph nodes are affected in the majority of cases, with 
cervical lymph node involvement as the most common site (90). The presentation is 
frequently a unilateral, discrete, firm, painless neck mass above 2 cm in diameter (91). 
With time, as a results of periadenitis, fixation and matting of the nodes can be found, 
and if left untreated abscess formation and spontaneous drainage of the node with 
sinus formation can develop (90). TB lymphadenitis commonly affects young adults 
and children (92, 93) and is reported to be more frequent among women than men 
(94). Constitutional symptoms can be absent but described more often in males 
compared to females (94) and in patients with HIV coinfection (95). 
An acute presentation of symptoms is often seen among TB pleuritis cases (96). The 
most frequent presenting symptoms are pleuritic chest pain, non-productive cough and 
fever (97). The patients can have varying degrees of dyspnea depending on the 
magnitude of pleural effusion. The pleural effusion following TB pleuritis is generally 
unilateral (98), of any size, but reported in a study of 254 pleural TB patients to 
occupy less than 2/3 of the hemithorax in the majority of patients (99). The size of 
pleural effusion has been described to be similar in HIV negative and HIV positive 
patients, but a longer and more severe illness is often seen among HIV positive 
patients (100).  
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Spinal TB (Pott`s disease) is the most frequent form of bone and joint TB (6), and it is 
more common among younger individuals in TB-endemic countries, while in 
developed countries, the disease is generally seen among the adult population (101-
103). The clinical presentation depends on the duration and severity of the disease. 
Characteristic features are local pain, stiffness and muscle spasms, cold abscess and 
prominent spinal deformity (102). Symptoms onset is generally slow and insidious and 
constitutional symptoms are reported in about 20-30 % of the patients (102, 103).  
Back pain is almost always present, usually localized to the involved site, and spinal 
deformities and neurological deficits are common (102, 103). The clinical 
presentation, the site of spinal TB and number of vertebral bodies involved have been 
reported to be similar in HIV negative and HIV positive patients (104, 105). 
Abdominal TB is mostly seen in young adults and intestinal TB disease and peritoneal 
involvement are the most prevalent forms (106). Abdominal swelling and pain are 
typical presenting symptoms of peritoneal TB, in addition to constitutional symptoms 
such as weight loss, fever and night sweats, with ascites as the most frequent physical 
sign (107). Intestinal TB can involve all areas of the intestine, but commonly affects 
the ileocecal region (108). The presenting symptoms with chronic diarrhea, abdominal 
pain, intestinal obstruction, hematochezia and constitutional symptoms can resemble 
Crohn`s disease (108). 
The most devastating form of EPTB is TB of the central nervous system (CNS), where 
the mortality rates are high and there is a risk of disabling neurological sequela (86, 
109). Increased risk of CNS TB is found in young children and TB/HIV coinfected 
patients (86, 110). Clinically, the most common presentation, TB meningitis, often has 
an insidious onset with a prodromal phase including symptoms such as fatigue, fever, 
headache, vomiting, weight loss and behavioral changes, followed by seizures, 
neurological deficits and altered consciousness (90, 111). Some patients can present 
with a rapid progression and sudden onset of symptoms simulating other bacterial 
meningitides (111, 112). Studies comparing the clinical manifestations of TB 
meningitis in HIV positive and HIV negative cases report similar presenting symptoms 
in both groups (113). However, others have described altered level of consciousness or 
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cognitive dysfunction to be more prominent in HIV-infected cases (86, 114) and that 
this patient group more likely presents with additional sites of EPTB (112). 
Disseminated/miliary TB has a wide range of clinical manifestations, from a prolonged 
vague illness to acute fulminant disease. Symptoms and signs depend on the organs 
involved (115). Still, the presenting symptoms are usually nonspecific, and dominated 
by constitutional symptoms such as fever, fatigue, reduced appetite, weight loss and 
night sweats (115-117). Among HIV negative patients with miliary TB, predisposing 
conditions such as malignancy, organ failure, diabetes mellitus or immunosuppressive 
therapy are present in about 40-45% of the cases (117-119). In HIV positive patients 
with early HIV infection (CD4+ count >200 cells/µL) the prevalence of miliary TB is 
similar to that reported among immunocompetent patients, while it is reported more 
often with advancing stages of HIV infection (115). In children, occult dissemination 
following primary infection is common, but seldom progresses to disseminated TB, 
with the exception in immunocompromised children and in young children (< 3 years) 
(110). The mortality rate of miliary TB remains high despite available effective 
treatment (115, 116). 
 
1.5 The diagnosis of extrapulmonary tuberculosis in low-resource 
settings 
EPTB poses more diagnostic challenges compared to PTB. First, the clinician must 
have a clinical suspicion of EPTB, and given that extrapulmonary disease may present 
with a wide range of signs and symptoms depending on the site affected, the patient’s 
immune status and disease stage, the EPTB differential diagnosis may come late in a 
clinical evaluation. Next, laboratory facilities and diagnostic capacity are often limited 
in low-resource settings. The biological samples for laboratory investigations often 
require invasive sampling, sometimes from relatively inaccessible sites, which can 
pose a risk to harm the patient and raises the need of facilities and trained personnel 
performing these procedures. Further, the access to competent laboratory technicians 
performing the various sample processing methods of the heterogeneous specimen 
material must be in place. Adding to the challenge is that many forms of EPTB are 
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paucibacillary, i.e. disease due to a lesser number of bacteria, reducing the sensitivity 
of the most commonly used laboratory diagnostic methods (9, 120-123). There are also 
limited possibilities of adaption of newer and improved diagnostic techniques in low-
resource settings.  
The diagnosis of EPTB is thus often based on an integration of clinical suspicion of 
TB, and if laboratory and imaging facilities are available, results from different 
investigations, without a microbiologically confirmed diagnosis. The decision to start 
empirical anti-TB treatment could potentially lead to both over- and underdiagnoses of 
TB disease. This highlights the need to improve laboratory diagnostic methods for 
EPTB, with the objective of increased confirmation and case detection of active forms 
of EPTB disease, providing a rapid and reliable diagnosis regardless of the site of 
infection, age and HIV status. The aim should be to develop a diagnostic test which is 
highly specific and sensitive (improved accuracy compared to existing tests), quick to 
results, inexpensive, cost-effective, easy to use and interpret and doable in TB-
endemic low-resource settings. In addition, it would be valuable if the diagnostic test 
is performed using technological platforms already established in low-resource, high 
TB prevalent settings.  
1.5.1 Current laboratory methods for diagnosis of active extrapulmonary 
tuberculosis disease 
Direct laboratory methods detect or demonstrate the Mtb organism itself or its product, 
indirect methods detects the Mtb organisms impact on the host, measuring the host`s 
cellular or humoral immune response against Mtb (124).  
1.5.1.1 Direct methods 
Microscopy 
Demonstration of acid-fast bacilli (AFB) directly in clinical specimens using the light 
microscope and Ziehl-Neelsen (ZN) staining method still plays a fundamental role and 
is often the only TB diagnostic tool available in many settings. Under optimal 
conditions the detection threshold of AFB microscopy is between 104-105 bacilli/ml 
(125), and although usually identifying the most infectious PTB patients, the 
sensitivity is variable and relatively low (range 20-80%) in detecting active PTB cases 
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(126). Microscopy shows limited sensitivity in paucibacillary disease, such as pediatric 
TB, HIV-associated TB and extrapulmonary disease (110, 124, 127-129). The 
suboptimal sensitivity of AFB microscopy in identifying EPTB disease (sensitivity 0-
40%) has been shown in several studies including various sites of infection and sample 
material (9, 122, 123, 130-133). Measures to improve the diagnostic performance of 
ZN microscopy such as examining larger CSF volume and using ≥ 30 minutes to 
examine the ZN stained slide (134, 135) and cytocentrifugation of pleural fluid and 
pleural biopsies (136), have been described to increase the yield of ZN microscopy, 
but it is still suboptimal. 
Numerous studies have described improved diagnostic performance of sputum smear 
microscopy by the use of conventional fluorescence microscopy (FM) using 
fluorochrome dye (auramine-rhodamine or auramine O) compared with ZN staining 
and light microscopy (137, 138). In addition, the slides can be evaluated at lower 
power magnification which reduces the screening time (139). A systematic review 
reported higher sensitivity (average improvement 10%) and similar specificity of FM 
compared with conventional ZN sputum smear microscopy (140). Improved sensitivity 
of fluorescent methods in comparison to ZN microscopy has also been described in 
extrapulmonary specimens (141, 142). Development of the light emitting diode 
fluorescent microscopy (LED-FM), which is cheaper, require less power, has a light 
source with longer lifespan (>50 000 hours) and not requiring a dark room, have made 
the FM technology (either as LED microscopes or by the conversion of conventional 
FM to LED light sources) more feasible in resource-constrained settings (126, 139, 
143). After reviewing the evidence, where the LED-FM was found at least as sensitive 
and specific as conventional FM, the WHO issued a policy statement recommending 
LED-FM replacing conventional FM in settings already using FM and a switch from 
ZN light microscopy to LED-FM following a careful implementation plan (126). 
However, the sensitivity of fluorescent microscopy in EPTB samples is low. 
Regarding the specificity of AFB microscopy, smears can have particles other than 
MtbC organisms that are acid-fast, such as precipitates, inorganic material, artefacts, 
fibers and pollen (144). In addition, acid-fast staining does not differentiate organisms 
in the MtbC, nor the MtbC organism from other acid-fast microorganisms like 
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Nocardia species (partially acid-fast) and nontuberculous mycobacteria (NTM) (144, 
145). Identification of the mycobacterial species is vital as the management of MtbC 
infection and NTM disease differs (146). 
Culture  
Culture is still regarded as the gold standard for bacteriological confirmation of TB 
disease (147). Culture is a lengthy and relatively cumbersome process, starting with 
clinical specimens often needed to be transported to reference laboratories (148), 
decontamination of non-sterile specimens, inoculation and incubation of media, 
detection of growth and identification of mycobacteria (149). Traditionally, 
mycobacteria are cultured on solid media which are either agar-based, e.g. 
Middlebrook (7H10/7H11), or egg-based, e.g. Ogawa and Lowenstein-Jensen (LJ) 
media (150). LJ is the culture medium most commonly used worldwide, whereas 
Middlebrook media are seldom used in routine diagnostics in resource-limited settings 
due to higher costs (149). Observation of growth characteristics, colony morphology 
(distinctive appearance on Middlebrook agar) and microscopy of the cultured material 
can provide a presumptive TB diagnosis, but additional tests are needed for a 
confirmatory identification of isolates of the MtbC and its differentiation from NTM 
(151-153). In addition to species identification, culture is necessary for phenotypic 
drug susceptibility testing (DST) (154). Mycobacteria may often be detected on solid 
media in <4 weeks, but incubation for 8 weeks is required before solid culture is 
classified as negative (155). The slow growth of Mtb inevitably delays the results. 
Further, Mtb culturing is time-consuming, complex and thus requires skilled 
laboratory personnel and a well-functioning infrastructure and health care system and 
specialised laboratories with high biosafety level. In sub-Saharan Africa many clinics 
do not have access to a laboratory performing TB cultures (156). Culture shows a 
higher sensitivity than microscopy as only 10-100 bacilli/ml material are required to 
detect Mtb (157). Still, in EPTB disease the sensitivity of culture has been reported in 




Figure 4. Culture test tubes. Test tubes showing growth on Lowenstein-Jensen media. Photo: Melissa 
Davidsen Jørstad. 
Mycobacterial culture and growth detection through commercial broths systems, such 
as the radiometric BACTEC™ 460 TB system, the Mycobacteria Growth Indicator 
Tube (MGIT™) system and the nonradiometric BACTEC™ MGIT™ 960 system (BD 
Diagnostic Systems, Sparks, MD, USA) are seen as major improvements. DST can 
also be performed using liquid culture systems (161). Liquid culture systems are more 
sensitive and give faster results than culturing on solid media, but are also more 
expensive (162). Further, higher contamination rates are found among liquid culture 
systems  and the possibility of increased frequency of isolating NTM emphasises the 
need of available rapid species identification tests  and clear, feasible guidelines on 
how the clinical staff should manage NTM results (162-164). Optimal yield of culture 
is by a combination of solid media and automated liquid systems (165). In 2007, the 
WHO endorsed phased implementation and use of liquid culture and DST in low- and 
medium-income settings (166), and now recommends the use of both solid and liquid 
culture, regarding liquid culture as the gold standard (167). However, TB laboratories 
in resource-limited settings often use only solid media, largely due to cost of liquid 
culture (162).  
Molecular methods 
Nucleic acid amplification tests (NAATs) are molecular techniques allowing detection 
and amplification of minute amounts of target genetic (deoxyribonucleic acid (DNA)  
or ribonucleic acid (RNA)) material and have the capability to produce abundant 
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quantities of identical copies of the nucleic acid target sequence if the particular 
sequence is present in the sample (168). Several amplification methods are available, 
but the first and most commonly used method is the polymerase chain reaction (PCR) 
(169). Amplification of the nucleic acid is accomplished in a thermocycler. 
Advantages of PCR is the reduced time to detect Mtb compared to culture, it can be 
performed in fresh specimens and in formalin-fixed, paraffin-embedded tissue and 
alcohol-fixed aspirate smears and using the genetic material, species identification and 
sometimes detection of genes encoding antibiotic resistance can be done (160, 168, 
170-172). Further, the benefit that the technique can detect minute amounts of DNA is 
also a limitation since cross-contamination might lead to false-positive results. Meta-
analyses and systematic reviews, including both commercial and in-house NAATs for 
the diagnosis of various EPTB cases, report inconsistent and profoundly variable 
results (168, 173-176). Commercial NAAT, can play a role as a rule-in-test in EPTB 
disease due to often high specificity, but the moderate and highly variable sensitivity 
impedes the use as a rule-out-test (173-175, 177). The abundant cost, technical skills 
and laboratory equipment needed have precluded the scale-up and widespread use of 
conventional NAATs in routine diagnostics in low-resource settings. 
Development of the Xpert® MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, CA, USA), 
a cartridge-based, fully automated nucleic acid amplification assay, utilizing 
heminested real-time PCR for amplification of a Mtb-specific DNA sequence of the 
rpoB gene, concurrently detecting both Mtb and rifampicin resistance, is undoubtedly 
seen as a landmark event in TB diagnostics (178-181). The Xpert assay was in 
December 2010 endorsed by the WHO, and the initial policy statement published early 
in 2011, recommended using the Xpert assay as the first diagnostic test in sputum 
specimens among presumptive PTB patients suspected of having HIV-associated TB 
or multidrug-resistant tuberculosis (MDR-TB) or as an add-on test to microscopy in 
other patients (182). The assay was initially developed, assessed and optimized for the 
diagnosis of PTB cases using sputum, and was found sensitive and specific in the 
diagnosis of PTB among adults, showing increased TB case detection in culture-
positive cases compared to microscopy, though exhibiting lower sensitivity in smear-
negative compared to smear-positive cases (183, 184). Evaluation of the Xpert assay in 
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the diagnosis of EPTB have been more complex due to a variety of specimen types, 
diversity of sample processing before analysis and suboptimal reference standards 
(185). Studies including various extrapulmonary sample material report highly 
heterogeneous sensitivity, also varying depending on the sample material (10, 185-
187). Based on the growing body of evidence, the WHO published a policy update in 
2013, expanding the recommendations using the Xpert assay for the diagnosis of PTB 
among adults, and added guidance for the use in children and in subgroups of EPTB 
patients (188). The next generation of the assay, the Xpert® MTB/RIF Ultra (Xpert 
Ultra) was recently launched, and further endorsed by the WHO, offering improved 
performance compared to the Xpert assay (189, 190). In sputum samples the Xpert 
Ultra assay was reported to have decreased specificity compared to the Xpert assay, 
but higher sensitivity than the Xpert assay in paucibacillary disease (smear-negative, 
culture-positive) and among patients with HIV-associated PTB (191). Studies 
assessing the Xpert Ultra assay in different extrapulmonary clinical samples are 
continuously being published (159, 192-196). Although the results look encouraging, 
the sensitivity vary across the diverse sample types, thus more studies, where results 
are classified according to sample types, are needed (197). Updated guidelines was 
released by the WHO in 2020, strongly recommending the use of the Xpert/Xpert 
Ultra assay as the initial diagnostic test in CSF among presumptive TB meningitis 
cases (198). Further, conditionally recommending the use of the Xpert assay in other 
extrapulmonary sample materials and the Xpert Ultra assay in lymph node biopsies 
and aspirates. There are several advantages with the Xpert/Xpert Ultra assay such as 
rapidity of the test results compared to culture, detection of both Mtb and rifampicin 
resistance (rifampicin resistance being strongly indicative of MDR-TB (181)), 
relatively simple to perform and thus easy to train health care workers in its use, not 
prone to sample cross-contamination and requires minimal biological safety facilities 
(185, 199, 200). However, some aspects of the diagnostic test can generate operational 
problems such as the need of a stable electricity supply, annual recalibration of the 
instrument, possibility of swap or repair if module failure, the instrument has a critical 
temperature ceiling of 15-30°C and the need of regular supply of cartridges to be 
stored at a temperature range of 2-28°C (167, 201). Next, the test is expensive and thus 
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funding and an assurance of reliable procurement of consumables and equipment is of 
vital importance in low-resource settings (201). While more studies on diagnostic 
performance and operational feasibility are necessary to evaluate the Xpert/ Xpert 
Ultra assay in the routine diagnosis of EPTB in low-resource settings to further guide 
the tests potential use, cost- effectiveness analyses and health impact studies assessing 
the actual impact on patient management and outcome also among EPTB patients need 
to be performed.  
Antigen detection tests 
Mtb antigens can be present in Mtb infected tissue, in fluids surrounding the tissues 
and after entering the circulation the antigens could be eliminated in the urine (202). 
Detection of Mtb antigens directly in clinical samples, such as sputum, CSF, peritoneal 
or pleural effusion, urine, fine needle aspirates cytology (FNAC) and biopsies from 
various tissues could potentially present rapid and direct evidence of active TB 
disease. Various formats of antigen detection tests have been developed such as 
enzyme-linked immunosorbent assays (ELISA), lateral flow immunochromatographic 
assays sometimes called strip-tests or dipstick tests, agglutination tests and antigen 
detection using immunocytochemical (ICC) or immunohistochemical (IHC) staining 
techniques (ICC/IHC staining hereinafter referred to as immunostaining) (203-208). 
Diverse target antigens have been assessed for their diagnostic potential in TB disease 
like 65-kilodalton (kDa) heat shock protein (Hsp65), 38-kDa protein, 45/47-kDa 
proteins, Ag85 complex, early secreted antigenic target 6 (ESAT-6), M.bovis bacillus 
Calmette-Guérin (BCG) antigens and lipoarabinomannan (LAM) antigen using 
different test designs in a diversity of sample material (124, 209).   
Of the different antigens, detection of LAM antigens in urine have been one of the 
most frequently targeted antigen in studies (209). The LAM antigen was in early 
studies shown to be detectable in urine from active TB cases (210). The first 
commercially diagnostic assays detecting LAM in urine was LAM ELISAs (211). 
After development of the LAM ELISAs several studies evaluating the diagnostic 
performance were conducted in diverse patients groups, mostly including presumptive 
PTB patients, showing variable diagnostic accuracy (212, 213). The conclusion from a 
meta-analysis in 2011 was that LAM urinary assays had “suboptimal sensitivity for 
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routine clinical use”, but it was noted a higher sensitivity of the assay among HIV 
positive (pooled estimated sensitivity 51%) compared to HIV negative patients (pooled 
estimated sensitivity 14%), and highest sensitivity among HIV positive TB patients 
with advanced immunosuppression (214).  Further studies among HIV positive, adult 
patients, confirmed the high specificity, and greatest sensitivity, although at best only 
moderate, among HIV positive cases with CD4 cell count < 50 cells/µL (215, 216). 
Development of the commercial lateral flow urine LAM immunochromatographic 
assay (LF-LAM), Alere DetermineTM TB LAM Ag (Alere Inc, Waltham, MA, USA), 
which could be used as a point-of-care test, was seen as a potential breakthrough. 
Although the LF-LAM showed similar results in urine samples as LAM ELISA with 
highest sensitivity in patients with reduced CD4 cell counts, the sensitivity of LF-
LAM remained suboptimal (205, 211, 217). The latest policy update for the use of LF-
LAM was issued in 2019, recommending the LF-LAM in all HIV positive patients 
with presumptive TB, regardless of the CD4 cell count (218). The LF-LAM was 
further recommended irrespective of TB symptoms in seriously ill HIV positive 
patients and among hospitalized patients with CD4 cell count ≤ 200 cells/µL (≤ 100 
cells/µL in out-patients) (218). LAM antigen detection tests have been investigated in 
other extrapulmonary specimens such as CSF and pleural fluid showing low sensitivity 
(219, 220), and is not recommended in other sample material than urine (221). 
Detection of Mtb antigens by immunostaining utilizing monoclonal or polyclonal 
antibodies could be an alternative to conventional AFB staining in biopsy tissue 
sections and cytological smears. Immunostaining applying specific antibodies could 
potentially detect any mycobacterial antigen and it is possible to demonstrate Mtb 
antigens within phagocytic cells, extracellular organisms, fragmented bacilli and 
antigenic debris, i.e. intact Mtb cell wall is not needed (208). Other advantages are that 
alcohol-fixated smears could be stored and transported to facilities performing 
immunostaining, the staining techniques are relatively simple, not prone to 
contamination and with operational advantages over conventional PCR, and thus 
suitable in laboratories in low-resource settings. Demonstration of mycobacterial 
antigens in extrapulmonary specimens and the use of immunostaining in the diagnosis 
of TB have been investigated using in-house made or commercially available 
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monoclonal or polyclonal primary antibodies (222-227). Many of the published studies 
investigating the potential of immunostaining to improve the diagnosis of TB have 
used commercially available polyclonal anti-BCG antibodies (207, 224-226, 228, 229) 
or in-house polyclonal anti-Mtb antibodies (227, 230, 231) in various tissue. One study 
by Kohli et al. assessing the value of IHC staining using anti-BCG antibodies in 
detecting mycobacterial antigens in various tissue sections described a higher 
sensitivity (96% versus 31%), but a lower specificity of IHC staining than ZN staining 
(35% versus 96%) (226). Similarly, Mukherjee et al. reported IHC staining to identify 
37/50 (74%) cases of TB lymphadenitis, whereas in only 22/50 (44%) cases ZN 
staining showed AFB (225). However, polyclonal anti-BCG and anti-Mtb antibodies 
are not specific for the MtbC complex organisms, and thus cannot differentiate 
between species of the MtbC complex and other mycobacteria, in addition anti-BCG 
antibodies are known to show cross-reactivity with additional bacteria and fungi (229, 
232, 233). Goel et al. investigated the potential of ICC staining in FNAC from lymph 
nodes as an adjunct to cytological diagnosis of TB lymphadenitis using species-
specific primary monoclonal antibody (mAb) to 38-kDa protein antigen, and reported 
a sensitivity of ICC staining > 95% in both archival and fresh FNAC smears (208). 
The 38-kDa protein antigen is reported to be a quantitatively Mtb-specific antigen 
compared with BCG (the protein is present in BCG culture fluid but in lower 
concentrations than in Mtb culture fluids) (234), and even though the gene encoding 
the antigen is described absent in several NTM, it is found in M. intracellulare (235) 
and suggested to be present in M. malmoense (236). Thus, detection of the 38-kDa 
protein antigen cannot indicate infection due to MtbC with certainty. MAbs (61.3, 
60.15, 105.10 and 2.16) reacting with different mycobacterial proteins, 35-kDa 
protein, 28-kDa proteins and Hsp65, was assessed by Barbolini et al. for detection of 
mycobacterial antigens in lymph node, joint and lung tissue of TB patients (223). The 
mAbs reacting with 28-kDa protein and Hsp65 show broad cross-reactivity in 
mycobacteria, while the mAb 61.3 was described to recognize an epitope on the 35-
kDa protein showing a more limited cross-reactivity (223, 237). Sumi et. al evaluated 
IHC in the diagnosis of TB lymphadenitis using polyclonal primary antibodies 
directed towards mycobacterial antigens, HspX, Tb8.4, PIcA and ESAT-6 (222). They 
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reported the anti-ESAT-6 antibodies to be highly sensitive and specific, advocating the 
use of IHC with primary anti-ESAT-6 antibodies among TB lymphadenitis patients 
where conventional laboratory diagnostic methods cannot confirm the TB disease 
(222). The use of primary antibodies targeting antigens restricted to MtbC organism, 
but absent in M. bovis BCG substrains and NTM, could increase the performance of 
immunostaining and discriminate TB infection from NTM. The MPT64 antigen is a 
26-kDa protein produced and actively secreted by MtbC organisms (238-241). The 
protein was initially purified and isolated from M. bovis BCG Tokyo culture filtrates 
by Harboe et al. (242). Subsequent studies indicated that the gene encoding the antigen 
was absent in several  M. bovis BCG substrains (239, 243), and further showed that the 
DNA segment containing the corresponding gene, region of difference (RD) 2, was 
deleted in some BCG substrains (244). In addition, the antigen MPT64 has not been 
demonstrated in NTM (242, 245). Studies assessing the diagnostic potential of 
immunostaining in tissue sections and cytological smears from different 
extrapulmonary sites using in-house polyclonal primary anti-MPT64 antibodies show 
promising results, with higher sensitivities than AFB staining and Mtb culture in 
paucibacillary extrapulmonary TB disease (122, 123, 246, 247).  
Although various studies have suggested a potential role of immunostaining as a 
diagnostic adjunct to conventional laboratory methods for the confirmatory diagnosis 
of EPTB, it has not been extensively studied and embraced, and thus conceivably an 
underutilized diagnostic method for EPTB disease. Hence, the exact application and 
role of immunostaining in the routine laboratory diagnosis of EPTB should be assessed 
in further studies in endemic areas. 
1.5.1.2 Indirect methods 
Antibody-based serological tests 
TB serological tests usually refer to tests detecting antibodies, i.e. humoral immune 
responses to Mtb antigens, as opposed to tests relying on Mtb antigens being 
recognized by cellular immune responses, such as in IGRA tests, or Mtb antigens 
being directly detected in specimens, e.g. LAM in urine (248, 249). Serological tests 
have the potential to be developed into point-of-care tests, as they are rapid and 
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usually have simple technological and training requirements (250). However, 
commercial serological antibody-based tests for the diagnosis of both PTB and EPTB 
show insufficient diagnostic accuracy and have restricted clinical value (251), and the 
use of these tests are discouraged in international TB care guidelines (3). After 
reviewing the available evidence, the WHO, in 2011, issued a negative policy 
statement (249). The statement announced a strong recommendation against the use of 
the present serological tests for the diagnosis of PTB and EPTB (249). Still, 
serological tests are marketed and extensively used in several high TB-burden 
countries (252). 
Tuberculin skin test and Interferon-γ release assays 
There are two established methods for the immunodiagnosis of latent TB infection, the 
TST and IGRAs (253), but the role of these tests in the diagnosis of active TB is still 
unclear (254, 255). The two tests are indirect markers of Mtb exposure and indicate 
adaptive immunity and immunological sensitization towards Mtb antigens, but not 
inevitably infection with Mtb (41). They do not differentiate between latent and active 
TB disease, nor accurately predict progression to active disease (40, 255), and show 
reduced sensitivity among immunosuppressed individuals (40).   
The TST consists of intradermal injection of purified protein derivate (PPD) of 
tuberculin, where a delayed-type hypersensitivity inflammatory reaction occurs after 
2-3 days in individuals with a cell-mediated immune response towards these antigens 
(40). In the interpretation of a positive test the three dimensions; size of skin 
induration, positive predictive value and risk of active disease should be considered 
(256). The PPD is a mixture of Mtb antigens, and contains antigens shared by NTM 
and MtbC organisms, including M. bovis BCG strains (257). Thus, prior BCG 
vaccination, especially repeated BCG booster vaccination and post-infancy 
vaccination, and exposure to NTM can give false positive results, and comprise the 
test`s specificity (258). The sensitivity of the TST is limited in certain subgroups, such 
as malnourished individuals and people living with HIV (40), and even among active 
TB patients, with no obvious immunosuppression, a considerable proportion has 
negative results on TST (259).  
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The IGRAs are in-vitro blood test measuring INF-γ release by T cells following 
stimulation by Mtb specific antigens (260). The antigens used are culture filtrate 
protein 10 (CFP-10) and ESAT-6 (40). The QuantiFERON®-TB Gold In-Tube test 
(Cellestis/Qiagen, Carnegie, Australia) includes one additional Mtb specific antigen, 
TB7.7 (Rv2654). ESAT-6 and CFP-10 are encoded by genes located in the RD1 
segment of the MtbC genome, a genomic region missing in M. bovis BCG substrains 
(244, 261)  and the antigens are absent in most NTM (262), and thus show increased 
specificity compared to PPD (257). However, like the TST, not being able to 
distinguish latent and active TB, the specificity for active TB will be low in settings 
with a high TB burden (263). It has also been reported suboptimal sensitivity in active 
TB disease and no consistent proof that IGRAs are more sensitive than TST for the 
diagnosis of active TB in low/middle-income countries (40, 254). Fan et al. concluded 
in a systematic review and meta-analysis that IGRAs, notably in low/middle-income 
countries, have limited value as screening tools and “rule-out-tests” for EPTB (264). 
The diagnostic performance of IGRAs for the diagnosis of EPTB have been assessed 
using other specimens than blood. Moderate diagnostic accuracy has been reported 
using pleural fluid and CSF IGRA among patients with presumptive TB pleuritis and 
TB meningitis, respectively (265, 266). 
 
Adenosine deaminase activity, white blood cell differential count and other 
basic biochemistry analyses 
Estimation of adenosine deaminase (ADA) activity is a widely studied marker in 
effusions and fluids for the EPTB diagnosis. ADA is an enzyme catalysing the 
conversion of 2'deoxyadenosine and adenosine into 2'deoxyinosine and inosine, 
respectively (267). It is released by activated immune cells and even though seen as a 
unspecific marker of inflammation (268), using various ADA activity cut-off values, it 
has been shown that measuring ADA activity may be helpful as an indirect and 
adjunctive diagnostic marker of EPTB in different effusions and fluids (269-271). 
However, the clinician must have knowledge of situations increasing the likelihood of 
false-positive and false-negative results. Low levels can be found in the early disease 
phase and in current smokers and the older patients (272, 273). Whereas, increased 
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ADA levels can be observed in other conditions, including empyema caused by other 
bacteria, cancer, parapneumonic effusion, rheumatoid effusions and haematological 
malignancies (272). As an example, ADA cannot differentiate between bacterial and 
TB meningitis (274). Further, the diagnostic utility of the test depends on the local TB 
prevalence. Among populations with presumptive TB effusions from high TB 
prevalence settings, an increased ADA level provide a high post-test probability of TB 
disease (268, 272). However, in low TB prevalence settings, the positive predictive 
value is low, whereas the negative predictive value is higher (272, 275). The 
combination of ADA ≥ 40-50 U/L and lymphocyte/neutrophil ratio ≥ 0.75 or 
lymphocyte/total white cell count ratio ≥ 0.50 in pleural effusions have been reported 
to increase the specificity for the TB pleuritis diagnosis (276, 277).  
In fluids and effusions, estimation of the white blood cell count, white blood cell 
differential count, pH, protein and glucose concentration and lactate dehydrogenase 
level are generally part of the routine laboratory diagnostic work up. In the CSF, 
findings usually seen as supporting a TB diagnosis among patients with clinical 
presumptive TB meningitis are pleocytosis (> 20 cells/µl) with a predominance of 
lymphocytes, CSF/blood glucose ratio < 0,5-0,6 or absolute glucose concentration in 
CSF < 2,2 mmol/L and protein concentration > 1g/L (278). In pleural TB, the effusion 
is usually a straw-coloured, exudative (using lactate dehydrogenase or protein criteria 
(279)), lymphocyte predominant fluid, generally showing a protein concentration > 30 
g/L, elevated lactate dehydrogenase (often exceeding 500 IU/L), glucose 
concentrations between 3,3-5,6 mmol/L and pH < 7,4 in the majority of cases (272). In 
2006 the WHO published recommendations on how to improve the diagnosis of 
smear-negative PTB and EPTB in resource-constrained settings (91). As for pleural 
effusion, TB pleuritis should be suspected if clinical presumptive TB, a clear and 
straw-coloured unilateral effusion with protein level > 30g/L and ≥ 50% lymphocytes 
(91). In patients with clinical features of TB meningitis, a clear CSF with lymphocytes, 
low glucose and high protein, and negative Gram stain and cryptococcal antigen (or 
fungal culture and India ink) in the CSF, should give a high suspicion of TB 




Cytological examination of effusions, fluids and FNAC smears from various tissues is 
often performed as it is relatively easy and gives rapid results. In TB, cytology of 
fluids and effusions usually shows a lymphocytic predominance, however lymphocytic 
pleocytosis is not specific for TB infection as it can be found in other conditions such 
as viral and fungal infection and malignancies (280, 281). Further, TB cases may also 
present a polymorphonuclear cell predominant fluid or effusion (282, 283). FNAC of 
palpable mass lesions, the most frequent site being aspirates from peripheral lymph 
nodes, is a widely used diagnostic method in the diagnosis of EPTB. FNAC is a safe, 
simple, minimally invasive technique, providing material for various investigations 
including cytological examination, and practical in peripheral health care units and 
feasible in resource-limited settings (284). Excision biopsy with histopathological 
examination is advised in cases with negative or equivocal cytology results. The 
invasive nature and unavailability of personnel and facilities performing biopsy and 
histopathological procedures constrain the use in many resource-limited settings. 
Several studies have assessed the value of the cytomorphologic diagnosis of TB 
lymphadenitis using FNAC (285, 286). There are well defined cytological and 
histological criteria suggestive of TB infection with chronic granulomatous 
inflammation with or without caseous necrosis defined as the classic features seen in 
TB disease (285, 287). Immunocompetent patients often present with the classic 
morphological pattern of epitheloid granulomata with multinucleated giant cells and 
caseous necrosis, whereas immunocompromised patients often show “dirty” necrosis 
with cellular debris and abundant neutrophils, but there is a wide range of 
morphological pictures between these extremes (285, 287). The classical patterns of 
granulomatous inflammation are not specific for TB disease, and other conditions such 
as NTM, other bacterial, viral, parasitic or fungal infections, sarcoidosis and 
malignancies may present a similar cyto/histomorphological picture (288). Thus, 
differentiating Mtb infection from other etiologies of granulomatous inflammation is 
not possible based on cytology/histology alone. NTM are a common cause of 
mycobacterial lymphadenitis, especially among children and HIV-infected individuals 
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(289, 290). Still, these features are strongly suggestive of an inflammatory response to 
Mtb in TB endemic countries.   
Considering the currently available diagnostic tests for EPTB, an algorithm including 
clinical signs and symptoms, imaging results and a combination of available laboratory 
diagnostic tools is the best diagnostic approach in presumptive EPTB patients at 
present.  
 
1.6 Care pathway and diagnostic delay in extrapulmonary 
tuberculosis 
In many TB endemic settings, TB case detection is still primarily dependent on passive 
case finding. As shown in prevalence surveys, relying on passive case finding in high-
prevalence settings is not enough to detect all TB cases in the community (291, 292) 
and there is still a large gap in notified and estimated TB cases (293). Active case 
finding is acknowledged as a complementary strategy, and comprises any approach for 
TB case finding not reliant on patients reporting to the health care provider (HCP) of 
own accord (294). Systematic screening among possible risk groups (295) and 
investigation of contacts of TB patients (296) are examples of active case finding 
strategies covered in guidelines published by the WHO, and give some guidance to 
active case finding in low-resource settings (147, 297). Still, implementation and 
feasibility of active case finding can be challenging for a health care system already 
struggling to handle the current burden of known TB disease. Thus, in low-resource 
settings most patients are detected trough passive case finding. Passive case finding 
depends on affected individuals’ awareness of symptoms, access to health care 
facilities and on the individual taking appropriate care seeking actions after symptom 
onset (147). In a study among 1220 EPTB cases in India a minority of patients (12%) 
sought medical advice as their first action after onset of symptoms, while the majority 
practiced self-medication, consulted traditional healers or drug stores (298). A review 
including studies from high TB and HIV burden sub-Saharan African countries 
reported that first visit to traditional healers was consistently associated with patients 
delay and travel time for return visits associated with health system delay (299). Thus, 
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assessing the level of EPTB knowledge, awareness of signs and symptoms of EPTB 
and the patients` health care seeking actions after onset of symptoms are valuable 
when trying to identify potential areas of intervention to reduce diagnostic delay and 
increase case detection among this patient group. Further, when the individual visits 
the HCP, the HCP needs to recognize the signs and symptoms as presumptive EPTB 
and take relevant actions to confirm the diagnosis and timely initiate effective 
treatment (147). Studies have shown that patients often have repeated visits to HCPs 
before being started on anti-TB treatment (298, 300). In low-resource settings the 
scarcity of laboratory and imaging facilities especially in peripheral health care units, 
can potentially delay the diagnosis. Factors with possible impact on delay are various 
sociodemographic characteristics such as gender, age, household size, residence, 
educational level and occupation, patients health care seeking behaviour, awareness 
and knowledge about EPTB among the patients and formal and non-formal HCPs, 
travel time or distance to health care facilities, type of the first HCP visited and the 
number of HCPs consulted.  
Assessing the length of patient, health system and total delay, the number of patients 
experiencing unacceptable delays, the various care seeking pathways among EPTB 
patients and factors associated with the distinct delays is important. Delayed diagnosis 
and initiation of anti-TB treatment could increase morbidity, mortality and economic 
loss for the patients and affected families (301-303). Studies from various settings 
including both EPTB and PTB patients describe EPTB associated with longer delays 
(304, 305). Still, the majority of studies on diagnostic and treatment delay have been 
aimed toward the adult population and among PTB patients (299, 300). It is essential 
to increase the evidence base regarding the extent of the distinct delays experienced by 
EPTB patients, preferentially divided according to the various sites of EPTB infection, 
and evaluate potential factors contributing towards patient and health system delays in 
these specific patient groups. Achieving an increased understanding can aid actors 
working with EPTB patients to place the efforts and provide a basis for development 
of evidence-based strategies and interventions to accomplish the goal of improved and 
prompt detection and treatment of all TB patients. In this regard searching among 
studies performed in other settings can be helpful, but the factors affecting delay can 
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vary between settings and populations, and thus cautions should be taken when 
generalizing findings and conclusions from one setting to another. In some settings 
patient delay accounts for the major part of the total delay (306, 307), while in other 
settings, studies report health system delay as the main contributor (301, 308). It is 
thus meaningful to assess the various delays, variables associated with the delays, TB 
knowledge and patients care seeking pathways in each individual setting. Even though 
there have been some studies performed at the Tanzanian mainland (309-311), data 
exclusively and specifically for EPTB patients at Zanzibar are missing, and studies in 
this setting and among this patient group are needed. 
 
1.7 Treatment of extrapulmonary tuberculosis 
Standard TB treatment consist of four first-line antimicrobials; isoniazid (H), 
rifampicin (R), pyrazinamide (Z) and ethambutol (E) (35). National and international 
guidelines currently recommend 6 months of chemotherapy as the standard first-line 
treatment regimen for new TB cases with known or presumed drug-susceptible TB 
(312-314). The treatment is divided in two phases, the intensive or initial phase and the 
continuation or consolidation phase. The 2 months intensive phase comprises a four-
drug treatment regimen with H, R, Z and E, which is followed by a two-drug regimen 
with H and R in the 4 months continuation phase (312). Children are generally 
recommended to receive the same 6 months regimen (2HRZE/4HR), but ethambutol 
could be omitted in peripheral TB lymphadenitis in HIV negative children and in 
children who live in settings with low prevalence of HIV and/or isoniazid resistance 
(315). Extended treatment regimens with first-line drugs, have been recommended by 
expert groups in drug-susceptible osteoarticular TB and TB meningitis (312, 313). 
Adjuvant corticosteroid treatment is advised in the initial weeks of treatment in TB 
meningitis (316) and some also recommend corticosteroids in addition to anti-TB 
treatment in TB pericarditis (312).  
In previously treated TB patients, the choice of the regimen depends on the probability 
of the patients having MDR-TB and the availability of DST in the specific setting. The 
recommendation is a retreatment regimen with first-line drugs including streptomycin 
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(S) (2HRZES/1HRZE/5HRE) in patients returning after relapsing if the MDR-TB 
levels are low/medium in this specific patient group in the country-specific setting. In 
patients returning after failure, empirical MDR regimen is advised, which can be 
modified depending on the DST results (312). National TB programmes should 
modify or verify the assignment of relapsing and failure patients to low/medium/high 
likelihood of MDR according to country-specific data on the MDR-TB levels in these 
patients. Treatment of MDR-TB and extensively drug-resistant TB are longer and 
more complicated and should whenever possible be guided by the results from the 
DST of the Mtb isolate in each individual patient. If DST is unavailable, empirical or 
standard treatment regimens is advised (312, 317). 
HIV testing is advocated in all presumptive TB patients, and is especially important 
among EPTB cases, because of the higher proportions of extrapulmonary sites 
involved in patients with immunosuppression. In HIV positive patients not receiving 
antiretroviral therapy (ART) when TB is diagnosed, ART should be initiated within 8 
weeks of starting anti-TB treatment in patients with CD4 count > 50 cell/mm3 and 
within 2 weeks in patients with severe immunosuppression (317). 
Correct treatment regimens and adherence to treatment are of vital importance to 
promote cure of the individual patient, prevent emergence of drug resistance and 
impede transmission of TB infection. Some of the recommended strategies to achieve 
this are a patient-centred treatment approach, giving the patient an opportunity to be 
included in decisions regarding overall care and supervision of treatment, standard 
treatment, DOT relating to a second person directly observing the patient taking the 
prescribed medication and fixed-dose combination regimen (3, 312, 318).  
1.7.1 Paradoxical reactions 
Paradoxical reactions, defined as development of new TB lesions or worsening of 
existing TB disease in patients initially responding to effective anti-TB treatment 
(319), have been described in previous studies to occur rather frequently in HIV-
uninfected EPTB patients (319, 320). In HIV positive patients, the immune 
reconstitution inflammatory syndrome (IRIS), often occurring during the first months 
of ART (321), is well recognised. As a result of immunologic recovery and restoration 
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of immune responses induced by ART, IRIS usually presents as a new presentation of 
a previously untreated subclinical infection (unmasking IRIS)  or as a paradoxical 
exacerbation of a treated opportunistic infection (paradoxical IRIS) (322). In 
paradoxical TB-IRIS, HIV positive patients diagnosed with active TB, receive and 
typically respond to anti-TB treatment, but subsequently experience aggravation of TB 
signs and symptoms after commencing ART (321). The condition has been reported to 
be quite common in TB/HIV co-infected individuals given both anti-TB treatment and 
newly initiating ART (323), and a meta-analysis reported an estimated incidence of 
15.7% of paradoxical worsening after initiating ART in patients with formerly 
diagnosed TB infection (324). Recognition of deterioration resulting from paradoxical 
reactions or paradoxical TB-IRIS could be difficult to distinguish from drug-resistant 
TB, treatment failure, adverse drug reactions or the presence of another infection or 
condition (325). 
1.7.2 Monitoring response to treatment 
The establishment of a microbiological or histological diagnosis is recommended 
among EPTB patients, and every effort should be made to confirm the TB diagnosis 
(326). However, an accurate diagnosis of EPTB is difficult and complex, and thus 
many EPTB cases are initiated on empirical anti-TB treatment. Monitoring response to 
treatment is crucial in this regard to assure correct diagnosis and appropriate disease 
management, and clinical response to treatment is often used to support the EPTB 
diagnosis (91, 327). Further, the early and timely detection of non-responders is 
important and attempts to uncover the reason for treatment failure such as poor 
compliance, drug-resistant TB or alternative diagnoses should be sought.  
Several modalities have been investigated and much research is ongoing to find tools 
to monitor treatment response and cure among TB cases (328, 329). But still, the 
recommended method for monitoring treatment response among PTB patients is 
sputum smear microscopy at specific time points during treatment, and ideally sputum 
cultures among patients remaining sputum smear positive (3, 328). In EPTB cases 
microbiologic evaluation is usually not feasible, and clinical assessment is the 
recommended approach for monitoring response to treatment, especially in low-
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resource settings (3, 91, 312). In real-world TB programmatic settings recording 
response to treatment could be challenging due to the diversity of EPTB cases, 
different HCPs performing the follow-up visits and absence of simple, user-friendly 
criteria for treatment response in EPTB. The definition of satisfactory clinical  
response among the various sites of EPTB infection remains to some extent unclear 
and there is currently no established criteria (108).  
Clinical assessment of treatment response is partly subjective, and widely used 
indicators of improvement is disappearance of symptoms and ability to resume regular 
activities. Improvement of symptoms can be assessed by a symptoms count ratio 
(number of symptoms better or resolved compared to baseline) (330) or increase of 
self-reported health using standardized instruments such as the EQ-5D instruments 
(331), while the HCP can evaluate improvement of the patients performance status 
using a physician-rated functional scale like the Karnofsky Performance Status score 
(332-334). Objective measure such as weight gain is also a widely used marker of 
treatment response. Previous studies suggest weight gain to be associated with 
favorable treatment outcome, and unfavorable outcome with weight loss or lesser 
weight gain (335-338). Few studies have evaluated the association between weight and 
treatment outcome among EPTB patients (335, 336), and further if any weight gain is 
enough or should the weight gain exceed a certain percentage of body weight before 
taken as a marker of response to treatment.  
Repeated laboratory analysis of inflammatory markers or invasive procedures are often 
part of suggested definitions of good treatment response (108, 330). In low-resource 
setting, especially in peripheral health care units, there are often scarcity of health 
personnel and unavailability of both laboratory and radiologic investigations, thus 
defining simple clinical criteria could be helpful to the HCP in pinpointing patients in 
need of clinical reassessment, further investigations and referral to higher levels in the 
health care system. There is a need to develop better tools or clinical assessment 
algorithms for treatment follow-up among EPTB patients, ideally not dependent on 




1.8 Developing new tuberculosis diagnostic tools 
Important objectives in the fight against TB is the development, distribution and 
adaption of new TB diagnostic tools, with the potential to improve the detection of TB 
cases, including EPTB, by increased sensitivity and specificity of new tests compared 
to existing tests, that can be used in high TB burden settings. A new diagnostic tool 
should be thoroughly evaluated and validated and a comprehensive evidence base on 
test performance and user- and patient-important outcomes should be obtained, 
together with an assessment of the cost-effectiveness and quality of the evidence 
provided, before a new test is considered recommended for implementation in routine 
use (339, 340). A good test performance in controlled research settings needs to be 
complemented by evaluation of the test`s accuracy and reliability in routine diagnostic 
settings. In addition to the performance data under field conditions, studies providing 
evidence of the test`s ability to have impact on morbidity, mortality and the public 
health is important. Further, the feasibility of implementation, both in the routine 
laboratory and in the TB programmatic setting, the affordability for the health system 
and accessibility to the patients should be assessed. It could be challenging to adapt, 
implement and distribute new diagnostic tools in high burden TB settings where these 
tools are needed most. There is considerable ongoing research in the field of 
developing new TB diagnostic tools. In 2009 the New Diagnostics Working Group 
(NDWG) of the Stop TB Partnership published a blueprint; “Pathways to better 
diagnostics for tuberculosis: a blueprint for the development of TB diagnostics”. The 
blueprint offers a structured guide to those involved in the development of TB 
diagnostic tools, outlining the required phases from assessing the need, through 
development and evaluation of new tests, to assessing the feasibility of implementation 




Figure 5. The pathway for developing tuberculosis diagnostics, from assessing the need to delivery. 
Reprinted with permission from the World Health Organization from the publication “Pathways to better 
diagnostics for tuberculosis: a blueprint for the development of TB diagnostics”, World Health Organization 
Stop TB Partnership New Diagnostics Working Group (202). http://whqlibdoc.who.int/ 
publications/2009/9789241598811_eng.pdf. Copyright 2009.  
 
In the first stage, one must understand the context and the problems experienced by the 
patients in the setting were the test is planned to be performed, including the structure 
of the area`s health system, the infrastructure and capacity in the routine laboratory 
and patients` access to the health system. This needs assessment should provide a 
detailed description of the specific context, the target population, at what level of the 
health system and diagnostic algorithm the new test should be performed, equipment 
and technical needs, human resources required, expected turnaround time, information 
on the presumed performance in real-world settings and insight regarding anticipated 
increase of diagnosis and access to diagnosis (202). 
The next stage is developing the concept and reach a decision if a specific technical 
idea can be used for the required diagnostic purpose, then, decide if one should 
proceed with the development of a test prototype and optimization of the test through 
proof-of-principle studies and evaluation in the field using a partly validated test on 
various patient populations. Further, in the evaluation stage the performance of the 
new test should be assessed against gold standard techniques. First, in case-control 
studies or using well-characterized samples, here it is possible to use retrospectively 
collected data and specimens. In the later phases the performance of the test should be 
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evaluated in populations where such a test is typically indicated (clinical presumptive 
TB cases), among representative and consecutively included patients in settings or 
conditions of planned use, evaluating the clinical performance of the test in field 
settings (202). The test`s diagnostic accuracy refers to the test`s ability to correctly 
identify patients with a given disease and cases not having the disease (341). In 
diagnostic accuracy studies the test is usually assessed in comparisons to a set 
reference standard, and the accuracy of the test is thus referring to the extent of 
accordance between the reference standard and the test (341). Studies on diagnostic 
accuracy should be well designed and transparently reported, so others are able to 
assess potential bias and generalisability (342). Using tools such as “Standards for 
Reporting of Diagnostic Accuracy” (STARD), a reporting template for publications, 
(342), and “Quality Assessment of Diagnostic Accuracy Studies” (QUADAS), to 
assess the methodological quality of diagnostic accuracy studies (343), are 
recommended to improve the reporting and methodological rigor and evaluation of  
the quality of  diagnostic accuracy studies. Further, the reproducibility (reliability) 
should be assessed, such as an evaluation of the test reproducibility in different field 
sites or laboratories, but also intra- and inter-observer, within-run and run-to-run 
reproducibility (202).  
Diagnostic accuracy studies are required, but it can be difficult to determine the 
plausible impact on patient-important outcomes and public health just by evaluating 
how often the test classify patients accurately as diseased or non-diseased, in 
controlled performance trials (202, 344). It is important to demonstrate that the new 
test not only performs well in field conditions, but also has a valuable impact on TB 
morbidity and mortality, when implemented in real-world TB programmatic settings 
(339, 344), its influence on HCPs clinical decision-making, and detection and 
treatment of additional cases. At this stage, an evaluation of the feasibility of 
implementation of the new test in real-life settings and potential challenges to 
implementation is valuable. Further, to evaluate if the delivery systems, infrastructure 
and expertise needed for implementation is available in the specific context and are the 
HCPs able and willing to use the test (202, 339). It is also important to assess 
affordability (can the health system afford the test) and accessibility (will patients have 
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access to the test). The new diagnostic test is usually compared to a reference standard 
or other available diagnostic methods and algorithms and a cost-effectiveness analysis 
comparing the novel test to other alternative diagnostic tools is recommended (202). 
Collecting a comprehensive and solid evidence base is essential in the decision process 
and guide policy makers to reach a conclusion whether to adopt and implement a new 
diagnostic test (340).  
 
1.9 MPT64 antigen detection test 
A diagnostic test based on the detection of MtbC specific antigen MPT64 using 
immunostaining (MPT64 test) has been developed. This test is applicable on smears of 
effusions, aspirates and CSF and tissue sections from formalin-fixed, paraffin-
embedded biopsies.  
1.9.1 Developing the concept of the MPT64 test  
A study was done for in vivo expression of three somatic (MPT57, Hsp65 and Mce1A) 
and eight secreted mycobacterial antigens (MPT64, MPT63, MPT59, MPT53, MPT51, 
MPT46, MPT44 and MPT32) in Mtb infected lymph nodes and lung tissues, using 
IHC staining with primary in-house rabbit polyclonal antibodies (345). All the secreted 
antigens were reported to be found in high levels in the PTB lesions, while in lymph 
node TB the secreted antigens were absent or only detected in low levels, except for 
the MPT64 antigen. The MPT64 antigen was shown to exhibit a consistent 
intracellular expression in tissue sections from the TB lymphadenitis cases (345). 
From this, the hypothesis of a special ability of MPT64 to accumulate in infected host 
cells (Figure 6) was established, and further the idea of developing a diagnostic test 
based on detection of the MPT64 antigens in paucibacillary TB lesions. Additional 
work supported this hypothesis and led to the development of the immunochemistry-
based test using polyclonal anti-MPT64 primary antibodies to detect MPT64 antigens 




Figure 6. Schematic drawing of infected host mononuclear cell. A: Intracellular Mycobacterium 
tuberculosis. B and C: The hypothesis: Mycobacterium tuberculosis secretes protein MPT64 which accumulates 
in the infected host cell.  
 
1.9.2 Antigen detection using anti-MPT64 primary antibody 
The polyclonal anti-MPT64 primary antibody used in the MPT64 test was previously 
raised in-house by immunizing rabbits with purified MPT64 antigen (238, 246, 345). 
The specificity of the MPT64 antiserum was further enhanced by absorbing the 
antiserum with antigen extracts from BCGΔRD2, thus reducing cross-reactive 
antibodies (246). The in-house absorbed polyclonal primary antibody was utilized in 
subsequent studies evaluating the MPT64 test (122, 123, 247, 346, 347). The 
immunostaining is based on a two-step method (Figure 7). First the smear/tissue 
section is incubated with primary anti-MPT64 antibody attaching to and detecting 
MPT64 antigen if present in the sample. Then, the smear/tissue section is incubated 
with horseradish peroxidase (HRP) labelled dextran polymer conjugated with 




Figure 7. Illustration of the two-step method used in the immunostaining procedure. 
 
After these steps, the smear/tissue section is incubated with substrate-chromogen 
solution, 3-amino-9-ethylcarbazole (AEC) containing hydrogen peroxide, this will, in 
the presence of HRP, produce a red-coloured oxidation product. The smear/tissue 
sections are further counterstained with hematoxylin before mounting. The localisation 
and visualisation of the antigen detected by the primary antibody will appear as 
reddish granular precipitates. The identification of antigens is done in the light 




Figure 8. Immunostaining with anti-MPT64 primary antibody. Illustration of positive 
immunohistochemical staining with primary anti-MPT64 antibody. The tissue section is showing a high amount 
of reddish positive spots, and the hematoxylin blue-coloured counterstaining. Photo: Melissa Davidsen Jørstad 
 
1.9.3 Previous studies evaluating the performance of the MTP64 test  
An overview of the previous studies assessing the MPT64 test is presented in Table 1 
and 2. The first study assessing the expression of mycobacterial antigen MPT64 in 
tissue biopsies for diagnostic purposes was published by Mustafa et al. (246). The 
study demonstrated the proof-of principle and assessed the diagnostic potential of the 
MPT64 test in the diagnosis of TB lymphadenitis using formalin-fixed biopsies (246). 
The novel test was compared against nested PCR for IS6110 as the gold standard and 
reported a sensitivity and specificity of 90% and 83%, respectively. The study also 
demonstrated reproducible IHC staining results by repeated staining of all samples 
(246). The second study, by Purohit et al., aimed to further evaluate the performance 
of the MPT64 test among a different study population and including other disease 
sites, showing consistent high sensitivity and specificity of the new diagnostic test in 
different tissues (122). The third study, published by Baba et al., assessed the MPT64 
test in archival pleural biopsies in a high TB and HIV-endemic setting (South-Africa) 
(346), and the reported results agreed with previous studies. 
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Having evaluated the diagnostic potential of the MPT64 test in histological specimens 
from formalin-fixed, paraffin-embedded biopsies, Purohit et al. assessed the MPT64 
test in cytological smears from effusions, CSF and FNAC from various sites (123). 
The sensitivity and specificity of the MPT64 test was reported using a composite 
reference standard (CRS) and to nested PCR as reference standard. Compared to the 
CRS, the sensitivity of the MPT64 test was reported to be 54-76% in the various 
sample materials, but 95-100% using nested PCR as gold standard (123). Another 
important finding described in this study was the high agreement between ICC staining 
of aspirates and IHC staining of biopsies from the same patients (kappa=0.85), 
showing that the less invasive sampling technique can be used in TB diagnosis. 
Additionally, all the initial studies reported that the use of primary anti-MPT64 
antibodies had better performance than immunostaining with commercial anti-BCG 
antibodies and conventional diagnostic methods (122, 123, 246, 346). The findings 
described by Purohit et al. (123) was subsequently confirmed in a different setting by 
Tadele et al. (347). Purohit et al. extended the earlier research by assessing the 
diagnostic potential of the MPT64 test in additional EPTB sites showing consistently 
high sensitivity and specificity (247). 
One of the advantages of the MPT64 test is that it does not depend on sophisticated 
equipment but utilizes technology and procedures often already available in routine 
pathology laboratories. The evaluation of the stained slides is performed using the 
light microscope at x10-40 magnification and the staining gives strong and sharp 
signals with small amount of background staining (122, 123, 247) making the 
interpretation quite easy. The results can be available within 1-2 working days (1 day 
in effusions, aspirates and CSF; 2 days, biopsies due to paraffin-embedding). 
Immunostaining methods are robust and have the ability to detect fragmented 
mycobacterial antigens (224), and thus intact bacterial cell walls are not a prerequisite. 
The MPT64 test is shown to have substantially higher sensitivity than Mtb culture and 
ZN staining, comparable sensitivity and specificity to nested PCR (122, 123, 247, 
347), and advantages compared to PCR of being robust, simple, not prone to 
contamination and requires only minimal equipment. This makes the MPT64 test 
suitable for adoption in low-resource settings with rather modest laboratory facilities. 
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Even though the MPT64 test should be interpreted together with clinical history and 
other laboratory investigations, it can play a valuable role in cases where 
cytology/histology do not show typical features of TB disease. In addition, since the 
MPT64 antigen is specific for MtbC organisms, the MPT64 test can differentiate 
MtbC infections from NTM and other granulomatous diseases, potentially reducing 
overdiagnosis of TB and increasing correct diagnosis. 
As described, several studies, using various EPTB specimens from different settings, 
have assessed the diagnostic performance of the MPT64 test against either PCR or a 
CRS as the gold standard, mostly in case-control study designs in relatively controlled 
research settings. Using case-control comparisons is known to potentially overestimate 
a test`s diagnostic accuracy (202). Still, the positive and consistent findings from the 
previous studies show that the MPT64 test may have the potential to improve the 
diagnosis of EPTB and warrants the assessment of the diagnostic test performance 
under field conditions among patient populations where such a TB diagnostic test is 
clinically indicated. It would also be important to assess the feasibility of 
implementation of the new test in routine diagnostic settings and identify potential 
obstacles and challenges. Expanding and building a more profound and comprehensive 
evidence base for the MPT64 test will ultimately assist in the decision process whether 
to up-scale and adopt and implement this novel test in the diagnostic algorithm in 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2. RESEARCH AIMS 
 
The primary aim of this thesis was to improve the diagnosis and management of EPTB 
cases in a low-resource setting at a referral hospital in Zanzibar. 
Secondary aims: 
 To implement the MPT64 test in routine diagnostics and evaluate the test for 
the diagnosis of EPTB as compared with the routine tests and GeneXpert® 
MTB/RIF assay (paper I and unpublished data). 
 
 To study the health care seeking pathways by presumptive EPTB patients and 
identify factors associated with diagnostic delay, and to assess the impact of 
anti-TB treatment on self-rated health among EPTB patients (paper II). 
 
 To describe the clinical presentation of EPTB among patients, and to describe 
the effect of anti-TB treatment on clinical parameters. Further, to assess if 
simple clinical parameters, without laboratory support, could be used to reliably 







3. MATERIALS AND METHODS 
 
3.1 Study setting 
This study was performed at the main referral hospital in Zanzibar, Mnazi Mmoja 
Hospital (MMH). Zanzibar which comprises the two main islands, Unguja and Pemba, 
and some smaller inhabited and uninhabited islands, is situated off the coast of 
Tanzania mainland. In 1964, Zanzibar merged with Tanganyika to form The United 
Republic of Tanzania, but Zanzibar retained its own government and has substantial 
independence in internal affairs, whereas defense and foreign affairs are managed by a 
central government. Administratively, Zanzibar is divided into five regions, three in 
Unguja and two in Pemba, and each region is further divided in two districts.  
The population in Zanzibar is 1.3 million inhabitants, and 42.5% of the population is 
<15 years of age (348). Life expectancy increased from 57 years in 2002 to 65.2 years 
in 2012 and infant mortality rate declined from 61 in 2004/05 to 46 per 1000 live 
births in 2012 (349). The HIV prevalence is 1% in the adult population aged 15-49 
years, 1.1% HIV positives among women and 0.9% among men (350). According to a 
national survey in 2012, the estimated prevalence of bacteriologically confirmed PTB 
in the adult population is 124 per 100 000 (291). Although there has been an increase 
in TB cases notifications from 350 in 2000 to 855 notified TB cases in 2015 (351), the 
notified cases is far below the estimates. EPTB accounted for 23-30% of the new TB 
cases notified between 2013-2015, the TB treatment success rate in the same period 
was 87-91%, HIV testing was performed among 93-96% of the registered TB patients 
and 14-18% of the patients tested were HIV positive (351).  
3.1.1 The health care system in Zanzibar  
The Ministry of Health (MoH) regulates, governs and coordinates all health-related 
issues in the region. Health services are provided through operating departments of the 
MoH and specialized programs such as malaria, TB and leprosy control programmes. 
Besides public health facilities governed by the MoH, other health facilities are under 
the armed forces. In addition, the private sector, development partners, faith-based and 




geographical distribution of the various health facilities is shown in figure 9. Most of 
the private health facilities are located in urban areas, whereas there is a fair 
distribution of public health facilities across Zanzibar. Ninety-five percent of the 
Zanzibari citizens live within 5 km of a public health facility (352). 
 
Figure 9. Distribution of health care facilities in Zanzibar. In 2013/14, there were 71 private 
clinics/dispensaries (11 in Pemba, 60 in Unguja) and 4 private hospitals (all at Unguja) (353). In addition, but not 
shown in the figure, there were 25 private pharmacies and 335 over-the -counter drug shops (170 in Pemba, 165 
in Unguja). Abbreviation: FBO, faith-based organization. Figure from «Zanzibar Health Sector Strategic Plan III 
2013/14-2018/19 » (352), reprinted with permission from the Ministry of Health, Revolutionary Government of 
Zanzibar. 
 
In the public sector the health care system is divided in primary, secondary and tertiary 
level of health care (Figure 10) (352). At the primary level, the primary health care 
units (PHCU) deliver basic outpatient services, such as treatment of minor injuries and 
common diseases, maternal and child health care and health promotion activities, both 
at the facility and the community-level. The PHCU+ provides in addition basic 
laboratory, delivery, dispensing and dental services. The PHCU/PHCU+ refer to 




MMH. MMH, with a capacity of 400 beds, provides tertiary level of health care to all 
districts, and primary and secondary services to some districts.  
 
Figure 10. Levels of the public health care system in Zanzibar. The tertiary level comprises 1 referral 
hospital (Mnazi Mmoja Hospital) and the 2 special hospitals, Mwembeladu maternity home (34 bed capacity) 
and Kidonge Chekundu psychiatric hospital (110 bed capacity), all located in Unguja Island (352). The 
secondary level consists of 3 district hospitals (80-120 bed capacity) situated in Pemba Island, these hospitals 
have inpatient medical, basic surgical and diagnostic services, in addition to providing outpatient health care 
(352). The primary health care centres, deliver outpatient services, basic inpatient care (30 beds) and diagnostic 
services such as ultrasound and x-rays. Abbreviations: PHCC, primary health care centre;  
PHCU, primary health care unit.  
 
3.1.2 Zanzibar Integrated HIV, Tuberculosis and Leprosy Programme 
The Zanzibar Tuberculosis and Leprosy Programme (ZTLP) was established by the 
MoH in 1987 (351). In 2012, the ZTLP was officially joined with Zanzibar AIDS 
Control Programme to form the Zanzibar Integrated HIV, TB and Leprosy Programme 
(ZIHTLP) (351). The ZIHTLP facilitates and coordinates all activities related to HIV, 
TB and leprosy prevention, treatment and control in Zanzibar. The TB services are 
integrated and provided by the public health sector at all three levels. Anti-TB 
treatment, free of charge for the patients, is given according to international 




under DOT, as do a few private health facilities which has an agreement with the MoH 
to provide these services. The patient can choose to receive anti-TB treatment under 
facility-based or community-based DOT and a treatment supporter of their own chose. 
Most of the registered TB patients in Zanzibar are choosing treatment as community-
based DOT (351). TB case-finding is still predominantly passive, relaying on patients 
contacting the health care system, with exceptions of contact tracing around smear 
positive PTB patients and screening of HIV positive patients, prisoners and people 
staying in sober living houses. 
3.1.3 Tuberculosis diagnostic capacity in Zanzibar 
In 2015 there were 52 diagnostic sites (33 in Unguja and 19 in Pemba) performing 
AFB smear microscopy (351) and one laboratory providing mycobacterial culture. The 
implementation process of establishing a reference laboratory performing TB solid 
culture and identification of Mtb at the Public Health Laboratory-Ivo de Carneri (PHL-
IdC) was started in 2007 (148). Before this, if requiring mycobacterial culture and 
DST, the specimen was sent to the Central Tuberculosis Reference Laboratory 
(CTRL), Muhimbili Hospital, Dar es Salaam. In 2010, the PHL-IdC was recognized as 
the national reference laboratory for mycobacterial culture in Zanzibar (148). During 
the study period, if species identification and DST were required, the positive cultures 
had to be sent from PHL-IdC to CTRL. The Xpert assay was introduced at MMH in 
early 2014, and used mainly for Mtb detection in sputum specimens (351). The 
laboratory at MMH is the only public laboratory performing cytological and 
histological evaluation of body fluids, aspirates and biopsies. In the year before the 
current study, the PHL-IdC only received few specimens for mycobacterial culturing 
sampled from extrapulmonary sites. Thus, prior to the present study, the diagnosis of 
EPTB in Zanzibar relied almost entirely on clinical presumptive EPTB based on the 
patients` medical history and signs and symptoms suggestive of EPTB, supported in 





































































































































































































This was a prospective cohort study, consecutively including presumptive EPTB 
patients from various in- and outpatient departments at MMH hospital. The cohort was 
examined and interviewed at baseline, before the decision to start anti-TB treatment 
was reached, and followed until a local clinician decided to initiate anti-TB treatment 
or an alternative diagnosis was given. The patient group commencing anti-TB 
treatment was followed until the treatment was completed. A CRS was used to 
categorize the patients as TB, non-TB and uncategorized cases. Further local health 
personnel at MMH were interviewed in-depth by the PhD-fellow to get an 
understanding of the facilitators and challenges associated with the implementation of 
the MPT64 test and sustainability in the future.  
 
3.2.1 Preparation of the study  
The semi-structured study questionnaire (Appendix A) was developed after a literature 
review of other studies deliberating on similar topics. Most of the questions included 
were adapted or drawn from previous studies covering the same field of interest. The 
first English version was translated to Swahili, and then the first Swahili version back 
to English. The two English versions were then compared, reviewed and discussed 
with two experts familiar with the research subject and construct of interest to further 
assess the content validity. Both language versions were evaluated by two bilingual 
Zanzibaris and the Swahili version was tested in a pilot-study in May 2014 among 
inpatients at MMH. This, to further accommodate the language according to the study 
setting and identify questions that were ambiguous or poorly understood by the 
respondents.  
Standard operating procedures (SOP) for sample processing, storage, ICC and IHC 
staining (Appendix B) were developed, tested, optimized and adjusted to the specific 
setting prior to the inclusion of study samples. Two laboratory technologists at MMH 
were trained in performing the immunostaining technique, and the pathologist in the 
evaluation of the test and generation of reports. This training was done in collaboration 
with Muhimbili National Hospital, Dar es Salaam, The United Republic of Tanzania, 




south) collaboration. After the first training session the PhD-fellow provided 
continuous training and supervision of the laboratory technologists during the study 
period to optimize the staining procedure in this specific setting and assuring the 
quality.  
As EPTB can affect all organs we expected to find presumptive EPTB patients 
hospitalized in the various departments/wards, and in the outpatient Chest/TB clinic, 
fine-needle aspiration clinic and other outpatient departments. Information meetings 
were held for the clinicians in the different wards regarding the current study, the new 
diagnostic test, which specimens to collect and containers/tubes to use for the collected 
specimens and where to send the specimens. This information was repeated several 
times to the various wards during the study, to account for new staff members and 
rotation of clinician to other wards.   
AFB microscopy and cytological/histological evaluation of tissue/fluid samples were 
already established at MMH before the study. Mtb detection in sputum using the Xpert 
assay was also in place and was expanded to include extrapulmonary specimens during 
the study period. The extrapulmonary specimens were stored, prepared and analysed 
according to the WHO recommended protocol (167). The national TB reference 
laboratory, PHL-IdC, scarcely cultured extrapulmonary specimens prior to the study. 
An agreement was therefore established for transportation and culturing of 
extrapulmonary specimens during the current study.       
                                                                                                                                                    
3.3 Data collection 
3.3.1 Study participants and patient interviews  
Presumptive EPTB cases from various in- and outpatient departments at MMH were 
invited to participate in the study. The inclusions criteria were; clinical presumptive 
EPTB and written informed consent and a specimen sampled and sent for laboratory 
investigations from the presumptive site of EPTB infection. The exclusion criterion 
was anti-TB treatment during the previous year. Those fulfilling the criteria, were 
consecutively enrolled during thirteen months from August 2014 until the end of 





Figure 12. Study participants: presumptive EPTB patients. Picture A, presumptive TB lymphadenitis; 
Picture B, chest x-ray of a patient with presumptive TB pleuritis. Photo: Melissa Davidsen Jørstad. 
 
At the time of inclusion all patients were interviewed face-to-face at the MMH using 
the semi-structured questionnaire. All interviews were conducted in the local language, 
Swahili by two local clinicians (study clinicians), fluent in both Swahili and English. 
The interviewers had received prior training in the data collection by the PhD-fellow. 
If possible, the interviews were performed in a private room. The answers were 
handwritten by the interviewer in the patient`s study folder. A separate folder was used 
for each patient throughout the study. TB registers, TB treatment cards and patient 
medical records were used to countercheck some of the information given. 
The EQ-5D 3 level version (EQ-5D-3L), developed by the EuroQol Group (331), was 
used to assess the self-rated health status of the included adult EPTB patients before 
and after anti-TB treatment to evaluate the impact of treatment on self-reported health. 
The instrument was provided in Swahili and instructions were written in Swahili, and 





Figure 13. Patient interviews at the time of inclusion. Picture C, Dr Hasnu Makame Mwazini, one of 
the study clinicians performing a patient interview (reprinted with permission). Photo: Melissa Davidsen Jørstad. 
 
At baseline a full physical examination was performed and recorded in a standardized 
form in the patient’s study folder. Lymphadenopathy was drawn onto a figure (Figure 
14), and number and size of the lymph node enlargements, determined using an eye 
estimate or measuring tape when available, were carefully recorded. The physical 
examination was conducted by one of the study clinicians together with the PhD-
fellow.  
 
Figure 14. Schematic drawing used for documentation of lymphadenopathy at the time of inclusion. 
3.3.2 Biological specimens and sample processing 
At inclusion biological specimens were collected from the presumptive sites of EPTB 
infection. Effusions and CSF were aspirated aseptically into sterile tubes. FNAC was 
performed using 23-g needle from palpable lymph nodes. Surgical tissue biopsies were 




fixated in 4 % phosphate-buffered formaldehyde solution and the other half stored in 
0.9% saline for mycobacterial culture.  
 
Figure 15. Collection of biological specimens at the time of inclusion. Picture D, surgical biopsy; 
Picture E, fine needle aspiration cytology from a lymph node. Photo: Melissa Davidsen Jørstad. 
 
Smears from fine-needle aspirates were prepared bedside, two for ICC staining (air-
dried and alcohol fixated before transportation to the laboratory), and one each for 
AFB microscopy and cytology. Further, sterile 0.9% saline solution (2 ml) was used to 
rinse the needle and the fluid divided equally in two tubes, for mycobacterial culture 
and the Xpert assay. The formalin-fixed biopsies were embedded into paraffin blocks, 
and 5µm thick sections were obtained from the blocks using a sliding microtome. 
Effusions, CSF and pus/abscess material were sent directly to the laboratory in tubes, 
each specimen was divided in three to four tubes (or collected in three to four tubes if 
enough material), for mycobacterial culture, Xpert assay, microbiological culture, 
Gram stain or other special stains depending on the clinical presentation, cytology and 
ICC staining. Smears for cytology and ICC staining were made from the sediment 





Figure 16. Sample processing. Picture F and G, smears from fine-needle aspirates prepared bedside; 
Picture H, formalin-fixed biopsy, Picture I, pleural effusion. Photo: Melissa Davidsen Jørstad. 
 
3.3.3 Diagnostic laboratory procedures 
3.3.3.1 Acid fast bacilli microscopy 
The ZN staining technique was used to detect AFB by microscopy in smears and tissue 
sections from biopsies according to the standard SOPs at MMH.  
3.3.3.2 Mycobacterial Culture 
Specimens for mycobacterial culture was transported to PHL-IdC, on Pemba Island. 
At PHL-IdC the samples were centrifuged at 5040 rpm for 15 minutes, the supernatant 
was discarded and 100 µl of the sediment was inoculated into LJ medium. The 
remaining sediment was stored and examined after 1-2 days for contamination. If 
contaminated, the specimen was decontaminated with 4% sodium hydroxide for 15 
minutes, the suspension neutralized with phosphate buffer, centrifuged at 5040 rpm for 
15 minutes, and 100 µl of the sediment inoculated on LJ medium. The inoculated 
tubes were incubated at 36.1°C and examined for growth of mycobacteria weekly for 8 
weeks.  For tubes identified as positive (creamy colonies), the presence of 
mycobacteria was confirmed by ZN smear. Positive cultures were sent to the CTRL, 




specimens were stored at MMH at 4°C and shipped by air to PHL-IdC. Since 
transportation of extrapulmonary samples from MMH to PHL-IdC was not generally 
done in routine TB diagnostics some specimens were not sent for culture, further, 
shipment was occasionally delayed, and a few samples were sent for culture but for 
unknown reasons results were missing.  
3.3.3.3 Xpert ® MTB/RIF 
Before the current study, the Xpert assay was used in routine TB diagnostics 
preferably for detection of Mtb in sputum specimen. During the study, SOPs for 
processing of extrapulmonary samples was developed by the laboratory personnel at 
MMH based on the WHO recommend protocol (167). The Xpert assay was performed 
in aspirates and fluid samples, not in biopsies. Shortly, Xpert MTB/RIF sample 
reagent was added to the specimen container in a 2:1 ratio. The container was shaken 
for ≥ 10 seconds, incubated at room temperature for 10 min, shaken again for ≥ 10 
seconds and incubated for 5 min. Then, 2 ml of the processed sample was transferred 
to the Xpert MTB/RIF cartridge. The cartridge was loaded into and the specimen 
analyzed by the GeneXpert instrument according to instructions from the 
manufacturer. For CSF, equivalent volume of sample reagent was added if CSF 
volume was 1-5 ml, if CSF volume was < 1 ml, sample reagent was added to a total 
volume of 2 ml. The sample mixture (2 ml) was then added to the Xpert MTB/RIF 
cartridge and loaded into the instrument. As recommended, the specimens were stored 
at 4°C  and processed within 7 days (167). Due to scarcity in the availability of 
cartridges for some time periods during the study, sputum samples had to be 
prioritized and thus many of the extrapulmonary samples were not examined with the 





Figure 17. Diagnostic procedures. Picture J, technologist performing immunostaining (reprinted with 
permission); Picture K, mycobacterial culture on Lowenstein-Jensen medium; Picture L, supernatant of pleural 
effusion. Protein and glucose concentrations were estimated in the supernatant. Photo: Melissa Davidsen Jørstad. 
3.3.3.4 Histology/cytology 
The smears from FNAC, effusions and CSF, and tissue sections from biopsies were 
stained as per routine with Papanicolaou staining and haematoxylin and eosin staining, 
respectively. The cytological and histological evaluation was done by the experienced 
local pathologist. The results from cytology/histology were evaluated as 
morphological consistent with mycobacterial infection based on specific criteria 
(Table 3 and 4). In effusions and CSF, smears showing a lymphocytic predominance 
was noted as suggestive of TB.  
Table 3.  Histomorphological features taken as consistent with TB in tissue sections from biopsies  
Granulomas without necrosis  
Granulomas with necrosis 
Poorly formed granulomas with necrosis 
Necrotic material 
 Suppurative inflammation with necrotic background 
 Necrosis without granulomas, but with suggestive inflammatory component present 





Table 4.  Cytomorphological features taken as consistent with TB in fine-needle aspirates  
Granulomatous inflammation without necrosis 
Granulomatous inflammation with necrosis 
Necrotic material 
 Suppurative inflammation with necrosis 
 Lymphoid cells and necrosis 
 Necrosis only 
 
3.3.3.5 Immunostaining – the MPT64 test 
We assessed the reproducibility of the immunostaining procedures in the specific 
study setting before the inclusion of study specimens. Slides from the same specimen 
were stained on consecutive days by two laboratory technologists and the slides 
assessed by different observers (run-to-run reproducibility, inter- and intra-observer 
reproducibility). Further, several slides from the same specimen was stained in one run 
(within-run reproducibility). During the study, the laboratory technologists performed 
the immunostaining two times a week. Cohen`s κ was calculated to determine the 
inter-observer agreement between the local pathologist at MMH and two independent 
observers at HUH, Bergen, Norway. Slides were sent to HUH and evaluated separately 
by two of the PhD-fellow’s supervisors (T.M. and L.S.), who both were blinded for the 





Figure 18. Inter-observer agreement. Immunostaining was evaluated by three independent observers. 
Fourteen slides were assessed by observer 1 and observer 2. Observer 3 evaluated 13 of the same slides. 
 
Two controls were included in each run of the immunostaining. The positive control 
used were tissue sections form a lung biopsy (Mtb culture positive) provided by the 
Department of Pathology, HUH, Norway, previously showing consistently positive 
results with the MTP64 test. As negative control, we used the same specimen omitting 
the primary antibody in the staining procedure, thus assuring absence of nonspecific 
binding of the secondary antibody. 
 
 
Figure 19. The MPT64 test - positive signals. The pictures demonstrate positive signals in FNAC smears 
from lymph nodes. The MPT64 antigens were stained red-coloured and seen as intracytoplasmic granular spots 





3.3.3.6 Turnaround time of immunostaining and Mtb culture 
The time-to-results of immunostaining and mycobacterial culture were documented 
(Figure 20). The total median time, from specimen collection until the results were 
available to the clinician was 7.5 days (interquartile range (IQR) 6-13 days) for 
immunostaining and 64 days (IQR 62-69 days) for mycobacterial culture. 
 
Figure 20. Turnaround time for the MPT64 test and Mycobacterium tuberculosis culture. A: MPT64 
test. B: Mycobacterial culture. Abbreviation: PHL-IdC, Public Health Laboratory-Ivo de Carneri. 
 
3.3.4 Clinical follow-up of patients 
All patients were followed until a decision was reached by the local clinician to initiate 
anti-TB treatment. The alternative diagnoses were noted among those not starting anti-
TB treatment. The patients commencing anti-TB treatment were followed on at least 
two occasion; 1) after the intensive phase of treatment; 2) after treatment was 
completed. At follow-up visits the patients were examined by one of the study 
clinicians together with the PhD-fellow. A medical history was taken, and a physical 
examination was conducted. All reported symptoms and signs and objective findings 




and results of diagnostic imaging if available. Weight changes between baseline and 
follow-up visits were recorded. The longest diameter of the largest lymph node 
swelling was used when evaluating regression of lymph nodes at two intervals; 1) 
between baseline and 2 months of anti-TB treatment, 2) between 2 months of anti-TB 
treatment and treatment completion. Adult patients on anti-TB treatment were asked to 
complete the EQ-5D-3L at treatment completion. 
Figure 21.  Patient follow-up during treatment. Picture P, documentation of weight at follow-up 
(reprinted with permission); Picture Q shows a patient with TB lymphadenitis before the initiation of anti-TB 
treatment and picture R presents the same patient after 6 months of treatment. Picture S shows a chest x-ray in a 
TB pleuritis case at the time of commencing anti-TB treatment and picture T is a chest x-ray in the same patient 
after 4 months of anti-TB treatment. Photo: Melissa Davidsen Jørstad. 
 
3.3.5 In-depth interviews of health personnel 
Local health personnel working in the National TB programme and various 
departments at the MMH were purposively selected for in-depth interviews. This 
sampling strategy was chosen to cover the spectrum of health care workers being 
involved in the implementation of the new diagnostic test. In-depth interviews were 
performed as audio-recorded, face-to-face interviews, using a semi-structured 




PhD-fellow and discussion with co-authors, and comprised open and close-ended 
questions. The interviewer could change the order of the questions and rephrase or 
clarify confusing questions or ask follow-up questions not included in the interview 
guide to further investigate topics introduced by the respondent. All interviews were 
conducted in English by the PhD-fellow. The duration of each interview was between 
30-60 minutes. The interviews were carried out in various private offices at the study 
site.  
A qualitative researcher transcribed the interviews verbatim in English. When the 
transcriber experienced unclear conversation, the transcriber left an open field in the 
sentence. The audio-recordings and transcripts were double-checked by the 
interviewer, and together with consulting the field notes, unclear words/phrases were 
filled. The transcribed data was read, and re-read, together with listening to the audio-
recordings to get familiar with the data. One interview was coded manually by the 
PhD-fellow using OpenCode version 4.02 and a list of codes was developed from the 
first interview. Two other co-authors read the first interview and assessed the 
developed codes, followed by a thorough discussion of the content and codes in the 
research team to resolve ambiguities. Subsequently, the remaining interviews were 
coded, and the coding list were revised and expanded if new key issues emerged from 
reading the transcripts.  
 
3.4 Definitions  
TB case definition 
The study participants were categorized after the study as TB cases (confirmed, 
probable or possible) or non-TB cases using a CRS as described in paper I. The 
combination of the various diagnostic criteria defining each CRS category is presented 
in table 5. Patients not fulfilling the definition as a TB or non-TB case were defined as 
uncategorized cases and excluded from further analyses in paper I and III. In paper II, 
a less strict approach was used, and the uncategorized cases in paper I and III were 




TB treatment based on clinical presumptive EPTB and as a non-TB case if anti-TB 
treatment had not been initiated. 
Table 5.  Algorithm for defining categories of the composite reference standard 
a Positive: presence of pleural/peritoneal effusion, signs of skeletal TB, infiltrates/nodules consistent with 
tuberculosis. 
b Positive: cytology/histology shows morphological features consistent with tuberculosis, effusion/CSF shows 
lymphocytosis on fluid cytology and protein level > 3 g/dl (> 1 g/l for CSF). 
c Response to antituberculosis treatment evaluated at 2-3 months and treatment completion – response to 
treatment is marked with a positive sign.  
* Response to treatment not included in this definition. 
** Patients died or were lost to follow. 
*** Patients improving without anti-TB treatment or cytology/histology concluded other diagnosis than 
TB or alternative diagnosis concluded by the local clinician or non-response to anti-TB treatment. 
Abbreviations: CRS, composite reference standard; Xpert, Xpert® MTB/RIF assay, AFB, acid fast bacilli; PTB, 





Definitions of delay (Paper II) 
 
Figure 22.  Chart showing the different delays. All modern health facilities, both in the public and the 
private sector, and registered pharmacies were defined as health care providers, thus excluding non-formal health 
care providers such as over-the counter drug stores and traditional healers.  
 
3.5 Statistical analysis 
The Chi-square test was used in all papers to compare group differences in categorical 
variables. In paper I, cross-tabulations were used to evaluate sensitivity and specificity 
with 95% confidence intervals, further, positive predictive and negative predictive 
values and accuracy. In paper II and III, non-parametric tests were used to evaluate 
group differences of continuous variables, the Mann-Whitney test for two-group 
comparison, the Kruskal-Wallis test for more than two groups and the Wilcoxon-
signed rank test when comparing related samples. The significance level (α) was set to 
0.05 in all analyses. In paper II and III, due to multiple testing, Bonferroni correction 
was applied to the significance level (α = 0.05/number of tests).   
 
3.6 Ethical considerations 
Ethical clearance was secured from the Regional Committee for Medical and Health 
Research Ethics (REK), Western-Norway (2014/46/REK vest) and from the local 
authorities in Zanzibar, the Zanzibar Medical Research and Ethics Committee 




mentioned in papers I-III. The study participants gave written consent before being 
included in the study, and were additionally asked to sign a separate consent for the 
transfer of collected biological samples and de-identified data to HUH, Bergen, 
Norway. The samples were stored in an approved biobank (Project number NSD no 
12032) for future research studies. A material transfer agreement for the transferal of 
biological material was established between MMH and HUH, and a permission to 
transport the biological samples was received from MoH, Revolutionary Government 
of Zanzibar. Permission to publish data from the project was also obtained from 
ZAMREC.  
For in-depth interviews, all participants provided informed written consent before the 
interview. The participants were given the opportunity to read through the transcripts 
of their interview and give comments and/or corrections. Further, the participants will 
be given the possibility of reading the final manuscript before it is submitted for 




4. SUMMARY OF RESULTS 
 
4.1 MPT64 antigen detection test improves routine diagnosis of 
extrapulmonary tuberculosis in a low-resource setting: A study from 
the tertiary care hospital in Zanzibar (Paper I)  
Jorstad MD, Marijani M, Dyrhol-Riise AM, Sviland L, Mustafa T. PLoS One. 2018; 
13(5):e0196723. 
In total, 132 patients with presumptive EPTB were included at MMH and categorized 
as TB cases (confirmed TB, n = 12; probable TB, n = 34; possible TB, n=18), non- TB 
cases (n = 62) and as uncategorized cases (n = 6). Only categorized patients were 
included in the analyses. The specimens were FNAC from lymph nodes (n = 66), 
effusions (pleural, n=31; ascites, n=16; pericardial, n=1), CSF (n = 8), biopsies (n = 
21) and pus/abscess material (n = 2).   
Among specimens collected from the TB cases the MPT64 test showed the highest 
proportion of positive results (45/69, 65%), compared to ZN staining (8/69, 12%), 
culture (8/60, 13%) and the Xpert assay (6/38, 16%). Further, the MPT64 test 
demonstrated 81% positivity in specimens subjected to all four diagnostic tests. The 
MPT64 test was positive in 6/8 (75%) culture positive samples and in all Xpert assay 
and/or ZN positive samples. Compared to the CRS the MPT64 test showed an overall 
sensitivity and specificity of 69% and 95%, respectively, and the accuracy was 82%. 
The best test performance was found in TB lymphadenitis, with sensitivity, specificity 
and accuracy of 79%, 97% and 88%. Further, the sensitivity was significantly higher 
in paediatric TB compared to TB in adults (sensitivity, 100% versus 58%).   
Cytomorphological features consistent with TB were present in only 56% of the TB 
lymphadenitis FNAC specimens (n = 34). In TB specimens without cytomorphology 
consistent with TB, the MPT64 test, ZN staining, culture, and the Xpert assay was 





4.2 Implementation of the MPT64 test for diagnosing 
extrapulmonary tuberculosis: facilitators and challenges  
(partly included in paper I, and unpublished) 
A total of 9 in-depth interviews were conducted. All the informants were male, and the 
age range was from 28 to 53 years  
The data analysis of this study is not yet completed. The preliminary results show that 
the participants identified the need for improving the diagnosis of EPTB. Lack of 
trained personnel to perform invasive sampling, costs involved in laboratory 
investigations, procurement and availability of reagents and equipment, and challenges 
associated with changing the practice of empirical treatment were identified as some of 
the main challenges associated with the long-term sustainability of the test. Regular 
information and education in Swahili, improving the collaboration and communication 
between the hospital wards, the TB programme and the laboratory, guideline on what 
samples to collect and where to send the samples when EPTB is a differential 
diagnosis, and short turnaround time of the diagnostic test, were some of the 




4.3 Diagnostic delay in extrapulmonary tuberculosis and impact on 
patient morbidity: A study from Zanzibar (Paper II) 
Jorstad MD, Aẞmus J, Marijani M, Sviland L, Mustafa T. PLoS One. 
2018;13(9):e0203593 
Of 146 identified patients presenting with clinical presumptive EPTB at MMH, 132 
patients were included, and categorized as TB cases (n = 69) and non-TB cases (n = 
63). We evaluated care seeking pathways and behaviour among these patients. Most 
patients reported MMH (30%), PHCUs (24%) or private clinics/dispensaries (17%) as 
their first contact with a HCP after the onset of the current illness. Forty-six percent 
reported self-medication before care-seeking. When excluding cases only visiting 
MMH, repeated visits to the same health care level before being referred to MMH was 
reported among 45/99 (45%) of the patients. Among the TB cases, 56/69 (81%) 
reported repeated consultations at MMH, 31/69 (48%) described ≥ 4 visits to any 
HCPs and 18/69 (26%) had been in contacting with ≥ 3 different HCPs before anti-TB 
treatment was initiated.  
In TB cases, the median total, patient and health system delay were, 62 days (IQR, 31-
126 days), 14 days (IQR, 5-28 days) and 34 days (IQR, 19-76 days), respectively. In 
comparison to other extrapulmonary sites of disease, TB lymphadenitis cases reported 
both a significantly longer patient and total delay. A delay exceeding > 6 months was 
reported among 26% of the lymphadenitis patients. A shorter health system delay was 
experienced by patients initially seeking care at MMH and among patients with ≤ 3 
health care visits. 
The general PTB knowledge among the respondents was relatively good, but EPTB 
knowledge was low, only one respondent answered an extrapulmonary site of TB 
disease.  
Among the adult TB cases 39/47 (83%) experienced that the ongoing illness affected 
their working capacity. The median reported days of reduced capacity or stopped 
working altogether was 60 days (IQR, 21-90 days). Assessing the self-rated health 




lymphadenitis patients reported better EQ VAS scores (lymphadenitis, median 79%; 
other sites, median 50%) and lesser problems on the EQ-5D descriptive system at 
baseline as compared to patients with other disease sites, both groups reported 
significantly higher EQ VAS scores (lymphadenitis, median 96%; other sites, median 





4.4 Evaluation of treatment response in extrapulmonary 
tuberculosis in a low-resource setting (Paper III) 
Jorstad MD, Dyrhol-Riise AM, Aẞmus J, Marijani M, Sviland L, Mustafa T. BMC 
Infectious Diseases2019; 19:426 
In this study the 62 non-TB cases and 64 TB cases were included. The presumptive 
site of EPTB infection were lymphadenitis (n = 67), pleuritis (n = 31), peritonitis (n = 
16), meningitis (n = 8), spondylitis/osteomyelitis (n = 2), pericarditis (n = 1) and 
mastitis (n = 1). Local symptoms were described by all patients, while constitutional 
symptoms were reported by 73% of the patients. There was no difference between TB 
and non-TB patients regarding the type and frequencies of constitutional symptoms. 
Among TB cases, 52/64 (81%) patients were followed during the course treatment. 
After 2 months of anti-TB treatment an overall clinical improvement was reported in 
all patients, and regression of lymphadenopathy and pleural effusion was reported in 
the majority of patients. The weight increased with ≥5% in 36/49 (73%) after 2 months 
of treatment, and in 38/46 (83%) of the TB patients after finishing treatment.  
We suggest that a combination of three clinical parameters; clinical improvement, 
weight gain and regression of objective findings, can be incorporated in a simple 
assessment tool and used in the evaluation of treatment response in EPTB patients. 
Among the TB patients 47/48 (98%) fulfilled ≥2 parameters at 2 months as compared 
to 0 or 1 parameter among non-TB patients (n=7). A simple tool to assess treatment 
response is feasible for implementation in low-resource settings with the potential of 






5.1  Methodological considerations  
5.1.1 Study design, study population and follow-up period 
This study was designed as a prospective cohort study, where the study participants 
were consecutively included, followed and observed during anti-TB treatment or until 
alternative diagnoses were concluded. The enrolled study subjects were categorized as 
TB or non-TB patients based on a set of criteria, the CRS. The STARD checklist 
giving guidelines for the reporting of diagnostic accuracy studies (342) were followed 
as closely as possible in presenting the evaluation of the performance of the MPT64 
test (paper I). Further, data collected at baseline and follow-up visits, such as weight, 
regression of clinical findings and responses using the EQ-5D-3L instrument as a 
measure of self-reported health status were presented (Paper II and III). Even though 
the study was designed as a prospective cohort, some data gathered at baseline using 
the study questionnaire included retrospective data regarding variables such as health 
care seeking pathways and symptoms onset. One of the strengths of our prospective 
cohort study design is that all the patients went through the same interview (using the 
study questionnaire), clinical examination and laboratory investigations irrespective of 
their final diagnosis as TB or non-TB cases. The limitation with this design is that it 
was time consuming and some of the study subjects were lost to follow or died before 
follow-up.  
5.1.1.1 Recruitment of patients  
Even though our recruitment site was MMH, our aim was to invite all patients 
presenting with presumptive EPTB at Unguja Island, based on the knowledge during 
the project planning that all patients with presumptive EPTB at Unguja Island were 
referred to MMH. However, during the study, we experienced that many patients were 
not referred to MMH and anti-TB treatment was started outside the hospital, at 
peripheral PHCU and PHCC. We applied and received the approval from ZAMREC to 
include patients also from two PHCC, one in the north and one in the south at Unguja 




difficult to send samples from these sites. As one of the inclusion criteria was 
collection of a biological specimen from the presumptive site of TB infection, patients 
without specimens for laboratory investigations were excluded from the study. This 
led to study participants only being recruited from the various wards and outpatient 
departments at MMH, and we did not attain our goal of inviting all presumptive EPTB 
patients at Unguja Island. As a consequence our sample size is smaller than expected. 
At MMH, including patients from the fine needle aspirate outpatient clinic and patients 
who had been referred to the TB clinic were done without major difficulties. It was 
more challenging to trace and include patients admitted in the hospital. The study 
researcher went around the hospital several times a week consulting the hospital 
clinicians if there were any presumptive EPTB patients admitted. In addition, several 
information meetings regarding the current study and when to suspect EPTB were 
given on several occasions to the hospital staff. Still, some patients were missed due to 
various reasons, such as biological samples from the presumptive site of infection 
were not collected or patients being started on treatment prior to collection of 
specimens for investigations. 
5.1.1.2 Follow-up visits 
In our study design, the follow-up of patients commencing anti-TB treatment was 
planned after the intensive phase (2 months), and completion of treatment. However, it 
is recommended that that the clinical treatment response should be evaluated after one 
month among patients starting anti-TB treatment without histology suggestive of TB 
or bacteriological confirmed TB (91). Since the ZIHTLP offers TB treatment services 
as DOTS, we assumed that we could obtain information regarding clinical response to 
treatment after one month from the TB register or TB treatment cards. This proved to 
be challenging as the information available in the TB register and treatment cards 
among EPTB cases were limited. In addition, most patients in this setting were 
choosing community-based  DOTS (351),  as a result, many of the patients did not 
visit the hospital for routine follow-up during treatment. Thus, the follow-up data is 
available for only 2 and 6 months. This is a limitation of the study design and we 




differently, potentially as home visits, at least monthly for the first 3 months of 
treatment. This would have given the opportunity to evaluate the simple clinical 
parameters as an assessment tool for response to treatment (paper III) at an earlier time 
point.  
At the time of inclusion, medical history, including direct questions covering 
symptoms from various organ systems and the onset of symptoms, were included in 
the study questionnaire. Physical examination was reported using a standardized form 
formatted as check boxes. At follow-up visits standardized questions or examination 
forms were not used, and signs, symptoms and findings from the physical examination 
were instead documented as a continuous text in the patients’ study folder. Due to lack 
of standardized questionnaires and forms during follow-up visits some details of the 
clinical information could have been missed, and this potentially avoided using such 
tools. Further, the comparison of symptoms and findings from clinical examinations at 
baseline and follow-up visits would have been easier using standardized questionnaires 
and forms at all visits.  
5.1.2 Imperfect reference standard and composite reference standard 
When evaluating the performance of a new diagnostic test, the results from the new 
test frequently are compared to a gold standard that label a patient as diseased or non-
diseased (354). Ideally, the new diagnostic test should be evaluated against a perfect 
gold standard, but gold standards are seldom absolute predictors of disease. Using an 
imperfect reference standard when evaluating a new diagnostic test, potentially lead to 
misclassification of patients (187, 354), and bias the measures of performance of the 
new test (354, 355). Culture is still regarded as the gold standard when developing and 
evaluating new TB diagnostic tools, but is known to be a suboptimal reference 
standard in the diagnosis of EPTB (10, 187). Given the assumption that the new test 
rightly identifies TB infection in a culture-negative sample, the result from the new 
test would be regarded as false positive and underestimate the true specificity of the 
new test (187). A CSR, combines the result of various imperfect component tests or 




reclassify patients evaluated as false positive (classified as non-TB using only culture) 
as true positives and increase the estimate of the new tests’ specificity (187).  
To assess the performance of our new test in field conditions, the MPT64 test was 
evaluated by comparison with a CRS (table 5), dividing the patients in TB and non-TB 
cases. The CRS used in this project was composed of laboratory diagnostics available 
in the current setting, imaging and clinical findings and follow-up of patients at certain 
time points assessing response to treatment or improvement without anti-TB treatment 
or other specific non-tuberculous therapy. The TB cases was further divided according 
to the level of certainty of TB disease as confirmed, probable and possible TB cases, 
representing high, medium and lower certainty of the true TB diagnosis respectively. 
In the study design all patients were intended to receive the same component tests of 
the CRS, which would be interpreted and combined in a fixed way for all patients to 
be categorized according to the CRS criteria. However, diverse challenges led to some 
samples not being subjected to all the various laboratory component tests, some 
patients died before follow-up or were lost-to-follow, which may have had an impact 
on the accuracy of the CRS and on the estimated performance of the new test under 
evaluation. Further, patients with clinical presumptive EPTB responding to anti-TB 
treatment were defined as possible TB cases, this does not necessarily give a correct 
diagnosis, as some patients may have alternative infections responding to anti-TB 
treatment and thus incorrectly classified as TB cases. There were limited possibilities 
to perform various investigations to distinguish TB from other infections to secure 
specificity. On the other hand, poor treatment response can be due to drug resistant 
TB, poor compliance or other intercurrent conditions, potentially leading to the 
misclassification of true TB cases. 
5.1.3 Reliability and validity 
5.1.3.1 The study questionnaire 
The content validity of the study questionnaire was properly evaluated, however the 
reliability of the questionnaire was not assessed. The test-retest reliability (stability) of 
the study questionnaire, that is assessing whether the same respondent would produce 




occasions, or the inter-rater reliability, referring to the consistency of re-interviewing 
the same respondents by two distinct interviewers (357), was not evaluated. This can 
be seen as a limitation. The test-retest and inter-rater reliability can depend on the 
complexity or ambiguity of the questions and the interviewer`s skills. However, all the 
interviews were conducted by one of two well trained medical doctors. In addition, 
most of the questions included in the questionnaire were relatively simple and close-
ended, offering specific feedback regarding focused areas, limiting the possible 
responses and making the statistical analysis easier. Still, some open-ended questions 
were included to give the researcher the opportunity of more insight into some areas.  
5.1.3.2 Information bias 
In our study, self-reported data during interviews using the study questionnaire, 
promote the possibility of interviewer and self-reporting bias, both forms of 
information bias. Interviewer bias, is where the interviewer through behavioural and 
personal characteristics and interviewing technique and skills can influence the 
interview process and the answers given by the respondents (358). The interviewers in 
our study were both local medical doctors, familiar with the study and subject areas, 
who received training prior to conducting the face-to-face interviews. Further, as the 
study questionnaire was mainly structured, where the interviewers asked standardized 
questions, committed to the settled structure and order of the questions with minimal 
opportunity to alter the content we tried to minimize the possibility of interviewer bias.  
Self-reporting bias, is a common problem in observational study designs (359). Using 
face-to-face interviews and questionnaires to collect data, the respondents may give 
information that they perceive as more socially acceptable, i.e. social desirability bias 
(358, 359). This can specially influence subjects perceived as sensitive or shameful. 
Assessing the questions in the questionnaire, self-reported HIV status and visiting 
traditional healers can fall into this category. In the cohort the HIV status was known 
in 99/132 (75%) (information retrieved from TB register books and patient hospital 
files), 22/99 (22%) were HIV positive and 77/99 (78%) HIV negative. Among these, 
16/99 (16%) reported being HIV positive, 48/99 (48%) being HIV negative and 35/99 
(35%) did not know their HIV status. In addition to patients being hesitant to divulge 




self-reported HIV status and actual HIV status can be due to some patients being tested 
for HIV after the study baseline interviews were performed. Another potential 
sensitive subject is consulting traditional healers instead of or in addition to modern 
health care facilities. Zanzibar has a long historical use of various forms of traditional 
medicine, and reports have stated that most of the population use traditional medicine 
and seek traditional health care for prevention and treatment of various diseases (360, 
361). In 2012 it was estimated that around 800 traditional healers’ practiced in 
Zanzibar (361). Among our cohort, 12/132 (9%) of the respondents reported having 
visited a traditional healer during the care seeking period. This is a lower proportion 
than reported in two studies from the Tanzanian mainland. In one study, including 
smear positive PTB patients from 6 districts in various regions, 20% of the 
respondents described seeing a traditional healer prior to receiving their diagnosis 
(311). Whereas a study in Mwanza region, among smear positive PTB cases, reported 
that 38.9% of the respondents had first consulted a traditional healer after symptom 
onset (309). It is thus plausible to assume that the responses regarding traditional 
healers among our cohort can be biased, conceivably due to some respondents being 
reluctant to disclose consulting traditional healers to the professional HCPs.  
Another form of self-reporting bias is recall bias, where the respondents provide 
erroneously responses due to a dependence on her/his ability to remember past events, 
resulting in recall error (359). The range of the recall period and acute versus insidious 
onset of symptoms can influence recall bias, where a shorter recall period is preferred, 
and an acute onset of symptoms is apparently easier to remember than subtle symptom 
onset. In the study questionnaire, the information requested regarding variables such as 
symptoms, symptom onset and duration, first HCP consulted and number of HCPs 
visited,  where the data was used to estimate the various delays and assess health 
seeking trajectories (Paper II), relied to a great extent on the study participants 
recalling previous events. Measures to reduce recall bias can be to use validated and 
well-structured instruments for data collection, gain information from alternative 
sources or helping the patients remember the date of events by using a local calendar 
with holidays and happenings. Among the study cohort, information gathered in the 




(each patient usually has their own notebook where the clinician write handwritten 
notes during visits to outpatient clinics or PHCU), TB treatment cards and laboratory 
reports, when these sources were available. Still, there is a possibility of recall bias 
influencing the results. Other means of minimising recall bias are including patients 
with new onset of symptoms, but this was not feasible in the current project since 
many patients had been to various peripheral health care units before being referred to 
MMH.  
5.1.3.3 Selection bias 
We aimed to include patients with all forms of EPTB disease from the whole island, 
however we had fewer presumptive TB patients as mentioned in section 5.1.1.1 adding 
a selection bias. Furthermore, all forms of EPTB were not included in the study 
population. Only 13 of the included patients had presumptive bone, pericardial or 
neurological TB, and none had genitourinary tract TB. This could be due to the 
inclusion criteria of only including those patients with a representative biological 
sample. Another challenge was that we quickly experienced that some patients could 
not afford the laboratory investigations and diagnostic imaging included in a routine 
diagnostic work-up. It was thus decided that the research project would fund all the 
investigations and diagnostic work-up of the invited study participant. To overcome 
the ethical issue of patients feeling pressured to participate in the study to get all 
expenses covered, we chose to fund all invited patients, regardless of their decision to 
participate or not. We identified and invited 146 patients, where 132 were enrolled in 
the study. Among those excluded, 3 patients had been given empirical anti-TB 
treatment the last year, in 6 a representative sample was not obtained and 5 patients did 
not consent to participate. Patients lost to follow can also introduce bias if they 
somehow differ from the patients remaining in the study. Among the 64 patients 
defined as TB cases in Paper I and III, 10 patients died before follow-up (2 culture 
positive EPTB patients died before starting anti-TB treatment, 8 died during anti-TB 
treatment) and 2 patients were lost to follow.  
5.1.3.4 External validity  
Since the inclusion of the study participants only took place at one hospital, we 




a third level referral hospital, and even though the hospital was also providing primary 
and secondary health care services to some of the district during the project period, 
one cannot disregard that there is a possibility that patients being referred to the 
hospital had a more advanced disease state than patients seen and treated in peripheral 
health care units. One the other hand, one could assume that some patients were 
referred to MMH for diagnostics, who before the study would have been started on 
empirical treatment outside the hospital. This could have been due to the information 
given to TB programme health personnel regarding the current TB project.  
To get an impression whether our included study participants represented the intended 
study population it would be valuable to know how many of the anticipated study 
population were included in the study and evaluate eventual differences among the 
included and not included patients. In this respect, finding the number of patients with 
presumptive EPTB, where another diagnosis was concluded, and thus not initiating 
anti-TB treatment (Group A in figure 23), was not doable. On the other hand, it was 
possible to receive an overview of the presumptive EPTB patients initiating anti-TB 
treatment and by that registered in the TB register during the inclusion period. In 
retrospect, a review of the manually written TB registration books from Unguja TB 
districts was performed. Available features among the TB patients not included (Group 







Figure 23.     The intended study population. aPatients defined as non-TB cases in paper I and III. bTB cases 
not included in the project, only reported as EPTB cases in TB registration books at Unguja Island during the 
project period.  cPatients defined as TB cases in paper I and III. Abbreviations: EPTB, extrapulmonal 
tuberculosis; TB, tuberculosis. 
 
In the current project period, 140 patients were registered as EPTB patients in the TB 
registration books at Unguja Island. Of these, 76 cases were not included in the study 
(Group C in figure 23). The median age was similar among the study participants and 
patients not included in the study (included cases, median age 25 years, IQR 7.5-38; 
not included cases, median age 25.5 years, IQR 6-46.8). The two groups did not differ 
significantly with regard to sex, HIV status or residence, but there was a significant 
difference in the site of infection. Among the included patients the most frequent 
registered sites of infection were lymphadenitis (53%), pleuritis (31%) and abdominal 
TB (9%), whereas among the TB patients not included in the study, no site registered 
(43%) and pleuritis (38%) were most commonly reported.  
The patients included in this project are thus a subgroup of patients presenting with 
presumptive EPTB at Unguja Island. Consequently, the study results may not 
necessarily be generalizable to all the EPTB patients in Zanzibar and should be 




5.1.3.5 Controls for immunostaining  
In the current study, we used biopsy tissue sections as controls for both the IHC and 
the ICC staining procedures due to limited numbers of cell smears which could be 
used as controls. Using biopsy tissue sections as controls for ICC staining is 
suboptimal as tissue sections and smears from fluid material have different sample 
processing and fixation steps, leading to some variation between the IHC and ICC 
staining protocols. In addition to only having tissue sections as controls, some of the 
staining procedures were run without controls due to limited access. Our intention was 
to use material from our own study samples or specimens from the local laboratory as 
controls during the study. However, we faced challenges in having access to controls 
as few non-sputum samples had been sent for Mtb culture prior to the study, further, 
only a minority of the study samples were reported as Mtb culture positive. Among the 
8 Mtb culture positive study samples none were applicable as a control specimen. The 
given context is a limitation of the study, and may potentially have led to improper 
interpretation of the staining in some runs of immunostaining. However, we are 
reasonably confident about the authenticity of the staining method based on correlation 
of staining results with other diagnostic methods and the CRS. 
5.1.3.6 Reliability of immunostaining 
We assured the run-to-run, within-run, intra-observer and inter-observer 
reproducibility of the immunostaining prior to the inclusion of patients` study material. 
Furthermore, inter-observer agreement between pathologists was assessed on the study 
material, showing substantial agreement as shown in figure 18, section 3.3.3.5. It was 
difficult to assess run-to-run or within-run reproducibility on study samples due to 
limited number of slides being prepared from each specimens.  
5.1.3.7 Data management  
False data entry is another potential source of error. Answers in the questionnaire and 
EQ-5D-3L and results from the physical examination and laboratory reports were all 
hand-written and subsequently coded and entered into Excel spreadsheets. To limit the 
possible error, data cleaning was performed to detect and correct inaccurate or invalid 




data and answers form the EQ-5D-3L were entered twice and cross-checked. Further, 
double entry was performed in 10% of the study questionnaires and cross-checked 
showing 3/2769 (1.1‰) typing errors.  
5.1.4 Statistical considerations 
The sample size in all three papers are relatively small, this reduces the statistical 
power of the analyses and increases the risk of type II errors, i.e. not rejecting the null 
hypothesis when it is false, believing there is no effect in our population, when, truly 
there is. Further, the risk of Type I error, i.e. rejection of the null hypothesis when it is 
true, believing there actual is an effect in our population, increases with multiple 
testing performed. In paper II and III we used the Bonferroni correction of the 
significance level, using a significance level of α/m, where α was the set overall 
significance level and m the number of tests, to adjust for the possible effect of 
multiple comparison. On the other hand, using the Bonferroni adjustment to counteract 
the effect of multiple testing may have been too conservative. 
 
5.2  Discussion of the main results 
5.2.1 Improving the laboratory diagnosis of extrapulmonary tuberculosis 
in a low-resource setting 
We have showed that the MPT64 test is implementable in a low-resource, routine 
diagnostic setting. The immunostaining can be performed by local laboratory 
technologists and the local pathologist is able to evaluate the stained slides. The 
performance of the new test in this routine diagnostic setting is comparable with prior 
studies evaluating the MPT64 test in more controlled contexts, particularly for TB 
lymphadenitis (123, 347). We found a better overall performance of the MPT64 test 
compared to Mtb culture, ZN staining and the Xpert assay. The high performance of 
the MPT64 test among TB lymphadenitis cases and in paediatric patients could have 





TB lymphadenitis, together with TB pleuritis, are the most common forms of EPTB 
(12, 82, 83). In TB endemic areas, TB lymphadenitis is a prevalent cause of persistent 
peripheral lymphadenopathy in children. Enlarged lymph nodes is a typical clinical 
presentation of EPTB in paediatric patients, responsible for around 50% of 
extrathoracic TB in children (93, 362-365). Biopsy and subsequent Mtb culture, ZN 
staining and histopathological examination of the tissue sections is considered one of 
the most important methods for diagnosing EPTB (124). However, biopsy requires 
manpower and facilities, often lacking in low-resource settings. FNAC from lymph 
nodes is a cost-effective, simple and safe diagnostic modality. It can be performed in 
out-patient clinics, requires minimal unsophisticated equipment and provides 
representative specimens from lymph nodes for Mtb culture, ZN staining and material 
for cytological evaluation (366, 367). It is the diagnostic modality advised in paediatric 
patients with persistent enlarged lymph nodes (365, 368), and has an undeniable role 
in the diagnosis of EPTB in all age groups (286, 369-371). Even though considered the 
gold standard for TB diagnosis, Mtb culture has its challenges in resource-constrained 
settings such as the need of highly specialized laboratories, trained personnel and long 
turnaround time for results. Further, ZN staining of FNAC specimens from lymph 
nodes shows suboptimal yield (123, 285). The cytomorphological picture can be 
suggestive of TB disease (285, 287, 372) but it is not confirmatory as the 
morphological features found in TB disease are not specific and other conditions may 
present similar features (288). In addition, immunocompromised TB patients often 
present with atypical cytological features, and even FNAC from immunocompetent 
patients can show other morphological features such as suppurative acute 
lymphadenitis (285). Relying just on cytological examination can thus lead to both 
over- and under-treatment. In our study participants categorized as TB lymphadenitis 
cases, 19/34 (56%) had FNAC showing a cytomorphological picture consistent with 
TB, whereas the MPT64 test was positive in 26/34 (76%) of these cases. The 
immunostaining using primary anti-MPT64 antibody showed superior sensitivity 
among TB lymphadenitis cases in FNAC specimens compared to the Xpert assay, Mtb 
culture and ZN staining, and excellent specificity, being negative in all non-TB cases 




confirmed TB lymphadenitis cases (Mtb culture positive and/or Mtb detected by the 
Xpert assay). FNAC from lymph nodes is also helpful in distinguishing TB from 
metastatic lesions or lymphoma (373, 374). Among our cohort, suspected malignancy 
was noted in 10/66 (15%) of the patients included with peripheral lymphadenopathy. 
Combining cytological evaluation and Mtb culture of FNAC samples from lymph 
nodes with a sensitive and rapid diagnostic technique can contribute considerably to 
effective management of TB lymphadenitis. We believe the MPT64 test could be a 
valuable confirmatory add-on test in presumptive TB lymphadenitis cases. It can 
differentiate Mtb infection from NTM and other etiologies in samples showing 
granulomatous inflammation, and further indicate TB infection in samples potentially 
discarded as TB due to cytomorphological inconsistent with TB.  
Many patients in developing countries live in remotes areas far from hospitals and 
reference laboratories and the referral system from low-level to higher level of health 
care are also often weak. We acknowledge the importance of diagnostic tests being 
available at health care units in proximity to patients` residence. The new MPT64 test 
needs to be performed in a histopathology laboratory but uses only procedures and 
technology already available in most routine pathology laboratories. The possibility of 
collecting the sample at other health care units and sending the specimen to centralized 
units, such as MMH, for examination, as is done for sputum samples examined with 
the Xpert assay, could be possible in this setting. Nurses or other medical personnel in 
peripheral health care units can be trained in the correct technique to perform FNAC of 
peripheral lymph nodes (366, 373), this can be particularly helpful in resource-
constrained settings. FNAC and other sample material can be collected and slides 
prepared and fixated at other health care units using very basic laboratory equipment. 
The slides can then be transported to MMH for immunostaining and cytological 
examination. In addition, material can be collected in tubes and sent for Mtb culturing 
and the Xpert assay. Adapting the new diagnostic technology to the local infrastructure 
is crucial, increasing the opportunity for success and accessibility for patients not able 




We found a significantly higher sensitivity of the MPT64 test in children compared to 
adults. Most of the specimens among the paediatric TB cases were FNAC from lymph 
nodes (FNAC from lymph nodes, n=11; pleural effusion, n=3; ascites, n=1; pericardial 
effusion, n=1). The sensitivity of the MPT64 test in children was higher compared to 
adults in FNAC samples from peripheral lymph nodes (100% sensitivity versus 65% 
sensitivity). In the recent years, childhood TB has received increased attention (375). 
Estimates indicate that only a portion of active paediatric TB cases are notified (376). 
The challenge of establishing a bacteriologically confirmed diagnosis, due to difficulty 
in acquiring adequate samples for laboratory investigations and the lower diagnostic 
yield of traditional diagnostic methods, such as smear microscopy and Mtb culture, is 
one of the reasons why many active TB cases in children go unreported (110, 375). 
Our test can contribute towards microbiological confirmation of TB lymphadenitis in 
children by using a relatively less invasive procedure of FNAC. We acknowledge that 
more studies with a larger sample size are needed to further explore these results.  
A limitation of the study is that not all samples were subjected to each of the various 
laboratory tests, this can have affected the estimated diagnostic performance of the 
component tests of the CRS and the MPT64 test. Mtb culture was performed in 86%, 
ZN staining in 99% and the Xpert assay in only 50% of the samples, respectively. The 
low number of samples analysed with the Xpert assay was due to limited number of 
Xpert cartridges which had to be prioritized for sputum specimens. Further, there was 
lack of equipment for sample processing of biopsies, thus, the Xpert assay was not 
performed in any of the biopsies. We still included the results of the Xpert assay in our 
paper, but the results should be interpreted in the clarified context. Before the study, 
specimens from extrapulmonary sites of infection was not usually sent for Mtb culture. 
We got an agreement with the ZIHTLP and PHL-IdC and were able to send specimens 
for culture. The low performance of mycobacterial culture in our study could possibly 
partly be explained by reduced viability of bacilli during storage and transportation to 
PHL-IdC at Pemba Island, as the samples was received at PHL-IdC with a median of 
7.5 days (IQR 5-13 days) after sample collection. Further, dividing the samples into 
separate tubes may lead to uneven distribution of bacilli, and the possible impact on 




Generally, it is thought that more accurate, rapid and preferably easily implementable 
diagnostic tests have the potential to improve patient management and decrease 
disease burden by reducing diagnostic delay and increase case detection. The ability of 
a new test to convey these benefits is not necessarily evident based purely on studies 
of test performance in routine diagnostics. We were not able to evaluate the potential 
impact on delay as the study was not designed for such analysis. To do this we would 
have had to include two separate arms in our study design, were patients were 
randomized to receive or not receive the new diagnostic test. We still argue that the 
MPT64 test has the potential to improve the diagnosis of EPTB in Zanzibar, and 
conceivably also in other low-resource settings. However, we acknowledge that there 
are several challenges which need to be addressed to ensure the sustainability of the 
MPT64 test in this setting, such as feasible procurement of equipment and reagents, 
continuous training and supervision of laboratory personnel performing the 
immunostaining and the evaluation of the test results and establishment of external 
quality control programs. In addition, a cost-effectiveness analysis is a critical aid and 
undoubtedly needed in the decision process whether to adopt the new test in a 
diagnostic algorithms. It should be emphasized that the MPT64 test must be 
interpreted in conjunction with the patient’s clinical history, results of clinical 
examination, imaging and other established routine laboratory diagnostic tests. The 
MPT64 test should thus be regarded as an add-on test to the already established 
diagnostic procedures, and by that should not replace other investigations such as 
cytology/histology, which is invaluable also in the diagnosis of other conditions. 
5.2.2 Diagnostic delay and impact of treatment on self-rated health status 
This is the first project assessing the diagnostic delay, health care seeking pathways 
and EPTB knowledge among presumptive EPTB patients in Zanzibar. The small 
sample size limits the possibility of stratifying the results according to all the distinct 
sites of EPTB disease. Still, we believe that these findings could help HCPs working 
with TB patients in Zanzibar identifying potential interventions and strategies to 
improve EPTB case finding and possibly reduce the diagnostic delay among EPTB 




5.2.2.1 Diagnostic delay and health care seeking pathways 
As an example of the delay experienced and health care seeking pathways followed, 
we present one of the patients included, a young child with culture-confirmed TB 
lymphadenitis (Figure 24). The guardian described local signs and symptoms which 
had been present for almost 2 years. The first documented visit to a HCP was 654 days 
prior to the study baseline interview. The patient had 8 documented visits to the same 
public health care unit prior to referral to MMH, and during these visits had been given 
multiple antibiotic treatments, without obvious improvement. There was no 
documentation that any microbiological investigations had been performed despite 
incision and drainage of the enlarged lymph nodes/abscesses were documented on two 
previous health care visits.  
 
Figure 24. TB lymphadenitis patient. Picture U and V, before anti-TB treatment; Picture W and X, after 
anti-TB treatment.  
This study participant illustrates our main findings showing that many EPTB cases 
experience a delay exceeding two months from symptom onset until treatment is 
initiated. Significantly longer patient and total delay were described among TB 
lymphadenitis cases, with ¼ of the TB lymphadenitis patients experiencing an overall 
delay > 6 months. In concordance with studies from diverse settings we found health 




378). Among the TB patients in our study, 80% experienced longer health system 
delay than patient delay. This is contrast to others reporting patient delay as the 
primary contributor (306, 307, 379). We also noted that when adopting cut-offs for 
acceptable/unacceptable delay used by others (unacceptable; patient delay >30 days, 
health system delay >14 days) (380, 381), unacceptable patients delay was noted 
among 24% of the TB cases, whereas 83% of the TB patients experienced 
unacceptable health system delay. A longer health system delay was noted among TB 
cases consulting other HCPs than MMH at first visit and in patients with > 3 visits to 
any HCP. Thirty-eight percent of the TB patients reported ≥5 visits to any HCP before 
starting anti-TB treatment. Others have also reported health system delay associated 
with number of HCPs visited before TB diagnosis (308). When evaluating the care 
seeking pathways, we found that the majority of patients first visited a public HCP, 
and many had repeated visits to the same health care level before referral to MMH. In 
a systematic review assessing diagnostic and treatment delay in TB, repeated 
consultations within the same level of health care, which resulted in unspecific 
antibiotic treatment and not being referred to specialized TB health care services, was 
concluded as the core problem causing delay (300). Recognition of presumptive EPTB 
cases requires adequate training of HCPs, and for correct diagnosis, both identification 
of the presumptive EPTB patients and effective and accessible diagnostic tools are 
vital. In Zanzibar, during the study period, many peripheral health care units were 
performing ZN staining and sputum smear microscopy, but to our impression, 
extrapulmonary material was not examined at these sites and rarely sent for Mtb 
culture. Further, cytological and histological examinations were only performed at 
MMH. There were few sites performing X-ray, and computer tomography was only 
available at MMH. Thus, the health system delay reported in our study does not 
inevitably reflect HCPs not recognizing possible EPTB cases, but can also reflect 
shortage of facilities and personnel performing various invasive procedures, 
inadequate diagnostic tools and knowledge regarding available diagnostic possibilities, 
insufficient follow-up routines and incomplete algorithms on when to refer 
presumptive EPTB to higher levels of health care. To achieve a reduction of health 




training in early recognition of the various EPTB clinical presentations to HCPs at all 
levels, but especially at the primary health care level, both in the public and private 
sectors, are essential. In addition, the HCPs should be given regular information 
regarding the currently available EPTB diagnostics in the specific setting. As 58% of 
the patients reported a course of antibiotics given at first visit, proper scheduled 
follow-up of these patients and establishment of timely algorithms including 
recommended diagnostics and when to refer presumptive EPTB cases to higher level 
health care facilities with capacity and expertise to perform invasive diagnostic 
procedures could be valuable. We recommend developing such diagnostic and referral 
algorithms for presumptive EPTB patients specifically for the current setting. Finally, 
the development of new and improved diagnostic tools, implementable, feasible and 
sustainable in low-resource settings is of uttermost importance, in combination with 
strengthening and supporting TB laboratory personnel and facilities.  
5.2.2.2 Extrapulmonary tuberculosis knowledge 
Among the cohort, the knowledge regarding EPTB was remarkably low. Most had 
heard of PTB disease prior to the study, but only one respondent mentioned an 
extrapulmonary site and none reported other local symptoms than respiratory 
symptoms. The reality that most public and patients` educational TB campaigns only 
include cardinal symptoms of PTB, can lead to the population being unaware of EPTB 
and its symptoms. The findings among our cohort of scarce knowledge regarding 
EPTB represents a cause of concern, as awareness and knowledge of signs and 
symptoms could have impact on patients` care seeking action, but also identifies a 
possible area of intervention. Higher TB knowledge has been shown associated with 
care seeking behaviour (382), and lack of awareness has been reported by patients as 
one of the reasons for delayed care seeking (383). We believe that enhancing the 
knowledge of EPTB as a disease and increasing the awareness of signs and symptoms 
suggestive of EPTB in the general population are valuable. This can be done by 
systematically incorporating information regarding EPTB in the already ongoing 
public campaigns covering PTB disease. This can potentially contribute towards a 




5.2.2.3 Improvement of self-rated health after treatment 
Although EPTB patients are no threat to a community in terms of transmission of 
disease, still, these patients can suffer continuing disability, reduced quality of life, 
higher morbidity and mortality due to late diagnosis, loss of income and economic 
constraints. We thus wanted to get an impression among the study cohort on the 
impact of EPTB disease on regular activities, work capacity and general health status 
as reported by the patients. Instruments assessing self-reported health-related quality 
of life (HRQoL) are generally classified as either disease-specific or as generic tools 
which are applicable to diverse conditions (384). Most studies assessing HRQoL 
among TB patients have used generic instruments in cross-sectional study designs to 
evaluate impairment of health associated with TB, fewer studies have used prospective 
longitudinal study designs reporting the effect of anti-TB treatment on quality of life 
(384-386). Some TB disease-specific instruments have been developed (384, 387-
389). Few studies have included EPTB patients. Differentiating EPTB from PTB 
appear important when assessing health status and quality of life, in addition, the data 
should also be stratified by site of EPTB disease (385). To the best of our knowledge, 
no TB-specific instrument translated into Swahili has been published and validated. In 
our study, we included questions in the study questionnaire covering work capacity, in 
addition, we chose to administer one version of the EQ-5D instruments, the EQ-5D-
3L, to measure self- perceived health status and potential changes after anti-TB 
treatment. The standardised EQ-5D is an easy, generic measure of self-reported health 
status or HRQoL, developed to value and describe health. It has been reported to be 
reliable and valid in diverse populations and conditions (390), and has been used 
among TB patients (391). It is a frequently used instrument to value health utility and 
measure quality of life for economic evaluations (392). Further, it is a short 
questionnaire, quick to complete, simple to understand and translated and validated in 
Swahili (Swahili version for Tanzania, validated for Haydom, Manyara Region, © 
EuroQoL Group 1990). Most of the adult TB patients, irrespective of site of TB 
infection, reported at the time of inclusion that they had reduced work capacity or had 
entirely stopped working due to the current disease, with a median of 60 days (IQR, 




within the five dimensions of the EQ-5D descriptive system were substantially larger 
before compared to after completing anti-TB treatment (Table 6). At baseline, patients 
with TB lymphadenitis described lesser problems than patients with other sites of TB 
infection in all five dimensions, still, both patient groups, reported considerably lesser 
problems at treatment completion. This was also reflected in the EQ visual analogue 
scale (EQ VAS).  
Table 6.  Number of patients and proportions reporting levels within the five dimensions of the 
EQ-5D descriptive system before and after anti-TB treatment, n (%)a 
a Thirty-one adult TB patients completed the EQ-5D form both before anti-TB treatment and at treatment 
completion. 
To give an example, an adult TB patient from the cohort, described onset of symptoms 
2 months prior to the baseline interview, with gradual increasing weakness and pain of 
the lower extremities and pain in the lumbar region during the last 2-3 weeks. The 
patient was totally confined to bed when included in the study and had not been 
working since the onset of symptoms. The computer tomography showed involvement 
of vertebrae Th12, L1 and L2, in addition bilateral psoas abscesses and abscess in the 
right musculus erector spinae. The patient reported extreme problems in the three first 
dimensions of the EQ-5D descriptive system (mobility, self-care and usual activities) 
and some problems in the last two dimensions (pain/discomfort and 
anxiety/depression), and rated his health to 20% of best imaginable health on the EQ 
VAS before commencing anti-TB treatment. After anti-TB treatment, the patient 
reported working as normal and described no problems in either dimension of the EQ-




tomography after treatment showed no significant vertebrae collapse or canal stenosis 
and complete resolution of the abscesses.  
Our findings give a clear impression that completing anti-TB treatment has an impact 
on the quality of life among EPTB cases. Showing improvement in self-reported 
health status with treatment is valuable and gives considerable motivation to reduce 
the diagnostic delay among EPTB patients. Further, it would be interesting to assess 
how TB affects the health status before treatment and potential residual deficits or 
impact on quality of life after treatment when compared to the health status of the 
general population. This can be done by comparing problems reported in the EQ-5D 
instrument among the patient group to problems reported in a sample from the general 
population in the current setting (393, 394). However, such reference scores have not 
been derived in Zanzibar or the Tanzanian mainland, and such a comparison was thus 
not possible. Despite this, in addition to the small sample size, we still argue that our 
findings imply that early and correct treatment of all forms of EPTB could have 
important impact on the morbidity, quality of life and the economic situation for 
afflicted patients and families.  
5.2.3 Evaluation of treatment response 
We showed that among patients presenting to MMH with presumptive EPTB the 
clinical presentation alone could not separate the TB and the non-TB cases. In the 
current setting empirical treatment is often initiated, emphasizing the importance of 
monitoring treatment response among these patients. Clinical assessment is still the 
recommended approach to evaluate improvement and response to treatment among 
EPTB patients (3, 91, 312), and should include resolution of constitutional and local 
symptoms, overall improved performance status and weight gain (395). However, the 
criteria for what constitutes adequate clinical treatment response in the heterogeneous 
disease EPTB is presently not established. We wanted to assess if a combination of 
simple clinical parameters can predict good treatment response. The included study 
participants starting anti-TB treatment were followed during treatment and clinical 
findings, weight, symptoms reported and general condition as evaluated by the 




We included regression of objective clinical findings, weight gain and improvement of 
symptoms as the three clinical parameters for assessing treatment response. Among the 
patients categorized as TB cases by the CRS, 47/48 (98%) patients satisfied ≥2 
parameters after 2 months of anti-TB treatment. Regression of peritoneal and pleural 
effusion were noted in 3/3 (100%) abdominal TB and in 14/15 (93%) TB pleuritis 
cases at 2 months, respectively. Among the 34 TB lymphadenitis cases, 32 patients 
were seen after 2 months of anti-TB treatment, and partial or full regression of lymph 
node swellings were reported in 29/32 (91%) patients. Complete resolution of 
lymphadenopathy was noted in 24/28 (86%) cases at treatment completion. Among the 
remaining 4 patients (all confirmed TB cases) residual palpable lymph nodes were 
noted after 6 months of treatment. Three of these were followed further and no 
enlarged lymph nodes were described after 3 months in 2 patients and 6 months in 1 
patient. Other studies have reported enlargement and appearance of new nodes during 
treatment and residual lymphadenopathy at treatment completion without necessarily 
indicating relapse or treatment failure (396-398). Still, paradoxical reactions and 
residual lymphadenopathy can complicate the clinical assessment.  
Both ≥5% weight gain and any weight gain were evaluated as a potential clinical 
parameter. A weight gain ≥5% was reported in 12/13 (92%) of the paediatric TB cases 
and among 24/36 (67%) of the adult TB patients, and any weight gain was noted in 
46/48 (96%) of the TB cases after the intensive phase of anti-TB treatment. Including 
any weight gain as one of the clinical markers of treatment response is simpler, still, 
using a certain percentage weight gain, such as ≥5%, can be more sensitive in 
capturing non-responders or identifying patients requiring closer follow-up. More 
studies are needed to describe the association between treatment outcome and weight 
gain in EPTB patients. Weight gain in relation to the commencement of ART could 
bias the effect of weight gain measured as a result of effective anti-TB treatment. In 
the current cohort, only 7 HIV positive patients were followed during anti-TB 
treatment. Among these, 4/7 patients were already receiving ART, while 3/7 initiated 




Improvement of symptoms were the third clinical parameter included when assessing 
treatment response. This was done by evaluating symptoms described in the 
questionnaire at baseline with symptoms reported by the patients at follow-up visits. In 
our study we only assessed if the patients overall reported improvement of symptoms. 
In retrospect we acknowledge that if we had used a consistent form for documentation 
of symptoms also at the follow-up visits, it would have given us the opportunity to 
calculate the symptoms count ratio (number of symptoms reported by the patients as 
improved at follow-up divided by the number of symptoms reported at baseline). 
Including a symptoms count ratio above a certain level, as Wilson et al. included as 
one of the parameters in their criteria of response to treatment among HIV infected 
adults with smear negative PTB and EPTB (330), could have reduced the potential 
bias when assessing improvement of symptoms. Incorporating results of the symptoms 
count ratio, self-rated health using the EQ-5D instruments (331) and the clinicians 
evaluation of the performance status using the Karnofsky Performance Status score 
(332, 334), can make a treatment response assessment tool potentially more user 
friendly. Further studies are required to establish clinically relevant criteria or cut-off 
points to define treatment response. 
One of the limitations of this study in addition to the small sample size is the inclusion 
of mainly lymphadenitis, pleuritis and peritoneal TB patients, and few or no cases with 
other forms of EPTB disease. We recognize that these simple clinical parameters 
should ideally be evaluated on a sub-group level divided according to the site of EPTB 
disease. In addition, we did not have a comparable control group, as only 7 patients 
initiating anti-TB treatment and categorized as non-TB cases were followed during 
treatment. The non-TB cases did however fulfil only 0 or 1 of the clinical parameters 
after the intensive phase of anti-TB treatment. Still, we believe that a combination of 
simple clinical parameters, without the need of laboratory support, can be developed 
into and used as an easy tool for monitoring of treatment response early during anti-TB 
treatment in EPTB patients. Further, such an assessment tool can be incorporated 
systematically into standard follow-up protocols, attached to the patients TB treatment 
cards or in TB registers, and assist the HCP in low-resource settings in timely 






 The immunochemistry-based MPT64 test for EPTB is implementable in a 
routine diagnostic laboratory in a low-resource setting.  
 The MPT64 test was sensitive and specific for the diagnosis of EPTB in this 
setting, especially in TB lymphadenitis and paediatric TB. The overall 
performance of the MPT64 test was better compared to both the Xpert assay 
and conventional diagnostic methods, with potential to improve the diagnosis of 
EPTB in low-resource settings. 
 Many EPTB patients experienced delays exceeding two months from the onset 
of symptoms until the initiation of anti-TB treatment. The longest delay was 
reported among the TB lymphadenitis patients. The major contributor to the 
overall delay was health system delay. 
 The majority of the adult TB patients reported reduced work capacity due to the 
ongoing illness and improved self-rated health status after treatment using the 
EQ-5D-3L instrument. This indicates that reducing diagnostic delay, early case 
detection and initiation of treatment is important among EPTB patients.  
 Strengthening the EPTB knowledge and awareness among the general 
population and HCPs at all levels can be valuable interventions for improved 
management of EPTB in this setting.  
 Monitoring of treatment response among EPTB patients often starting empirical 
treatment by using a combination of simple clinical parameters can be a useful 





7. FUTURE PERSPECTIVES 
 
Proper diagnosis and appropriate treatment of all individuals with all forms of TB are 
incorporated as one of the key components of the End TB strategy. Intensified research 
and development of new and improved diagnostic tool, also for presumptive EPTB, 
are needed, to reach these goals.  
We have shown that our new diagnostic test for the diagnosis of EPTB is 
implementable and doable in a low-resource setting and has the prospect to be a part of 
improving the diagnosis of EPTB. However, the MPT64 test needs to be implemented 
and validated in other routine diagnostic settings, to evaluate the feasibility and 
performance in various setting. Our research group is involved in the implementation 
and validation of this test in a multicentre study, where the MPT64 test are currently 
being assessed at two sites at the mainland of Tanzania (Mbeya Zonal Referral 
Hospital, Mbeya, and Muhimbili National Hospital, Dar es Salaam), in Pakistan 
(Gulab Devi Hospital) and in India (Ujjain Charitable Hospital).  
Showing that the MPT64 test is implementable, and further, has a good diagnostic 
performance in various settings is not enough. The sustainability of the MPT64 test 
needs to be evaluated. Will the test be performed in routine diagnostics even after an 
ongoing project? We tried to get an understanding of the possible facilitators and 
barriers for the implementation and sustainability of a new diagnostic test for 
diagnosing EPTB in our study setting, by performing a qualitative study interviewing 
health personnel working at MMH and in the national TB programme. The data 
analysis from this study is ongoing. Just as important are cost-effectiveness analyses, 
which should be performed not only in Zanzibar, but in different settings. This will all 
be valuable and necessary when evaluating where our new test fits in the diagnostic 
algorithm for EPTB. 
We believe that developing an easy assessment tool for monitoring of treatment 
response can be highly useful especially in low-resource settings to support HCPs in 
the follow-up of EPTB patients. Further studies are needed for the development, 




points for the distinct parameters among EPTB patients, separated and evaluated 
according to the site of EPTB disease. The validity and reliability of the assessment 
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Extrapulmonary tuberculosis (EPTB) is a diagnostic challenge. An immunochemistry-based
MPT64 antigen detection test (MPT64 test) has reported higher sensitivity in the diagnosis
of EPTB compared with conventional methods. The objective of this study was to implement
and evaluate the MPT64 test in routine diagnostics in a low-resource setting.
Methods
Patients with presumptive EPTB were prospectively enrolled at Mnazi Mmoja Hospital, Zan-
zibar, and followed to the end of treatment. Specimens collected were subjected to routine
diagnostics, GeneXpert® MTB/RIF assay and the MPT64 test. The performance of the
MPT64 test was assessed using a composite reference standard, defining the patients as
tuberculosis (TB) cases or non-TB cases.
Results
Patients (n = 132) were classified as confirmed TB (n = 12), probable TB (n = 34), possible TB
(n = 18), non-TB (n = 62) and uncategorized (n = 6) cases. Overall, in comparison to the com-
posite reference standard for diagnosis, the sensitivity, specificity, positive predictive value,
negative predictive value and accuracy of the MPT64 test was 69%, 95%, 94%, 75% and
82%, respectively. The MPT64 test performance was best in TB lymphadenitis cases (n = 67,
sensitivity 79%, specificity 97%) and in paediatric TB (n = 41, sensitivity 100%, specificity
96%).
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Conclusions
We show that the MPT64 test can be implemented in routine diagnostics in a low-resource
setting and improves the diagnosis of EPTB, especially in TB lymphadenitis and in children.
Introduction
Despite efforts to develop new diagnostic tools for tuberculosis (TB), the diagnosis of extrapul-
monary TB (EPTB) remains a challenge. The various clinical presentations of EPTB are non-
specific, and the disease is often paucibacillary leading to low sensitivities of routine diagnostic
methods such as; acid-fast bacilli (AFB) microscopy [1–3] and culture [1, 4, 5]. Furthermore,
mycobacterial culture has a long turnaround time, and its technical and logistic demands lim-
its its use in resource-limited settings. Histology can be used in the diagnosis of EPTB, but
lacks specificity as several other conditions may present similar histological features [6]. Most
nucleic acid amplification tests show better sensitivity, but are complex, expensive, technically
demanding and prone to contamination, limiting their use in low-resource diagnostic settings
[7–10]. The development of the GeneXpert1 MTB/RIF (Xpert) assay is a landmark in TB
diagnostics, but reported sensitivities of the assay for EPTB samples are highly heterogeneous
and vary widely across different sample types [11–14]. Due to lack of a low-cost, robust, rapid
and accurate diagnostic method, EPTB is either over- or underdiagnosed, leading to increased
morbidity and mortality. Thus, there is a need for better diagnostic tools, which are implemen-
table and sustainable in resource-limited settings.
MPT64 is a protein secreted by the Mycobacterium tuberculosis (Mtb) complex species, not
detected in non-tuberculous mycobacteria (NTM) [15, 16] and bacillus Calmette-Guérin strains
with RD2 deletion [17]. Earlier studies have investigated the diagnostic potential of an immuno-
chemistry-based MPT64 antigen detection test (MPT64 test) showing sensitivity and specificity
comparable to nested polymerase chain reaction (PCR) [4, 5, 18, 19].
Zanzibar is a semi-autonomous region of the United Republic of Tanzania and comprises
the main islands Unguja and Pemba. The region has 1.3 million inhabitants [20], a prevalence
of bacteriologically confirmed pulmonary TB of 124 per 100 000 [21], and a low adult human
immunodeficiency virus (HIV) prevalence of 1% [22]. In 2013, 30% of the new TB patients
were registered as EPTB cases [23]. The aim of the present study was to implement and evalu-
ate the performance of the MPT64 test in routine diagnostics at the tertiary care hospital in
Zanzibar, a low-resource setting with a high TB burden.
Materials and methods
Study participants
The study was conducted at Mnazi Mmoja Hospital (MMH), Unguja, Zanzibar. MMH is the
only tertiary referral hospital in Zanzibar, and provides in addition primary and secondary health
care for some districts. Patients of all ages presenting with symptoms suggestive of EPTB were
prospectively enrolled from hospital wards and out-patients departments between 1st August
2014 and 31st August 2015. Patients who consented and where a representative sample was col-
lected were included in the study. Those who had received anti-TB treatment (ATT) during the
previous year were excluded. All patients were interviewed using a pretested structured question-
naire, and a physical examination was performed. Diagnostic imaging was done if required and
possible. Response to ATT was assessed at 2–3 months and at the end of treatment by using crite-
ria based on improvement in signs and symptoms, weight gain and objective measures such as
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repeated chest radiographs, abdominal ultrasound and reduction of lymph node swellings.
Patients not starting ATT were followed until recovery or until a diagnosis other than TB was
established.
Study questionnaire
The study questionnaire was developed in English, translated to Swahili, then translated back
to English. The translations were performed by two separate individuals fluent in both lan-
guages. The original English version and the back-translated version were compared to assess
the validity. Prior to testing of the questionnaire among patients, two bilingual individuals at
Zanzibar evaluated both the English (S1 and S2 Texts) and Swahili versions (S3 and S4 Texts)
to assess the meaning of the questions according to the local setting. The questionnaire was
tested among three adult inpatients at the medical ward at MMH to identify unclear or ambig-
uous questions and the questionnaire was adjusted accordingly.
Sample collection and processing
Fine-needle aspiration cytology (FNAC) from peripheral lymph nodes was performed by the
hospital pathologist (MM) using a 23-g needle. Four smears were prepared from each aspirate;
one each for cytology and AFB microscopy, and two for immunocytochemical (ICC) staining.
The slides for ICC staining were fixed in 95% alcohol before being transported to the labora-
tory. The needle was rinsed with 2 ml of sterile 0.9% saline solution and distributed equally for
the Xpert assay and Mtb culture. All fluids were aspirated aseptically, and subjected to routine
diagnostic investigations, in addition to the Xpert assay. The specimens were centrifuged at
3000g for 10 minutes and smears were made from the 20μl of the sediment for cytology, AFB
microscopy and ICC staining. The biopsies were divided equally and one half transported in
0.9% saline for Mtb culture and the other half fixed in 4% phosphate buffered formaldehyde
for conventional paraffin embedding. From the formalin-fixed, paraffin-embedded biopsies,
five-μm-thick tissue sections were prepared for histology, AFB microscopy and immunohisto-
chemical (IHC) staining.
Diagnostic procedure
AFB microscopy was performed using Ziehl-Neelsen (ZN) staining. Culture was done at the
Public Health Laboratory–Ivo de Carneri (PHL-IdC) located at Pemba island, on Lowenstein-
Jensen medium according to the standard protocol. Positive cultures were confirmed by smear
microscopy and sent to the Central Tuberculosis and Leprosy Reference Laboratory at Tanzania
mainland for species identification and drug sensitivity testing. The Xpert assay was performed
according to the standard protocol recommended by WHO [24].The specimens were stored at
4˚C for a maximum of 7 days if it was not analyzed on the same day as the sampling. The Xpert
assay was not performed on biopsies. The slides for cytological and histological examination
were stained with Papanicolaou stain and haematoxylin-eosin, respectively. Two laboratory tech-
nologists working at MMH were trained to perform the ICC/IHC staining (immunostaining)
procedures and the pathologist at MMH (MM) received training in evaluation of the immunos-
taining. The immunostaining was performed as described earlier [5, 18] with some modifica-
tions, by using an in-house polyclonal anti-MPT64 primary antibody at 1/250 dilution and Dako
kit (Dako Envision1 + System-HRP, K4009, Dako, Glostrup, Denmark), to demonstrate the
presence of MPT64 antigens. Briefly, for ICC staining, the slides were hydrated through decreas-
ing grades of alcohol, washed in distilled water for 10 minutes and incubated with hydrogen per-
oxide for 15 minutes to inhibit the endogenous peroxidase activity. Thereafter, the primary
antibody was applied and incubated for 60 minutes. Anti-rabbit dextran polymer conjugated to
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horseradish peroxidase was then applied to the slides for 45 minutes. To visualize the bound anti-
body, the slides were incubated for 10 minutes with 3-amino-9-ethylcarbazol and hydrogen per-
oxide-containing substrate, and the background counterstained with Mayer’s hematoxylin. The
slides were mounted in Immu-Mount (Thermo Fisher Scientific). Between the incubation steps
the slides were washed with wash buffer (Dako Wash buffer 10x, S3006, Dako, Glostrup, Den-
mark). For IHC staining, tissue sections were deparaffinized with xylene, hydrated and after
microwave antigen retrieval using citrate buffer, pH 6.2, subsequently incubated with hydrogen
peroxide for 10 minutes. Additional steps were as in the ICC staining procedure.
Evaluation of immunostaining
The stained slides were evaluated at 20x magnification using a light microscope, and possible
positive signals were further assessed at 40x magnification. The pathologist (MM) evaluating
the slides was blinded for the ZN staining and the Xpert assay results. Signals were regarded
as positive if seen as reddish granular intracytoplasmic staining or extracellular staining in
necrotic areas. The sample was evaluated as weakly positive if 1–2 strong positive or 3 weakly
positive spots were seen, as positive if> 2 strong positive spots or > 3 weakly positive spots,
negative if no positive signal and as inconclusive if 2 weakly positive spots or only uncertain
spots were seen.
Patient categories and morphological criteria
The patients were categorized by using a composite reference standard (CRS) combining the
various diagnostic criteria into 5 separate groups as described in Table 1. The MPT64 test
results were not available during the categorization of patients. Briefly, the morphological cri-
teria taken to be consistent with TB were the presence of granuloma with or without necrosis,
poorly formed granulomas with necrosis or necrosis without granulomas in the biopsy speci-
mens. In FNAC smears from lymph nodes these were granulomatous inflammation with or
without necrosis or necrotic material without granulomas, and in cytological smears from
effusion/cerebrospinal fluid (CSF) the predominance of lymphocytes was taken to be sugges-
tive of tuberculosis.
Statistical analysis
Data was analyzed using Statistical Package for the Social Sciences (SPSS) for Windows version
24.0. Chi-square test was used to compare differences in categorical variables. The performance
of the different diagnostic procedures was calculated using the CRS as a reference. Cross-tabula-
tion was used to calculate sensitivity, specificity, positive predictive value (PPV), negative pre-
dictive value (NPV) and accuracy. P value< 0.05 was considered statistically significant.
Ethical considerations
Ethical clearance was obtained from the Regional Committee for Medical and Health Research
Ethics, Western-Norway (REK Vest) and the Zanzibar Medical Research and Ethics Commit-
tee (ZAMREC). All study participants provided informed written consent. For children, con-
sent was provided by the parent/guardian, in addition, children between 7–18 years had to
sign the consent form as well. The biological specimens were collected on clinical demand and
not based on participation in the study.
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Results
A total of 146 patients were approached and 132 patients were enrolled in the study. The total
number of collected biological specimens were 152 from the 132 study participants. Fig 1 pro-
vides an overview of patients included and specimens collected in the study. According to the
CRS, 12 (9%) were categorized as confirmed TB cases; 34 (26%) as probable TB cases; 18 (14%)
as possible TB cases, 62 (47%) as non-TB cases and 6 (5%) patients were uncategorized. The
uncategorized patients and the specimens collected in these patients were excluded from further
analyses. Thus, 126 patients and the laboratory results from 145 specimens were included in the
data analysis. In most patients, one specimen from the presumptive site of infection was collected
and examined with the various diagnostic procedures. Two different specimens were collected
from the same site in 19 patients (FNAC and biopsy, n = 17; ascites and biopsy, n = 1; pericardial
effusion and biopsy, n = 1). All specimens were examined with the MPT64 test, whereas the rou-
tine methods were missed in some specimens; 143 (99%), 125 (86%) and 72 (50%) of the speci-
mens were examined with ZN staining, culture and the Xpert assay, respectively.
Clinical characteristics
The demographic and baseline characteristics, as well as the distribution of presumptive sites
of infection among the study participants, are described in Table 2. The age distribution
Table 1. Criteria for categorization of patients into various categories of the composite reference standard.
Confirmed TB case Positive mycobacterial culture and/or M. tuberculosis detected by the Xpert assay
Probable TB case Clinical presumptive EPTB and a good response to ATT at 2–3 months and/or end of
treatment or clinical presumptive EPTB and bacteriologically confirmed concomitant
pulmonary TB
and one of the following
• AFB seen on ZN staining of extrapulmonary material
• Radiological findings suggestive of EPTB
• Effusions/CSF: lymphocytosis on fluid cytology and protein level > 3 g/dl (> 1 g/l for
CSF)
• FNAC/biopsy–morphological features consistent with TB
Possible TB case a) Patient started ATT based on clinical presumptive EPTBa
and one of the following
• AFB seen on ZN staining of extrapulmonary material
• Radiological findings suggestive of EPTB
• Effusions/CSF: lymphocytosis on fluid cytology and protein level > 3 g/dl (> 1 g/l for
CSF)
• FNAC/biopsy–morphological features consistent with TB




Negative mycobacterial culture and/or M. tuberculosis not detected by the Xpert assay
and one of the following
• Improvement without ATT and/or response to specific non-tuberculous therapy
• Cytology/histology examination concluded other diagnosis than TB
• Alternative diagnosis concluded by the clinician




not possible to categorize the patient
NOTE. TB, tuberculosis; EPTB, extrapulmonary tuberculosis; ATT, antituberculous treatment; AFB, acid fast bacilli;
ZN, Ziehl-Neelsen; CSF, cerebrospinal fluid; FNAC, fine-needle aspiration cytology.
a Patient died before observation time to assess response to treatment or was lost to follow-up.
b Culture was missing in 4 cases and the Xpert assay was missing in 28 cases. Among these, 3 patients had neither
culture or Xpert assay results.
https://doi.org/10.1371/journal.pone.0196723.t001
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differed significantly between the TB and non-TB cases. The majority of the TB patients were
between 15–44 years (59%), whereas the non-TB patients were predominantly either children
(40%) or above 44 years (29%). HIV status was known in 94 patients, and 21% of these were
HIV positive. In the HIV positive patients, 14/20 (70%) were categorized as TB cases; 3 as con-
firmed TB, 5 as probable TB and 6 as possible TB cases, respectively. Overall, there was a signif-
icant difference in the presumptive sites of EPTB between adults and children (P = .047). In
children, there was a higher proportion of lymphadenitis 29/41 (71%), and lower proportions
of pleuritis 7/41 (17%), peritonitis 2/41 (5%) and other sites 3/41 (7%), while the correspond-
ing proportions among adults were 38/85 (45%), 24/85 (28%), 14/85 (17%) and 9/85 (11%),
respectively. Among the paediatric TB cases (n = 16) the sites of infection were TB lymphade-
nitis (n = 11), pleural TB (n = 3), abdominal TB (n = 1) and TB pericarditis (n = 1).
Most patients (73%) presented with both local and systemic signs and symptoms, more so
in the TB cases compared to non-TB cases, but the difference in proportions was not signifi-
cant. The final diagnoses among the non-TB cases were malignant tumor (n = 18), benign
tumor (n = 5), benign reactive lymphadenopathy (n = 13), heart failure (n = 5), liver disease
(n = 6), meningitis/encephalitis (n = 6), pneumonia (n = 1), endometriosis (n = 1), hydatid
cyst (n = 1), sialadenitis (n = 1) and sclerosing lymphocytic mastitis (n = 1). In 1 patient spon-
taneous resolution of ascites and pleural effusion was observed, 2 patients did not respond to
anti-TB treatment and malignancy was suspected but not confirmed, and in 1 patient the treat-
ing physician did not suspect TB after throughout evaluation.
MPT64 test performance compared to routine laboratory diagnostic tests
and the Xpert assay
The results of all diagnostic procedures among various categories of patients and from avail-
able specimens are presented in Table 3. The MPT64 test was positive in a higher proportion
Fig 1. Flow-chart showing the study design and patient flow in the study. NOTE. EPTB, extrapulmonary
tuberculosis; TB, tuberculosis; CT, computed tomography; FNAC, fine-needle aspiration cytology. a Not included in
the composite reference standard.
https://doi.org/10.1371/journal.pone.0196723.g001
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of specimens as compared to the other tests. In total, 65% of the specimens in TB cases demon-
strated a positive MPT64 test, compared to 12%, 13% and 16% demonstrating positive results
with ZN staining, culture and the Xpert assay, respectively. In specimens examined with all
diagnostic tests, the MPT64 test was positive in 81%, compared to 14%, 16% and 16% of the
specimens showing a positive result with ZN staining, culture and the Xpert assay, respectively
(Table 3). In confirmed TB cases 83% of the specimens had a positive MPT64 test as compared
to 67% positivity for culture and the Xpert assay. All ZN and/or Xpert assay positive samples
were positive with the MPT64 test. Among culture positive samples, 6/8 (75%) were positive
with the MPT64 test. FNAC from lymph nodes was the specimen with the highest number of
positive MPT64 results (76%) compared to pleural fluid, ascites and CSF. Further, all FNAC
from lymph nodes that were positive by ZN staining, culture and/or the Xpert assay were also
positive with the MPT64 test. In non-TB cases, the MPT64 test was negative in 73/76 (96%) of
the specimens. Fig 2 shows the staining pattern at various sites of infection.







Male 35 (55) 35 (56)
Female 29 (45) 27 (44)
Age (years) .014
< 15 16 (25) 25 (40)
15–29 17 (27) 8 (13)
30–44 21 (33) 11 (18)
45 10 (16) 18 (29)
In/outpatient .216
Inpatient 22 (34) 28 (45)
Outpatient 42 (66) 34 (55)
HIV status .517c
Positive 14 (23) 6 (18)
Negative 46 (77) 28 (82)
Unknown 4 (-) 28 (-)
Presumptive site of infection .177
Lymphadenitis 34 (53) 33 (53)
Pleuritis 20 (31) 11 (18)
Peritonitis 6 (9) 10 (16)
Other sitesd 4 (6) 8 (13)
Symptoms/signs at time of inclusion .189
Local 14 (22) 20 (32)
Local and systemic 50 (78) 42 (68)
NOTE. TB, tuberculosis; HIV, human immunodeficiency virus.
a Confirmed, probable and possible TB cases.
b Comparing group differences between TB and non-TB cases.
c Only comparing patients with known HIV status.
d TB cases, meningitis (n = 2), spondylitis (n = 1), pericarditis (n = 1); Non-TB cases, meningitis (n = 6),
osteomyelitis (n = 1), mastitis (n = 1).
 Statistically significant.
https://doi.org/10.1371/journal.pone.0196723.t002
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Diagnostic validation of the MPT64 test
The diagnostic validity of the MPT64 test and other methods in lymphadenitis, pleuritis and
paediatric TB using the CRS as reference standard are shown in Table 4. The sensitivity, NPV
and accuracy of the MPT64 test was better than the other diagnostic tests. The performance of
the MPT64 test was best in TB lymphadenitis, were the sensitivity of the MPT64 test was sig-
nificantly higher as compared to TB pleuritis (P = .025).
The performance of the MPT64 test was better in children (n = 41) as compared to adults
(n = 85) with a sensitivity of 100% and 58% (P = .002) and a specificity of 96% and 95%, respec-
tively. In the HIV positive patients (n = 20) the sensitivity of the MPT64 test was lower
Table 3. Results of diagnostic procedures in effusions, CSF, aspirates and biopsies.
Final diagnosis
Total number of specimens Number of specimens (%) positive by
ZN LJ culture Xpert assay MPT64 test
TB cases–all tests performeda
All samples 37 5/37 (14) 6/37 (16) 6/37 (16) 30/37 (81)
FNAC LN 21 4/21 (19) 4/21 (19) 6/21 (29) 19/21 (90)
Pleural effusion 8 0/8 (-) 0/8 (-) 0/8 (-) 5/8 (63)
TB casesb
All samples 69 8/69 (12) 8/60 (13) c 6/38 (16) d 45/69 (65)
FNAC LN 34 6/34 (18) 5/30 (17) 6/22 (27) 26/34 (76)
Pleural effusion 20 0/20 (0) 1/19 (5) 0/8 (0) 10/20 (50)
Ascites 6 0/6 (0) 1/6 (17) 0/5 (0) 4/6 (67)
CSF 2 0/2 (0) 1/1 (100) 0/1 (0) 1/2 (50)
Biopsies 5 1/5 (20) 0/2 (0) - 2/5 (40)
Pericardial effusion 1 0/1 (0) 0/1 (0) 0/1 (0) 1/1 (100)
Pus 1 1/1 (100) 0/1 (0) 0/1 (0) 1/1 (100)
Confirmed TB cases 12 3/12 (25) 8/12 (67) 6/9 (67) 10/12 (83)
Probable TB cases 39 5/39 (13) 0/31 (0) 0/18 (0) 20/39 (51)
Possible TB cases 18 0/18 (0) 0/17 (0) 0/11 (0) 15/18 (83)
Non-TB casese
All samples 76 0/74 (0) f 0/65 (0) g 0/34 (0) h 3/76 (4)
FNAC LN 32 0/31 (0) 0/31 (0) 0/20 (0) 0/32 (0)
Pleural effusion 11 0/11 (0) 0/10 (0) 0/5 (0) 1/11 (9)
Ascites 10 0/10 (0) 0/9 (0) 0/3 (0) 1/10 (10)
CSF 6 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0)
Biopsies 16 0/15 (0) 0/8 (0) - 1/16 (6)
Pericardial effusion 0 - - - -
Pus 1 0/1 (0) 0/1 (0) - 0/1 (0)
NOTE. CSF, cerebrospinal fluid; ZN, Ziehl-Neelsen staining; LJ, Lowenstein-Jensen; TB, tuberculosis; FNAC, fine-needle aspiration cytology; LN, lymph node.
a Only specimens analyzed with all methods (ZN, LJ culture, Xpert and MPT64 test).
b Five patients with two different specimens from the same site (FNAC and biopsy (n = 4), pericardial effusion and biopsy (n = 1)).
c Contaminated (n = 2) and specimens not sent for culture (n = 7) excluded.
dInvalid results (n = 1) and specimens not analyzed with the Xpert assay (n = 30) excluded.
e Fourteen patients with two different specimens from same site (FNAC and biopsy (n = 13), ascites and biopsy (n = 1)).
fSpecimens not examined with ZN (n = 2) excluded.
g Contaminated (n = 1) and specimens not sent for culture (n = 10) excluded.
h Specimens not analyzed with the Xpert assay (n = 42) excluded.
https://doi.org/10.1371/journal.pone.0196723.t003
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compared to HIV negative cases (n = 74) (57% and 70%, respectively), but the difference was
not significant.
Fig 2. Patterns of immunostaining with anti-MPT64 antibody in various specimens. The signals are seen as granular, reddish staining. A, fine-needle aspirates
from lymph nodes, signals were extracellular probably due to cell lysis (A1), mostly intracytoplasmic (A2-A3), and in necrotic areas (A4); B, pleural effusion,
intracytoplasmic staining; C1-C2, pus/abscess, intracytoplasmic staining; C3-C4, pericardial effusion, intracytoplasmic staining, and non-specific staining mainly of
red blood cells; D1-D2, ascites, intracytoplasmic staining (D1), extracellular probably due to cell lysis (D2); D3-D4, cerebrospinal fluid, extracellular probably due to
cell lysis.
https://doi.org/10.1371/journal.pone.0196723.g002
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Table 4. Diagnostic validation of various procedures among lymphadenitis, pleuritis and children using the CRS as reference standard.











MPT64 test 67 79 (62–91) 97 (84–100) 96 82 88
ZN 67 18 (7–35) 100 (89–100) 100 54 58
Culture 62 16 (5–34) 100 (89–100) 100 54 58
Xpert assay 42 27 (11–50) 100 (83–100) 100 56 62
Pleuritis 31
MPT64 test 31 50 (27–73) 91 (59–100) 91 50 65
ZN 31 0 (0–17) 100 (72–100) NA 35 35
Culture 29 5 (0–26) 100 (69–100) 100 36 38
Xpert assay 13 0 (0–37) 100 (48–100) NA 38 38
Children 41
MPT64 test 41 100 (79–100) 96 (80–100) 94 100 98
ZN 41 13 (2–38) 100 (86–100) 100 64 66
Culture 38 19 (4–46) 100 (85–100) 100 63 66
Xpert assay 22 10 (0–45) 100 (74–100) 100 57 59
NOTE. CRS, composite reference standard; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; ZN, Ziehl-Neelsen staining; NA, not
applicable.
a Results from FNAC and biopsy (n = 17) are combined.
https://doi.org/10.1371/journal.pone.0196723.t004
Table 5. Relationship between various cytomorphological features in fine-needle aspirates from lymph nodes and results of diagnostic procedures.
Number of specimens positive (%) by
Cytomorphology ZN Culture Xpert assay MPT64 test
TB cases (n = 34)
Gr. infl with necrosis (n = 3)  0/3 (0) 0/2 (0) 0/1 (0) 1/3 (33)
Gr. infl without necrosis (n = 1)  0/1 (0) 0/1 (0) 0/1 (0) 1/1 (100)
Supp. infl with necrosis (n = 6)  1/6 (17) 2/5 (40) 2/4 (50) 6/6 (100)
Lymphoid cells and necrosis (n = 4)  2/4 (50) 1/3 (33) 1/2 (50) 3/4 (75)
Abundant necrosis (n = 5)  2/5 (40) 1/4 (25) 1/4 (25) 3/5 (60)
Reactive lymph node hyperplasia (n = 5)  0/5 (0) 0/5 (0) 0/3 (0) 5/5 (100)
Acute supp. infl (n = 8)  1/8 (13) 1/8 (13) 2/7 (29) 7/8 (88)
Inconclusive (n = 2)  0/2 (0) 0/2 (0) - 0/2 (0)
Non-TB cases (n = 32)
Reactive lymph node hyperplasia (n = 13) 0/13 (0) 0/12 (0) 0/8 (0) 0/13 (0)
Acute supp. infl (n = 2) 0/2 (0) 0/2 (0) 0/1 (0) 0/2 (0)
Abundant necrosis (n = 1) 0/1 (0) 0/1 (0) - 0/1 (0)
Benign tumor (n = 3) 0/3 (0) 0/3 (0) 0/1 (0) 0/3 (0)
Malign tumor (n = 10) 0/9 (0) 0/10) 0/9 (0) 0/10 (0)
Inconclusive (n = 3) 0/3 (0) 0/3(0) 0/1 (0) 0/3 (0)
NOTE. ZN, Ziehl-Neelsen staining; TB, tuberculosis; Gr. infl, granulomatous inflammation; Supp. infl, suppurative inflammation.
 Morphological features consistent with tuberculosis. 16% HIV positive.
 31% HIV positive.
https://doi.org/10.1371/journal.pone.0196723.t005
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Cytology/histology
In FNAC from lymph nodes, cytomorphological features consistent with TB were reported in
only 19/34 of the cases, even though the majority of these patients (78%) were HIV negative.
The proportion of HIV positives was slightly lower among the cases with cytology consistent
with TB (16%) as compared to those without (31%), but the difference was not statistically sig-
nificant. The sensitivity of cytology to detect TB was thus 56%. Table 5 shows the results of the
various diagnostic procedures in relation to the cytomorphological features. The MPT64 test
was positive in 14/19 (74%) of the cases showing cytomorphological patterns consistent with
TB, while ZN staining, culture and the Xpert assay were positive in only 5/19 (26%), 4/15 (27%)
and 4/12 (33%), respectively. Among the TB patients without cytomorphological features con-
sistent with TB, the MPT64 test was positive in 12/15 (80%), ZN staining in 1/15 (7%), culture
in 1/15 (7%) and the Xpert assay in 2/10 (20%) of the patients. In 4/34 TB lymphadenitis cases a
lymph node biopsy was performed and the histomorphological picture showed granulomatous
inflammation with necrosis (n = 3) and necrosis without granulomas (n = 1). In these biopsies,
the MPT64 test was positive in 1/4 (25%). Biopsy of pericardium was performed in one TB
patient showing necrosis infiltrated by inflammatory cells, the MPT64 test gave a positive result
in this biopsy.
Discussion
This is the first study to show that the immunochemistry-based MPT64 test, applied on human
specimens from patients with presumptive EPTB, can be implemented in a low-resource rou-
tine diagnostic setting leading to significant improvement in the diagnosis of EPTB. The results
are comparable with previous clinical studies performed in more controlled settings, especially
for TB lymphadenitis [5, 25]. The overall performance of the MPT64 test was better compared
to the other diagnostic tests, with a sensitivity of 83% in the confirmed TB cases.
In FNAC specimens from lymph nodes, the MPT64 test was positive in 76% of the TB cases
(confirmed, probable and possible TB cases) compared to none of the non-TB cases, demon-
strating high sensitivity and excellent specificity. The superior performance of the MPT64 test
for diagnosing TB lymphadenitis using FNAC specimens can have important clinical implica-
tions. FNAC is a simple, safe, cost-effective, minimally invasive procedure ideal for use in
resource-limited settings [26, 27]. The procedure can be performed in out-patient settings,
also in peripheral areas. Fixed slides can then be transported to a hospital with diagnostic facil-
ities for performing cytological evaluation [26, 27]. Further, the possibility of FNAC to distin-
guish TB and malignant disease is very important [28], as empirical use of ATT in patients
with peripheral lymphadenopathy may lead to undue delay of a malignant diagnosis. In the
current study, cytological evaluation of FNAC reported suspected malignancy in 10/66 (15%)
patients presenting with peripheral lymphadenopathy.
The cytomorphological features in patients with TB lymphadenitis varied greatly in our
study, and only 56% of TB cases had morphological features consistent with TB infection, even
if most patients were HIV negative, implying the limited use of cytology for an accurate diag-
nosis of TB. This emphasises the need of additional tests. AFB microscopy does not distinguish
between the M. tuberculosis and NTM, and has low sensitivity in TB lymphadenitis [25, 29].
Even though culture remains the gold standard of diagnosis, the need for advanced laboratory
facilities and the long turnaround time is a challenge in resource-limited settings. The MPT64
test could provide a rapid and confirmative diagnosis of TB lymphadenitis using FNAC speci-
mens, where culture results are absent or takes weeks to be completed. In the current study, all
culture positive FNAC from lymph nodes were positive with the MPT64 test.
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The sensitivity of the MPT64 test was significantly higher in children than in adults. This
could be biased by the higher proportion of TB lymphadenitis cases amongst the children. Still,
the sensitivity of the MPT64 test in FNAC specimens from lymph nodes was better in children
than in adults (100% vs. 65%). FNAC has been suggested as the diagnostic modality of choice
also in children [27]. In the recent years childhood TB has received increased attention, and
global estimates imply that the diagnosis of TB is often missed in children and only one third of
children developing active TB are notified [30]. In endemic areas, peripheral lymphadenitis is
the most common extra-thoracic site of TB in children [31]. The MPT64 test could therefore be
very useful in the correct diagnosis of TB lymphadenitis among children.
In the present study, we have also evaluated the MPT64 test according to HIV status, and
found no significant difference in sensitivity or specificity when comparing HIV negative to
HIV positive patients, implying that the MPT64 test could have an important clinical impact
also in this patient group. However, because of the low number of HIV positive cases (n = 20)
in this study, the test needs to be evaluated using a larger sample size.
Developing new laboratory diagnostic tests for EPTB is demanding, because of the range of
various specimens, challenges with obtaining adequate samples, defining optimal sample vol-
umes, the diverse ways of sample processing and the problem of imperfect reference standards.
Culture is still used as the gold standard, but is known to be of limited value in EPTB [12, 13],
which makes it difficult to evaluate a new diagnostic test. Using a suboptimal reference stan-
dard may potentially misclassify patients as TB or non-TB cases and bias the results of the test
under evaluation [32]. To overcome this challenge, we chose to compare the MPT64 test with
a CRS and the patients were categorized according to this CRS (Table 1). Culture and Xpert
assay results were available in 86% and 50% of the specimens included in the data analysis.
Only 8 specimens were positive with culture and 6 specimens were positive with the Xpert
assay. The CRS classified 64 patients as TB cases. Therefore, using only culture as a reference
standard would have underestimated the true value of the MPT64 test. The low sensitivity of
culture in this study could partly be explained by loss of viable bacilli during transport to
PHL-IdC at Pemba, the paucibacillary nature of EPTB disease and the possibility of uneven
distribution of bacilli in the specimens sent to analyses. Further, two patients had started ATT
for 5 and 17 days before specimens were collected, influencing the bacterial viability.
The evaluation of the Xpert assay is challenging in our study, as only 50% of the specimens
were examined with this method. A previous study described a sensitivity of 70.6% in lymph
nodes when the Xpert assay was compared against culture [33]. In a review, a pooled sensitivity
of the Xpert assay in lymph node samples was reported to be 83.1% when compared against
culture and 81.2% when using a CRS as a reference standard [12]. In the current study only 5
lymph node samples were culture positive, of these 3/4 (75%) were positive with the Xpert
assay. Even though the numbers are low, one could get an impression that the sensitivity of the
Xpert assay compared to culture is comparable to other studies using culture as a reference
standard. The reason for the low sensitivity of the Xpert assay compared to the CRS in the cur-
rent study could be due to different criteria incorporated in the CRS in our study and other
studies reporting a higher sensitivity of the Xpert assay assessed against a CRS.
There are some limitations of this study. The sample size is small which makes it difficult to
do further subgroup analysis of the performance of the MPT64 test according to all presump-
tive sites of infection. Secondly, there is a heterogeneity in the number of tests performed in
patients with different types of EPTB clinical presentation. This is due to the study design,
where the new MPT64 test was evaluated for its performance in the routine, without interfer-
ing with other routine diagnostic procedures. All samples were not subjected to all routine
diagnostic methods due to various reasons. This may have influenced the performance of the
component tests and the new test under assessment. Thirdly, the CRS may have reduced
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specificity, as defining a TB case based on clinical presumptive EPTB and response to ATT
does not provide an accurate diagnosis of TB. It was therefore decided to subdivide the TB
cases into “confirmed”, “probable” and “possible” TB cases and present the results of the vari-
ous diagnostic tests for the separate groups.
Conclusions
The MPT64 test is a robust, rapid, sensitive, and specific test for the etiological diagnosis of
EPTB. It can differentiate between Mycobacterium tuberculosis complex species and NTM, and
performs better than conventional methods and the Xpert assay. The test is particularly useful
in correct diagnosis of TB lymphadenitis and in childhood TB, and performs equally well in
HIV infected patients. Like any diagnostic test it should be interpreted together with the clini-
cal history, examination and routine investigations. We show that the MPT64 test can be
implemented in a routine laboratory in a low-resource setting, where improved diagnostics
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Early and proper treatment of tuberculosis could have an important impact on the morbidity,
mortality and the economic situation of patients. There is insufficient knowledge on the
extent of diagnostic delay and the associated factors in extrapulmonary tuberculosis
(EPTB). The aims of this study were to assess the health care seeking behaviour, EPTB
knowledge and diagnostic delay in presumptive EPTB patients at the main referral hospital
in Zanzibar, factors associated with longer delay, and the impact of untreated EPTB on self-
rated health.
Materials and methods
Prospective data collection using a semi-structured questionnaire in patients presenting
with symptoms suggestive of EPTB. The time between the onset of symptoms and first visit
to a health care provider (patient delay), and then to the initiation of treatment (health system
delay) and total delay were analysed according to sociodemographic and clinical factors
and health care seeking trajectories. The EQ-5D-3L was used among the adult EPTB
patients to assess the impact of treatment on self-rated health.
Results
Of the 132 patients with median age of 27 years (interquartile range 8–41), 69 were catego-
rized as TB cases and 63 as non-TB cases. The median patient, health system and total
delays were 14, 34 and 62 days respectively, among the EPTB patients. A longer health
system delay with repeated visits to the same health care level was reported. Significantly
better self-rated health status was described after treatment. The knowledge regarding
extrapulmonary disease was low.
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Conclusion
Many EPTB patients, presenting to the main referral hospital in Zanzibar, experience a long
delay in the initiation of treatment, specially patients with TB lymphadenitis. The health sys-
tem delay is the major contributor to the total delay. The improvement of self-rated health
after treatment implies that timely treatment has the potential to reduce morbidity and the
economic loss for the patient.
Introduction
Tuberculosis (TB) continues to be a major global public health problem. In 2015, the World
Health Organization (WHO) estimated that there were 10.4 million incident cases of TB
worldwide [1]. Of the notified new cases, extrapulmonary TB (EPTB) accounted for 15% of
the cases [1]. The proportion of EPTB is higher in females [2–6], people with African or Asian
origin [2–4], TB and human immunodeficiency virus (HIV) co-infected patients [2, 3, 7] and
at younger ages [2–6].
Timely detection and proper treatment of TB are two of the key elements of an effective TB
control programme [8]. In the context of the WHO‘s End TB strategy, which calls for early
diagnosis and treatment of all TB cases [9], the detection, treatment and follow-up of EPTB
cases should also be given priority. Diagnosing EPTB is challenging as it frequently has non-
specific clinical presentation and may simulate other conditions, which may contribute
towards delay in diagnosis. In addition, lack of rapid, simple and accurate diagnostic tools for
diagnosing EPTB may prolong diagnostic delay [10]. Since EPTB is rarely infectious the aspect
of transmission is not as important as in pulmonary TB (PTB) patients, but delay in diagnosis
and treatment could lead to increased disease severity, more complications and economic
costs for the patient and the families affected.
Most studies on the diagnostic delay in TB have focused on PTB and adults [11–13]. Fewer
studies have included children and EPTB patients, and these studies have reported longer
delays among EPTB patients as compared to PTB [14–17]. However, there is insufficient
knowledge on the extent of the various delays and the associated factors among EPTB patients.
It is important to identify factors contributing to the distinct types of delays in EPTB, which
could provide information for evidence-based intervention to improve case-finding and
prompt diagnosis and treatment.
The United Republic of Tanzania is among the 30 high TB burden countries in the world
[1]. Zanzibar, a semi-autonomous part of the United Republic of Tanzania, comprising the
two main islands Unguja and Pemba and some smaller islands, has 1.3 million inhabitants
[18]. According to a national TB prevalence survey in 2012, the estimated prevalence of
bacteriologically confirmed PTB in Zanzibar was 124/100 000 in the adult population [19].
Among the 814 notified incident TB cases in Zanzibar in 2015, 195 (24%) were EPTB cases
[20]. Zanzibar has 100% directly observed treatment coverage, however, the notified TB cases
are still below the estimated numbers of TB cases.
The aims of this study were to assess the health care seeking behavior, EPTB knowledge and
diagnostic delay in presumptive EPTB patients presenting at the Mnazi Mmoja Hospital
(MMH), Zanzibar, the factors associated with longer delay and the impact of untreated EPTB
on self-rated health status of patients. The presumptive EPTB cases were categorized into TB
and non-TB cases based on a composite reference standard allowing us to compare the TB and
non-TB cases with similar clinical presentation.
Diagnostic delay in extrapulmonary tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0203593 September 6, 2018 2 / 17
Funding: This work was partly supported by the
Research Council of Norway through the Global
Health and Vaccination Programme [project
number 234457]. This project is part of the
EDCTP2 programme supported by the European
Union. The Department of International
Collaboration (DIC), Haukeland University Hospital,
Norway, provided logistic and financial support for
relocation of the first author and her family in
Zanzibar during the study period. The funders had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. There was no additional external
funding received for this study.
Competing interests: The authors have declared
that no competing interests exist.
Materials and methods
Study setting
The study was conducted at MMH, which is the main referral hospital in Zanzibar. The public
health care system in Zanzibar is divided into three levels [21]. The primary level consists of
primary health care units (PHCU), PHCU+, which are supposed to provide additional services
of delivery, dental, dispensing and laboratory, and primary health care centres/cottage hospi-
tals (PHCC) which serve as referral level for PHCU and PHCU+. PHCCs has both in- and out-
patient services, average capacity of 30 beds, and provides additional services such as
diagnostic imaging (ultrasound and x-ray). The secondary and tertiary level consist of district
hospitals, special and referral hospitals. In 2013, there were 100 PHCUs, 34 PHCU+, 4 PHCCs,
3 district hospitals, 2 special hospitals and 1 main referral hospital (MMH) in Zanzibar [21].
MMH, situated in the capital at Unguja Island, provides primary and secondary health care for
some districts, in addition to tertiary health care. There is a good distribution and access to pri-
mary health care services, with 95% of the population living within 5 km to the nearest public
health facility [21]. However, there is a limited capacity to perform invasive procedures for
diagnostic purposes at the primary level of health care. MMH is the only public hospital with
the capacity to perform the diagnostic cytological/histological evaluation of fine-needle aspi-
rates and biopsies. In 2013/14, there were 4 private hospitals, all situated at Unguja Island, 71
private clinics/dispensaries, 25 pharmacies and 335 over-the-counter drug shops in Zanzibar
[22]. The private health facilities are predominantly located in the major towns. The TB pre-
ventive, diagnostic and treatment services are integrated into the public health service at all
levels. Anti-TB treatment (ATT) is free of charge and all public health facilities and some pri-
vate facilities are providing TB treatment services. TB/HIV collaborative activities are well-
organized, and all TB patients are offered HIV testing and counselling.
Study design and population
The study participants were prospectively enrolled at MMH, from 1st of August 2014 until 31st
of August 2015, from outpatient departments and the hospital wards. The study population
was patients of all ages presenting with symptoms suggestive of EPTB. The current study was
part of a larger study evaluating the implementation of a new diagnostic test for the diagnosis
of EPTB at MMH [23], and eligible patients were included if a representative biological speci-
men was sampled for laboratory investigations from the presumptive site of EPTB infection.
Those who did not give an informed written consent or had received ATT during the previous
year were excluded. All study participants were interviewed at the time of inclusion using a
pretested semi-structured questionnaire and closely followed until a diagnosis was concluded
by the local clinicians. Additional visits to health care providers after inclusion in the study
were documented. Patients starting ATT were further assessed at 2–3 months and at end of
ATT to evaluate response to treatment, and patients not starting ATT were followed until
recovery or until a diagnosis was established. At the end of the study, patients were categorized
as TB cases or non-TB cases using a composite reference standard, including clinical signs and
symptoms, radiological findings, results from various laboratory investigations, response to
specific non-tuberculous therapy and response to ATT [23].
Data collection and outcomes
The main outcomes were patient, health system and total delays in days. Additionally, we
assessed general TB knowledge and EPTB knowledge among all the study participants and
self-rated health status in adult EPTB patients before ATT and after the completion of ATT.
Diagnostic delay in extrapulmonary tuberculosis
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The following definitions were used. The onset of symptoms referred to the time at which
the first symptom appeared, either localized symptoms or constitutional symptoms which led
to the care-seeking. The patient delay was defined as the time interval between the onset of
symptoms and the patients‘first visit to a health care provider because of those symptoms. The
health system delay was defined as the time interval between the patients‘first visit to a health
care provider and the initiation of ATT. The total delay was defined as the sum of patient delay
and health system delay. Health care providers were defined as modern health facilities such as
private clinics/dispensaries, PHCU, PHCU+, PHCC or hospitals owned by the government or
the private sectors. Registered pharmacies were also included, whereas, non-formal health pro-
viders, such as traditional healers and over-the-counter drug stores were not included in this
definition.
A semi-structured questionnaire was developed in English and translated to the local lan-
guage, Swahili. Further, the Swahili version was translated back to English by a person who
had not seen the original version. The two English versions were compared to evaluate the
validity of the questions. To adjust the language to the local setting, two local bilingual individ-
uals assessed the questions prior to testing the questionnaire among inpatients (n = 3) at
MMH to clarify confusing questions and estimating the required time for filling in the ques-
tionnaire. Two local medical officers, who underwent training, conducted all the interviews.
Included in the questionnaire were questions related to sociodemographic characteristics,
symptoms and their duration, estimation of the time interval from the onset of symptoms
until the first contact with a health care provider, number of different health care providers
contacted due to the current illness and other questions regarding medical history, health care
seeking behavior and TB knowledge [23]. The date of starting ATT and medical history were
counterchecked from patient medical records and TB treatment cards.
The study participants‘TB knowledge was assessed by questions related to symptoms, site of
infection, transmission and treatment of TB (S1 Table). A scoring system was designed based
on these questions and the median score among all the respondents was used as a cut-off point
to dichotomize the responses into two categories, lesser (below the median) and higher (equal
or above the median) TB knowledge. The TB knowledge questions were answered by the par-
ent/guardian for study participants < 15 years of age.
In addition to the questionnaire, the adult patients starting ATT answered the EQ-5D 3
level version (EQ-5D-3L) [24], before and after ATT, to provide a simple descriptive health
profile on self-rated health. The EQ-5D-3L comprises the EQ-5D descriptive system and the
EQ visual analogue scale. The EQ-5D descriptive system consists of 5 dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression) with 3 levels (level 1, no
problems; level 2, some problems; level 3, extreme problems). The EQ VAS comprises a verti-
cal, visual analogue scale, with endpoints labelled “Best imaginable health state”, marked 100,
and “Worst imaginable health state”, marked 0, and records the respondent‘s self-rated health
at the time of completion. The EQ-5D-3L was provided in the local language (EuroQoL Group
1990).
The exposure variables included age, sex, educational level, housing, HIV status, site of TB
disease, self-treatment before care-seeking, distance to the nearest health care provider, initial
health care provider visited after the onset of symptoms, antibiotics given at first visit, number
of visits to health care providers, and TB knowledge.
Statistical analysis
Descriptive statistics were presented, and group differences were compared using the Chi-
square test for proportions. Differences in the delay variables were assessed by Mann-Whitney
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or Kruskal-Wallis tests for differences between the groups as well as Wilcoxon signed rank test
for repeated measures. The general significance level was set to 0.05. Due to the larger number
of tests we had to consider multiple testing effects. We used the Bonferroni adjustment, leading
to the marginal levels of 0.0083 (6 tests) for sociodemographic and clinical characteristics, 0.01
(5 tests) for first health care provider visited, 0.0042 (12 tests) for the delay, and 0.0125 (4 tests)
for TB knowledge score. Data analysis was performed using SPSS 24 (Armonk, NY) and
graphics was created using Matlab 9.0 (Natick, MA).
Ethical considerations
Ethical clearance was obtained from the Regional Committee for Medical and Health Research
Ethics, Western-Norway (REK Vest) and the Zanzibar Medical Research and Ethics Commit-
tee (ZAMREC). All study participants signed an informed written consent. In patients < 18
years, the written consent was signed by the parent/guardian, in addition, patients 7 years
had to sign the consent form.
Results
Sociodemographic and clinical characteristics
Of 146 eligible patients presenting with presumptive EPTB, 132 patients were enrolled in the
study and 14 excluded (5 refused to participate, 3 on treatment within the last year, 6 with no
representative sample for laboratory investigation). Sixty-nine participants were categorized as
TB cases, and 63 as non-TB cases. The sociodemographic and clinical characteristics of the
included study participants are described in Table 1. The TB and non-TB patients did not dif-
fer significantly with regard to sex, residence, educational level, HIV status or presumptive site
of infection. The median age was 27 years (interquartile range (IQR), 8–41 years). Most of the
non-TB patients were either children or 45 years, whereas the majority of the TB patients
were between 15–44 years. HIV status was known in 99 (75%) patients, and 22 (22%) of these
were HIV positive.
Health care seeking behaviour and care seeking pathways
Table 2 shows the distribution of health care seeking trajectories among the TB and non-TB
patients. The majority of patients consulted public health care providers as their first contact
with the health care system after the onset of symptoms. Patients who first visited a public
health care provider were similar to those who initially went to a private health care provider
with regard to sex, age groups, residence, HIV status and TB category (TB or non-TB cases)
(all P> .1). Further, no differences were found regarding the same variables when comparing
those who contacted MMH first with patients who initially visited any health care provider
other than MMH. Overall, 39 patients (30%) sought care at MMH as their first contact, while
32 (24%) at PHCUs, 22 (17%) at private clinics/dispensaries, 18 (14%) at PHCC/district hospi-
tals, 18 (14%) at private hospitals and 2 (2%) at pharmacies. The practice of self-medication
before contacting a health care provider was common and reported by 46% of the patients.
When excluding patients only consulting MMH, 45/99 (45%) patients, reported repeated visits
at the same level in the health care system before referral to MMH. Repeated visits to MMH
before the commence of ATT were reported by 56/69 (81%) of the TB cases. Nearly half of the
TB patients had> 3 visits to a health care provider, and 26% had visited 3 different health
care providers, either at the same level or different level of health care, before the initiation of
ATT. The most common care-seeking pathways among TB patients were; 18 (26%) patients
had only visited MMH, 14 (20%) private clinic/dispensary and MMH, 9 (13%) private hospital
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and MMH, 9 (13%) PHCU and MMH, and 7 (10%) patients had been in contact with PHCC/
district hospital and MMH. The patients were also asked to report if they had visited a tradi-
tional healer during the care-seeking interval. Only 7/69 (10%) of the TB patients reported vis-
iting a traditional healer, 6 of these patients were females and all were 15 years. An
illustration of health care seeking pathways among the TB cases is presented in Fig 1.
Table 1. Sociodemographic and clinical characteristics of the study participants, n (%).
Characteristics TB patients non-TB patients P value
n = 69 n = 63
Sex .811
Male 38 (55%) 36 (57%)
Female 31 (45%) 27 (43%)
Age groups, years .010
0–14 18 (26%) 25 (40%)
15–44 40 (58%) 20 (32%)
45 11 (16%) 18 (29%)
Residential status .871
Urban 48 (70%) 43 (68%)
Rural 21 (30%) 20 (32%)
Highest educational levela .592
 primary school 26 (51%) 21 (57%)
> primary school 25 (49%) 16 (43%)
Main household incomeb
Agriculture/fishing 19 (33%)
Governmental/private sector 15 (26%)
Self-employed 24 (41%)
Housingc
Own house 37 (59%)
Renting/living with relatives 26 (41%)





Negative 48 (75%) 29 (83%)
Positive 16 (25%) 6 (17%)
Unknown 5 (-) 28 (-)
Presumptive site of infectionf .263
Lymphadenitis 36 (52%) 33 (52%)
Pleuritis 20 (29%) 12 (19%)
Other sitesf 13 (18%) 18 (29%)
Abbreviations: TB, tuberculosis; HIV, human immunodeficiency virus.
a Only adult patients. Patients with missing values excluded (n = 1).
b, c, d Patients with missing values excluded (n = b; 11, c, d; 6). Not recorded for non-TB patients.
e Only comparing patients with known HIV serostatus.
f TB patients; meningitis (n = 4), spondylitis (n = 1), pericarditis (n = 1), peritonitis (n = 7). Non-TB patients; meningitis (n = 6), osteomyelitis (n = 1), mastitis (n = 1),
peritonitis (n = 10).
https://doi.org/10.1371/journal.pone.0203593.t001
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Table 2. Distribution of health care seeking trajectories and TB knowledge, n (%).
Variable TB patients non-TB patients P value
n = 69 n = 63
Self-treatment before care seekinga .959
Yes 31 (46%) 29 (46%)
No 37 (54%) 34 (54%)
Distance to nearest HCP (time)b
< 30 min 15 (23%)
30–60 min 32 (49%)
> 60 min 18 (28%)
First HCP visitedc .281
Public 44 (64%) 45 (73%)
Private 25 (36%) 17 (27%)
First HCP visitedc .861
MMH 21 (30%) 18 (29%)
HCP other than MMH 48 (70%) 44 (71%)
Antibiotics given at first visitd .869
Yes 38 (58%) 36 (59%)
No 28 (42%) 25 (41%)
Given a diagnosis prior to interviewe .672
No 36 (59%) 38 (66%)
Yes, other diagnosis than tuberculosis 21 (34%) 18 (31%)
Yes. Tuberculosis 4 (7%) 2 (3%)
Number of different HCPf
1 18 (26%) 14 (23%)
2 33 (48%) 28 (45%)
3 11 (16%) 13 (21%)
4 7 (10%) 7 (11%)
Number of visits to HCPg
1 2 (3%) 5 (9%)
2 10 (14%) 14 (25%)
3 24 (35%) 19 (33%)
4 7 (10%) 8 (14%)
5 26 (38%) 11 (19%)
TB knowledgeh .607
Good (median) 38 (56%) 38 (60%)
Poor (<median) 30 (44%) 25 (40%)
EPTB knowledgeh
Yes 1 (1%) 0 (-)
No 67 (99%) 63 (100%)
Abbreviations: TB, tuberculosis; HCP, health care provider; MMH, Mnazi Mmoja Hospital; EPTB, extrapulmonary
tuberculosis.
a Patients with missing values excluded (n = 1)
b Patients with missing values excluded (n = 4). Not recorded for non-TB patients.
c, d, e Patients with missing values excluded (n = c; 1, d; 5, e; 13).
f, g Patients with missing values excluded (n = f;1, g; 6). No comparison between TB patients and non-TB patient
because the number of various health carer providers visited and the number of visits for TB patients were recorded
until starting antituberculosis treatment, but for non-TB patients only to the day of the interview.
h Patients with missing values excluded (n = 1).
https://doi.org/10.1371/journal.pone.0203593.t002
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Diagnostic delay and associated factors
The patient, health system and total delays observed in TB patients are described according to
different variables in Table 3. The median patient delay was 14 days (TB cases IQR, 5–28 days;
non-TB cases IQR, 6–28 days) with no significant difference between TB and non-TB cases
(P = .794). Patients with TB lymphadenitis reported a significantly longer patient delay com-
pared to patients with other sites of TB disease. Interestingly, the median patient delay for
those who first consulted MMH was 28 days compared to 11 days for those who initially visited
other health facilities, but the difference was not statistically significant.
The median health system delay among TB patients was 34 days (IQR, 19–76 days). Patients
seeking care at MMH at first consultation reported a significantly shorter health system delay
as compared to the patients visiting other health care providers first (P = .001). A longer health
system delay was found in patients with > 3 visits to health care providers compared to those
with 3 visits (P< .001). The health system delay tended to be longer among respondents
with higher educational level, TB lymphadenitis and who were HIV negative, as compared to
those with lower educational level, other sites of TB infection and who were HIV positive,
respectively, but without reaching statistical significance. Among patients first consulting
other health facilities than MMH, the health system delay before referral to MMH was signifi-
cantly longer than the delay at MMH (median, 22 vs. 11 days, P = .011).
The median total delay among TB patients was 62 days (IQR, 31–126 days), 15% had much
longer total delay exceeding 6 months and 8% had total delay exceeding one year. Among the
patients delaying > 6 months, 90% were diagnosed with TB lymphadenitis. The health system
Fig 1. Health care seeking pathways in TB patients presenting at Mnazi Mmoja Hospital, Zanzibar. The size of the
arrows shows the number of patients going in the direction of the arrow in the health care system. The size of the
circles correlates to the number of patients visiting each respective site as the first place of contact (Mnazi Mmoja
hospital, n = 21; private clinic/dispensary, n = 16; primary health care unit, n = 14; primary health care centre/district
hospital, n = 9; private hospital, n = 8; pharmacy, n = 1). Colour—Dark grey, public health sector; light grey, private
health sector. Repeated visits at the same health care level, either same place or different health care provider at the
same level. Abbreviations: PHCC, primary health care centre; PHCU, primary health care unit.
https://doi.org/10.1371/journal.pone.0203593.g001
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Table 3. Patient delay, health system delay and total delay among TB patients by sociodemographic and clinical variables and health care seeking trajectoriesa.
Variable Patient delay (days) Health system delay (days) Total delay (days)
n median (IQR) P value n median (IQR) P value n median (IQR) P value
Sex .400 .235 .777
Male 38 13 (5–28) 36 36 (20–106) 36 58 (29–151)
Female 30 18 (6–47) 29 28 (14–67) 29 69 (31–118)
Age groups, years .674 .585 .137
0–14 18 10 (5–28) 17 28 (22–65) 17 36 (28–113)
15–44 40 18 (4–42) 39 41 (16–115) 39 72 (34–163)
45 10 11 (7–26) 9 23 (16–61) 9 34 (26–94)
Educational levelb .831 .032 .297
primary school 25 17 (4–79) 23 23 (11–51) 23 61 (31–108)
>primary school 25 16 (6–28) 25 48 (22–118) 25 91 (33–171)
Housing .253 .318 .031
Own house 36 13 (4–21) 35 28 (21–51) 35 41 (28–96)
Renting/living with relatives 26 21 (5–47) 26 59 (16–118) 26 98 (54–167)
HIV status .734c .055c .727c
Negative 48 15 (5–36) 46 42 (21–110) 46 64 (30–155)
Positive 15 17 (5–41) 14 21 (10–67) 14 67 (31–121)
Unknown 5 8 (5–16) 5 28 (21–43) 5 36 (31–53)
Site of TB infection < .001 .091 < .001
Lymphadenitis 35 28 (14–76) 34 55 (22–118) 34 99 (62–189)
Pleuritis 20 6 (4–11) 19 28 (16–48) 19 34 (20–65)
Other sites 13 6 (3–17) 12 22 (16–42) 12 30 (26–60)
Self-treatment before care seeking .870 .962 .903
Yes 30 18 (4–42) 28 39 (17–80) 28 61 (30–141)
No 37 11 (6–28) 36 27 (20–79) 36 68 (30–127)
First HCP visited .025 .001 .445
MMH 21 28 (8–111) 19 21 (7–34) 19 91 (31–124)
Other than MMH 47 11 (4–21) 46 46 (23–111) 46 61 (28–133)
Antibiotics given at first visits .141
Yes - 35 41 (21–118) -
No - 27 24 (17–60) -
Distance to nearest HCP (time) .553 .500 .993
< 30 min 15 7 (6–38) 15 28 (16–86) 15 72 (21–179)
30–60 min 32 14 (4–28) 31 41 (23–86) 31 61 (30–129)
< 60 min 17 17 (6–67) 17 23 (14–56) 17 61 (30–124)
Number of visits to HCP < .001
3 - 34 21 (12–29) -
>3 - 31 69 (41–138) -
TB knowledge .930 .280 .531
Good (median) 37 14 (5–28) 35 28 (16–70) 35 62 (29–112)
Poor (<median) 30 14 (5–47) 29 41 (21–113) 29 65 (31–184)
Abbreviations: TB, tuberculosis; IQR, interquartile range; HIV, human immunodeficiency virus, HCP, health care provider; MMH, Mnazi Mmoja Hospital
a Patients with missing values excluded
b Only adult patients included.
c Only comparing patients with known HIV serostatus
 P value < 0.05
 Statistically significant, P value < 0.0042.
https://doi.org/10.1371/journal.pone.0203593.t003
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delay was significantly longer as compared to the patient delay (P< .001) and the greatest con-
tributor to the total delay. In 80% of the patients the health system delay was longer than the
patient delay. A longer total delay was noted for patients renting a house/living with relatives
compared to patients owning their house, but the difference was not statistically significant.
The only significant difference in total delay was found when comparing delay according to
the site of TB disease, where a longer total delay was experienced by patients with TB lymphad-
enitis (P< .001), where 26% of the TB lymphadenitis patients faced a total delay exceeding 6
months.
TB knowledge
Table 2 shows the level of TB knowledge among the TB and non-TB patients and S1 Table
presents the distribution of answers to the various TB knowledge questions according to TB
category, sex, HIV status and educational level. The knowledge about extrapulmonary site of
TB was extremely poor. Fifty-five percent knew that the lungs could be affected by TB, as com-
pared to only one patient who mentioned an extrapulmonary site. Most patients (93%) had
heard of TB disease before being included in the study, and 73% answered respiratory and/or
constitutional symptoms when asked about symptoms of TB disease. None of the respondents
mentioned any other local symptoms than respiratory symptoms. Most of the respondents
knew that TB is a curable disease (69%) and that TB can spread from person to person (79%).
The median TB knowledge score was 5 (IQR, 3–6). The respondents with education above pri-
mary level had a higher TB knowledge score compared to patients with lower educational level
(P = .007).
Morbidity due to TB and improvement in self-rated health status after
treatment
In the adult EPTB patients, 19/47 (40%) reported that they had completely stopped working
and 20/47 (43%) reported reduced working capacity due to the current illness. Among respon-
dents with TB lymphadenitis (n = 23), 70% reported reduced working capacity/stopped work-
ing, while this was noted in 96% of the respondents with other sites of TB infection (n = 24).
The TB lymphadenitis patients reported a median of 90 days (IQR, 60–120 days) of reduced
working capacity/stopped working, and patients with other sites of TB infection a median of
30 days (IQR, 14–60 days). Adult EPTB patients (n = 31) reported significantly higher self-
rated health in the EQ VAS after compared to before ATT. The median EQ VAS score before
and after ATT was 60% (IQR 48–80%) and 96% (IQR 90–100%) (P< .001), respectively.
Respondents with TB lymphadenitis (n = 17) had a relatively better self-rated health before
treatment, (EQ VAS; median, 79%, IQR, 50–91%) as compared to patients with other sites of
TB infection (pleuritis, n = 10; peritonitis, n = 3; spondylitis, n = 1) (EQ VAS; median, 50%,
IQR, 38.5–60%) (P = .015). Both groups reported significantly higher self-rated health after
treatment as compared to before treatment (TB lymphadenitis, P = .002; other sites of TB
infection, P = 0.001) (Fig 2). A similar pattern was observed when the health status was
assessed with the EQ-5D descriptive system. Before treatment, patients with other sites of TB
infection described more problems in all dimensions as compared to patients with TB lymph-
adenitis. Still, both groups reported lesser problems at the end of treatment than before treat-
ment (Fig 3).
Discussion
This study found that many EPTB patients, presenting to the main referral hospital in Zanzi-
bar, experienced significant delay from the onset of symptoms until the start of TB treatment.
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Fig 2. Scatterplot showing the EQ visual analogue scale scores before and after TB treatment. The scores are divided according to the site of TB infection,
where the TB lymphadenitis patients are indicated with blue colour and other sites of TB infection with orange colour. The median scores in both groups
before and after treatment are shown. Both groups reported significantly higher self-rated health after treatment.
https://doi.org/10.1371/journal.pone.0203593.g002
Fig 3. Stacked bar plot describing the patient statements in each of the 5 dimensions of the EQ-5D descriptive system before and after TB treatment.
Level 1, no problems; level 2, some problems; level 3, extreme problems. Both groups reported lesser problems after treatment.
https://doi.org/10.1371/journal.pone.0203593.g003
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Even though EPTB have been reported as a predictor of longer delays [14–16, 25–27], most
earlier studies have been focusing on delay and associated factors in PTB, particularly smear-
positive PTB. Cases of EPTB are seldom infectious and thus have less consequences for the
spread of the TB disease, and probably therefore have not been studied specifically. However,
for the patients, delay in the start of treatment may results in increased morbidity and mortal-
ity. A study from South-Africa [28], reported increased mortality when provider delay
was 30 days. Further, TB poses an economic burden on affected patients and their house-
hold [29, 30]. In our study, 83% of the adult EPTB patients reported that they had completely
stopped working or had reduced working capacity due to the current illness, a finding similar
to a study from Kenya [30], where 85% of the respondents reported a decrease in the number
of hours worked per week as a result of TB illness. Further, the adult EPTB patients in our
study reported significantly higher self-rated health using the EQ VAS and described lesser
problems in the EQ-5D descriptive system after TB treatment. Thus, this indicates that reduc-
ing the delay in the diagnosis and treatment of EPTB could decrease patient morbidity and
have a positive impact on the economic situation for the patients and their families.
To the best of our knowledge there is no defined consensus on what constitutes acceptable
and unacceptable delay in the diagnosis and initiation of treatment in EPTB patients. Some
studies also including EPTB patients have used> 30 days and> 14 days as unacceptable
patient and health system delay, respectively [17, 31]. Using these cut-offs, 76% of the EPTB
patients in the present study reported to a health care provider within the acceptable patient
delay, whereas only 17% had acceptable health system delay.
The total delay with a median of 62 days was found to be in agreement with previous
reports including EPTB patients from resource-constrained settings [17, 25, 32], while other
studies have found longer total delays [33]. Long total delays among EPTB patients have also
been reported in industrialized countries [16, 27]. Previous studies have demonstrated that
there is no consistent pattern of patient and health system delays between various settings. In
the current study, health system delay was the major contributing factor to the total time to
diagnosis and treatment, consistent with studies from settings as diverse as India [34], South
Africa [28] and France [35]. Other studies from Nepal [32], Ethiopia [26] and Denmark [27]
have reported patient delay as a major contributor towards total delay. These studies indicate
that factors contributing to delay may vary depending on the setting and the study population.
The median patient delay of 14 days in our study was short compared to the patient delay
reported in studies from Rwanda [25], Angola [36], Ethiopia [26] and mainland Tanzania
[37], but longer than a study among children in Delhi, India [34]. These differences may be
explained by the different distribution of urban and rural populations in the various studies,
and in the availability of medical care. Unlike the findings reported from the United Kingdom
[38] and Norway [14] we found no difference in patient delay according to age groups. In
addition, no difference in patient delay was noted between men and women, a finding similar
to Ethiopia [26], but different from South Africa [28], where a longer patient delay was
reported among males. Self-treatment before consulting a health care provider was common
in our study, but were not associated with longer patient delay, a finding different from a study
from Ethiopia [15] reporting self-treatment as a predictor of patient delay. In our study few
(10%) patients reported visiting a traditional healer, which may also be an explanation for the
relative short patient delay, as consulting traditional healers is consistently reported to be asso-
ciated with longer patient delay [12].
The median health system delay of 34 days was longer than acceptable and a significant
contributor towards total delay in our study. This is comparable with delay reported in previ-
ous studies also including EPTB patients from Ethiopia [15], South Africa [28] and Rwanda
[25], but longer than reported in another study from Ethiopia [26]. The shorter delay in the
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Ethiopian study could be explained by patients presenting with more advanced symptoms of
disease since the median patient delay was 60 days in this study. Again, other studies from
Norway [14] and United Kingdom [16] reported both longer patient and health system delay
among EPTB patients than the present study, which could be because of a lower index of suspi-
cion of TB in low-endemic countries. A long health system delay may partly be explained by
the wide range of clinical presentation of EPTB disease, the low sensitivity of routine diagnos-
tic methods such as acid-fast bacilli microscopy [39, 40] and mycobacterial culture [39, 41],
lack of trained personnel and facilities for performing invasive procedures, thus increasing the
difficulty in obtaining adequate biological samples for laboratory investigations, and the lim-
ited capacity for diagnostic imaging in low-resource settings. In addition, being dependent on
patients returning for follow-up visits to receive results from various investigations or patients
delaying consultation at a higher health care level even though a referral has been advised,
could be contributing factors to the health system delay. A longer health system delay was
found in patients with> 3 visits to a health care provider, which is in agreement with a study
from India reporting that number of providers consulted until TB diagnosis was associated
with health system delay [34]. As concluded in a review of delay in the diagnosis and treatment
of tuberculosis, “The core problem in delay of diagnosis and treatment seemed to be a vicious
cycle of repeated visits at the same healthcare level, resulting in nonspecific antibiotic treat-
ment and failure to access specialized TB services” [11]. In our study, 48% of the TB patients
reported> 3 visits and 38% 5 visits to a health care provider due to the current illness. Fur-
ther, 81% reported repeated visits to MMH before diagnosis and initiation of treatment. In TB
patients with initial visit to other health care providers than MMH, the health system delay
prior to referral to MMH was longer as compared to the delay at MMH, and 47% reported
repeated visits at the same level before referral to MMH. Advancing disease and the availability
of diagnostic tools as imaging and laboratory investigations could have contributed to the
shorter delay at MMH. At MMH, 37% of these patients were not started on ATT within 2
weeks of their first visit to the hospital. A high threshold for initiation of treatment, awaiting
diagnostic proof, could also cause delay in the management of EPTB patient. On the other
hand, starting treatment only based on clinical presumptive EPTB, leads to overtreatment. In
our study, ATT was given to 19% of the non-TB cases, highlighting the importance of labora-
tory confirmation of EPTB and close follow-up of EPTB patients during treatment.
Patients with higher educational level tended to have longer health system delay, which is
somewhat surprising. The explanation for this is uncertain, but there was a higher percentages
of TB lymphadenitis cases among those with higher educational level compared to patients
with lower educational level (56% vs 35%), which could explain the tendency for a longer
health system delay in these patients.
In our study, patients with TB lymphadenitis experienced the longest median total delay of
99 days as compared to TB at other sites. A study from Tanzania also reported a long median
diagnostic delay of 119 days (17 weeks) among TB lymphadenitis patients [36]. The indolent
course of disease, lesser local symptoms, and fewer or no constitutional symptoms in lymphad-
enitis may be the reason for longer delay. Frequent involvement of cervical lymph nodes in dif-
ferent infections and lack of confirmatory TB tests may also have contributed towards the
longer health system delay in lymphadenitis. Despite the indolent course, it is important to
reduce the delay as these patients experienced significant improvement in self-rated health
after treatment.
The level of TB knowledge in our study may be a reasonable indicator of the knowledge
regarding TB in the general population in Zanzibar, since TB knowledge was assessed in both
TB and non-TB patients and the TB patients were interviewed preferably before starting ATT,
and by that they had not yet received the information following initiation of treatment. Our
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study indicates that while patients had relatively good knowledge of PTB, the knowledge
regarding EPTB was very low, identifying a potential area of intervention.
Our study has some limitations. The samples size is small, limiting the possibility of per-
forming further statistical analysis on factors associated with longer delays. The patients were
enrolled only from the main referral hospital in Zanzibar, and patients initiated on treatment
at the primary or secondary care level are not represented in the study. Thus, the results may
not necessarily be generalisable to all patients presenting with presumptive EPTB to the health
care system in Zanzibar. The information regarding symptoms, onset of symptoms and health
care seeking behaviour are mainly self-reported and implies the possibility of recall bias. We
did not record the patients visit to over-the-counter drug shops, and there is a possibility that
some of the patient first sought care at these sites, further reducing the actual patient delay.
Further, the study participants were part of a study implementing and validating a new diag-
nostic test for EPTB at MMH, and being part of this study may potentially have influenced
health system delay in either direction. Finally, use of a composite reference standard for cate-
gorization of TB patients is not perfect and some patients with other chronic bacterial infec-
tions could have responded to the ATT and wrongly categorized as TB patients. Similarly,
inadequate response due to poor compliance or drug resistance could have led to wrong cate-
gorization of patients as non-TB cases. However, subanalysis of the bacteriologically or clini-
cally confirmed TB groups did not show difference in various outcomes (data not presented
due to small sample size), and unlikely to have an impact on the conclusions drawn in this
study.
Conclusion
Many EPTB patients presenting to the main referral hospital in Zanzibar had delay in the diag-
nosis and treatment exceeding two months, and the greatest proportion of this delay occurred
due to the health system delay. The self-rated health among adult EPTB patients was signifi-
cantly higher after treatment, implying that appropriate and timely treatment of EPTB disease
have the potential to reduce morbidity and the economic loss for the patient and their families.
A reduction of diagnostic delay could be achieved through strengthening the knowledge and
awareness of EPTB in the general population by incorporating information on EPTB in public
health educational campaigns, continuous training of all health care providers, at all levels, in
early recognition of symptoms suggestive of EPTB and the diagnostic possibilities, proper
information and a scheduled follow-up of patients receiving a trial of antibiotics and strength-
ening the collaboration between the national TB programme and private and public health
facilities such as outpatient clinics and hospital wards performing invasive diagnostic proce-
dures. Further, since most peripheral health units do not have diagnostic facilities for diagnos-
ing EPTB it could be feasible to establish algorithms of timely referral of presumptive EPTB
patients to health facilities with diagnostic capacity and higher medical expertise to shorten the
care-seeking pathway. Finally, support and strengthening of the laboratories performing TB
diagnostics services is of utmost importance.
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Abstract
Background: Diagnosing extrapulmonary tuberculosis (EPTB) is challenging and many patients are initiated on
empirical anti-TB treatment without a laboratory confirmed diagnosis. Monitoring treatment response is thus
important to ensure correct diagnosis and proper disease management. The definition of satisfactory response to
treatment in EPTB remains unclear. The objectives of this study were to describe the clinical presentation of EPTB
and the effect of treatment on clinical parameters. Further, to assess if simple clinical parameters, without laboratory
data, could evaluate treatment response.
Methods: Prospective cohort study of presumptive EPTB patients at Mnazi Mmoja Hospital, Zanzibar. By using a
composite reference standard, patients were categorized as TB or non-TB cases. The TB patients were followed
during anti-TB treatment.
Results: There were 64 TB and 62 non-TB cases. The frequency of symptoms at baseline were comparable in TB
and non-TB patients, with lymphadenitis and pleuritis as the most common manifestations. Among TB cases, there
was a trend towards regression of lymphadenopathy after 2 months, and at treatment completion 24/28 (86%)
cases showed full regression. Weight gain ≥5% was reported in 36/49 (73%) of the TB patients at 2 months and in
38/46 (83%) at treatment completion. After 2 months of treatment, a combination of clinical parameters;
improvement of symptoms (50/50), ≥5% weight gain (36/49) and regression of physical signs (45/49) correlated
with the treatment response.
Conclusions: An algorithm including only simple clinical parameters could be used as an easy tool to assess
treatment responses in low-resource settings. However, this needs to be tested on a larger sample size.
Keywords: Treatment outcome, Clinical parameters, Weight gain, Tuberculous lymphadenitis, Tuberculous pleuritis
Background
Globally, extrapulmonary tuberculosis (EPTB) accounts
for 15% of the notified incident tuberculosis (TB) cases
[1]. Laboratory confirmation of EPTB is challenging due
to the paucibacillary nature of disease and limited
resources in high-TB endemic settings. The diagnosis is
therefore often made only on medical history and clin-
ical signs and many patients are started on empirical
anti-TB treatment. It is thus important to monitor
response to treatment to ensure diagnosis and appropri-
ate disease management. Monitoring response to treat-
ment in EPTB is challenging and clinical assessment is
generally recommended [2]. However, the definition of
satisfactory clinical response to treatment among the
various forms of EPTB remains unclear. Earlier studies
have suggested a combination of clinical and laboratory
criteria for evaluating response to treatment [3, 4].
Repeated invasive procedures or measurement of inflam-
matory markers are often incorporated in the definition
of treatment response [4]. In low-resource settings with
limited capacity for laboratory investigations and
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invasive procedures, it would be useful to assess
response to treatment in EPTB by using simple clinical
criteria.
In Zanzibar the estimated prevalence of bacteriologic-
ally confirmed pulmonary TB (PTB) among the adult
population is 124/100000 [5]. In 2015, EPTB accounted
for 24% of the notified TB cases [6]. In contrast to PTB,
the EPTB patients are not followed systematically by the
TB programme during anti-TB treatment. Symptoms
and signs are often not documented in the TB records
and the only information available is “treatment com-
pleted”, which does not always correspond to successful
remission.
The objectives of this study were to describe the
clinical presentation of EPTB among patients presenting
at Mnazi Mmoja Hospital (MMH), Zanzibar, and to
describe the effect of anti-TB treatment on clinical
parameters. Further, to assess if simple clinical parame-
ters, without laboratory support, could be used to
reliably evaluate treatment response.
Methods
Study setting and population
This prospective cohort study was nested in a larger
project at MMH [7], the main referral hospital in
Zanzibar. Children and adults presenting with symptoms
suggestive of EPTB were enrolled from in- and outpatient
departments for a period of thirteen months starting 1st
of August 2014. Patients were excluded if a specimen
from the presumptive site of infection was not sent for
laboratory investigations, if they did not give consent or
had received anti-TB treatment during the previous year.
Data collection
A medical history was obtained from the patients using
their local language, Swahili, and a physical examination
was performed at the time of inclusion and at follow-up
visits after the intensive phase of anti-TB treatment at 2
months (median 71 days, 5–95 percentile 55–109 days)
and at the end of treatment (median 175 days, 5–95
percentile 145–244 days). At inclusion, a pretested
semi-structured questionnaire was used [7]. At the
follow-up visits, clinical assessment was done without a
standard questionnaire. Improvement of symptoms;
cough, fever, appetite, fatigue, local symptoms and
general condition reported by the patient and assessed
by clinician, and results from the physical examination
were registered in the patient’s study folder. Patients
who were not started on anti-TB therapy were followed
until a diagnosis was established or until recovery.
Clinical investigation
Enlarged lymph nodes were measured by the size of the
long axis of the largest swelling using a measuring tape,
if not available, an eye estimate was used. Any change
during anti-TB treatment in the size of nodes, appear-
ance of new nodes, formation of fistulae and/or ab-
scesses were recorded. Size of the lymph nodes was
designated to one of four categories; not palpable
(palpable lymph nodes < 1 cm was also included in this
group), ≤2 cm, > 2–4 cm or > 4 cm. Residual lymphaden-
opathy after treatment was defined as palpable lymph
nodes > 1 cm. Pleural or peritoneal effusions were evalu-
ated clinically and by X-ray and ultrasound when avail-
able. All patients were weighed, and weight change was
recorded in kilograms (kg) and as percentage change in
weight at two intervals; 1) between treatment onset and
2months of treatment, and 2) between treatment onset
and end of treatment.
Laboratory investigations
Acid-fast bacilli (AFB) microscopy, Mycobacterium
tuberculosis (Mtb) culture, GeneXpert® MTB/RIF (Xpert)
assay, and cytological/histological evaluation were
performed on extrapulmonary specimens. In addition,
other laboratory investigations such as bacteriological
culture and Gram staining, and protein quantification
and white cell count in effusions, were performed if
available. CD4 cell counts and human immunodeficiency
virus (HIV) ribonucleic acid levels were not available for
the HIV positive patients.
Composite reference standard for categorization of
patients
A composite reference standard (CRS) was used to
categorize the study participants as “confirmed TB
cases” (positive Mtb culture and/or Mtb detected by the
Xpert assay), “probable TB cases” (clinical presumptive
EPTB and either response to anti-TB treatment or
bacteriologically confirmed PTB, and one of the follow-
ing; AFB on Ziehl-Neelsen stain of extrapulmonary
specimen or cytology/histology consistent with TB or
lymphocytosis on fluid cytology or radiological findings
suggestive of EPTB), “possible TB cases” (clinical
presumptive EPTB and one of the following; AFB on
Ziehl-Neelsen stain of extrapulmonary specimen or
cytology/histology consistent with TB or lymphocytosis
on fluid cytology or radiological findings suggestive of
EPTB or response to anti-TB treatment) and “non-TB
cases” (negative Mtb culture and/or Mtb not detected by
the Xpert assay and one of the following; improvement
without anti-TB treatment or cytology/histology con-
cluded other diagnosis than TB or alternative diagnosis
concluded by the local clinician or non-response to
anti-TB treatment) [7]. Patients unable to be categorized
by the CRS were termed “uncategorized” and excluded
from further analyses [7].
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Statistical analysis
Chi-square test was used in the analysis of categorical
variables and Mann-Whitney U test and Kruskal-Wallis
test for group-wise comparison of continuous variables.
The general significance level was set to 0.05. Bonferroni
correction was used to adjust for multiple testing effects
leading to a marginal level of 0.0071 for symptoms (7
tests), 0.01 for presumptive TB lymphadenitis (5 tests)
and 0.017 for weight gain (3 tests). Data were analysed
using IBM SPSS Statistics for Windows, version 24
(Armonk, NY, USA), and graphics were created using
Matlab 9.0 (Natick, MA, USA).
Results
Study participants
A total of 132 patients were enrolled and based on
the CRS categorized as TB (confirmed, n = 12; prob-
able, n = 34; possible, n = 18) and non-TB (n = 62)
cases, while 6 patients were uncategorized and excluded
from further analyses. Baseline sociodemographic and
clinical characteristics are presented in Table 1.
Among the 64 TB cases, 10 (16%) died before first
follow-up, and 2 (3%) were lost-to-follow. Thus, 52 TB
patients were followed during treatment. Forty patients
received standard first-line anti-TB regimen (isoniazid
(H), rifampicin (R), pyrazinamide (Z) and ethambutol
(E), 2HRZE/4HR), 2 patients an extended standard
first-line regimen, 7 children received a regimen
without ethambutol (2HRZ/4HR), whereas 3 patients
received a retreatment regimen containing first-line
drugs including streptomycin (S) (2HRZES/1HRZE/
5HRE). An overall clinical improvement was noted in
all 52 patients after 2 months of treatment (one
patient only assessed after 5 months), but a transient
paradoxical reaction with increase in lymphadenop-
athy was observed in 2 HIV positive patients. Empir-
ical anti-TB treatment was initiated in 12/62 (19%)
non-TB patients. Among these, 5/12 patients received
a malignant diagnosis, 5/12 cases showed no response
to treatment and were further investigated for an
alternative diagnosis, 1/12 patients showed clinical
improvement before starting anti-TB treatment and 1/
12 cases (presumptive TB meningitis) only received
anti-TB treatment for 2 weeks due to side-effects and
improved without anti-TB therapy.
TB and non-TB patients present with similar symptoms
Table 2 presents the distribution of symptoms among
TB and non-TB cases according to site of infection, age
and HIV status. There was no significant difference in
the frequency or type of constitutional symptoms when
comparing TB with non-TB patients. All patients
reported local symptoms from the site of infection.
Among the TB cases, patients with lymphadenitis
reported less frequently constitutional symptoms as
compared to patients with pleuritis and other sites of
infection. Paediatric patients described less constitu-
tional symptoms compared to adults. Weight loss,
reduced appetite or fatigue were reported more often in
adults. Constitutional symptoms were more frequent in
HIV positive patients.
Table 1 Characteristics of the study participants
Total Lymphadenitis Pleuritis Other sites of infectiona
n = 126 n = 67 n = 31 n = 28
TB Non-TB TB Non-TB TB Non-TB
Characteristics n = 34 n = 33 n = 20 n = 11 n = 10 n = 18
Female, n (%) 56 (44%) 17 (50%) 14 (42%) 7 (35%) 5 (45%) 5 (50%) 8 (44%)
Age, years, median [IQR] 27 [8–41] 27 [7–38] 13 [7–49] 32 [23–50] 20 [6–41] 27 [19–34] 40 [26–50]
Children (< 15 years), n (%) 41 (33%) 11 (32%) 18 (55%) 3 (15%) 4 (36%) 2 (20%) 3 (17%)
HIV status, n (%)
HIV positive 20 (16%) 7 (21%) 2 (6%) 5 (25%) 0 (−) 2 (20%) 4 (22%)
HIV negative 74 (59%) 25 (74%) 10 (30%) 15 (75%) 6 (55%) 6 (60%) 12 (67%)
Unknown 32 (25%) 2 (6%) 21 (64%) 0 (−) 5 (45%) 2 (20%) 2 (11%)
Comorbidities, n (%)
Diabetes 4 (3%) 0 (−) 1 (3%) 1 (5%) 1 (9%) 1 (10%) 0 (−)
Heart disease/HT 12 (10%) 2 (6%) 3 (9%) 0 (−) 2 (18%) 1 (10%) 4 (24%)
COPD/Asthma 7 (6%) 3 (9%) 2 (6%) 0 (−) 1 (9%) 1 (10%) 0 (−)
Outpatient, n (%) 76 (60%) 32 (94%) 32 (97%) 7 (35%) 0 (−) 3 (30%) 2 (11%)
Abbreviations: TB tuberculosis, IQR interquartile range, HIV human immunodeficiency virus, HT hypertension, COPD chronic obstructive pulmonary disease
a TB cases: peritonitis (n = 6), meningitis (n = 2), pericarditis (n = 1), spondylitis (n = 1); non-TB cases: peritonitis (n = 10), meningitis (n = 6), mastitis (n = 1),
osteomyelitis (n = 1)
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Findings in presumptive TB lymphadenitis
There was no statistically significant difference in the
site or symmetry of lymph node involvement between
TB and non-TB patients (Table 3). Still, a higher propor-
tion of larger lymph nodes > 4 cm, matted or painful
nodes and discharge/fistulas were seen in TB patients
compared to non-TB patients.
There was a significant regression in lymph node size
with anti-TB treatment, as shown in Fig. 1. During
treatment enlargement of nodes, new fistulae or fresh
abscesses were reported in 5 (2 HIV positive) patients.
However, overall reduction in lymph node size was seen
as an indicator for treatment response among TB
patients.









appetite≥1 symptoms ≥3 symptoms
Diagnosis
TB 64 50 (78%) 23 (36%) 33 (52%) 36 (57%) 21 (33%) 16 (26%) 20 (32%)
Non-TB 62 42 (68%) 22 (35%) 26 (42%) 25 (42%) 18 (29%) 24 (39%) 18 (30%)
P valuec .189 .958 .279 .086 .604 .109 .741
TB cases
Confirmed TB 12 9 (75%) 3 (25%) 6 (50%) 6 (50%) 3 (25%) 3 (27%) 4 (33%)
Probable TB 34 28 (82%) 16 (47%) 21 (62%) 23 (70%) 12 (35%) 8 (24%) 13 (38%)
Possible TB 18 13 (72%) 4 (22%) 6 (33%) 7 (39%) 6 (35%) 5 (29%) 3 (19%)
Site
Lymphadenitis
TB 34 22 (65%) 7 (21%) 14 (41%) 15 (45%) 7 (21%) 2 (6%) 5 (15%)
Non-TB 33 15 (45%) 6 (18%) 9 (27%) 8 (25%) 4 (12%) 5 (16%) 7 (21%)
Pleuritis
TB 20 20 (100%) 12 (60%) 13 (65%) 16 (80%) 11 (55%) 9 (47%) 12 (63%)
Non-TB 11 11 (100%) 6 (55%) 7 (64%) 6 (55%) 7 (64%) 8 (73%) 4 (40%)
Other sites
TB 10 8 (80%) 4 (40%) 6 (60%) 5 (50%) 3 (33%) 5 (50%) 3 (30%)
Non-TB 18 16 (89%) 10 (56%) 10 (56%) 11 (65%) 7 (39%) 11 (61%) 7 (39%)
Age
Children
TB 16 12 (75%) 2 (13%) 8 (50%) 5 (31%) 6 (38%) 1 (6%) 0 (−)
Non-TB 25 14 (56%) 6 (24%) 8 (32%) 6 (25%) 6 (24%) 7 (28%) 6 (25%)
Adults
TB 48 38 (79%) 21 (44%) 25 (52%) 31 (66%) 15 (32%) 15 (33%) 20 (43%)
Non-TB 37 28 (76%) 16 (43%) 18 (49%) 19 (53%) 12 (32%) 17 (47%) 12 (32%)
HIV statusd
HIV positive
TB 14 13 (93%) 6 (43%) 8 (57%) 8 (62%) 5 (38%) 6 (46%) 6 (43%)
Non-TB 6 6 (100%) 4 (67%) 6 (100%) 3 (60%) 1 (17%) 4 (67%) 3 (50%)
HIV negative
TB 46 33 (72%) 16 (35%) 21 (46%) 27 (59%) 14 (30%) 9 (20%) 14 (32%)
Non-TB 28 20 (71%) 10 (36%) 11 (39%) 15 (54%) 8 (29%) 11 (39%) 8 (29%)
Abbreviations: TB tuberculosis, HIV human immunodeficiency virus
a Patients with missing values excluded
b The following were included as constitutional symptoms; fever, weight loss, night sweats, fatigue, loss of appetite. ≥1 and ≥ 3 refers to number of patients
reporting one or more or three or more symptoms respectively
cP value < 0. 0071 (0.05/7) considered statistically significant
d Patients with unknown HIV status excluded
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Regression of pleural and peritoneal effusion during anti-
TB treatment
Among the 20 TB pleuritis cases, any regression of effu-
sion was assessed by chest x-ray in 15 patients after 2
months and in 13 patients at treatment completion.
Regression was noted in 14 (93%) and 13 (100%),
respectively. Only 3/6 (50%) with abdominal TB were
evaluated, and partial regression of peritoneal effusion
was seen at 2 months and full regression at the end of
treatment, as assessed by ultrasound.
Weight gain as indicator for treatment efficacy
Weight change during anti-TB treatment was recorded
according to age, site of infection and HIV status (Fig. 2).
After 2 months of treatment, 36/49 (73%) of the patients
had ≥5% weight gain and 18/49 (37%) had ≥10% weight
gain. At treatment completion, 38/46 (83%) of the cases
had ≥5% and 26/46 (57%) ≥10% weight gain. Overall, the
median weight gain at 2 months of treatment was 2.9
kg (interquartile range (IQR), 1.4–5.1 kg) and the me-
dian percentage weight gain 6.7% (IQR, 4.6–13.4%).
After completion of treatment, the overall median
weight gain was 4.0 kg (IQR, 2.2–7.5 kg) and 12.9%
(IQR, 7.2–19.7%). The paediatric cases had a higher
median percentage weight gain compared to the adult
patients both at 2 months (11.1% vs 6.2%) and end of
treatment (17.9% vs 9.5%), but the differences were
not statistically significant. A weight gain ≥15% was
described in 71% of the paediatric TB cases at treat-
ment completion. In all HIV positive cases (n = 5)
≥5% weight gain was seen after treatment completion,
and 4/5 patients had a weight gain ≥15%. There was
no statistically significant difference in weight gain
according to site of disease.
Table 3 Findings in presumptive TB lymphadenitis at the time of inclusion, n (%)
Diagnosis
Total TB Non-TB P valuea
Characteristics n = 67 n = 34 n = 33
Localization .549b
Unilateral 40 (60%) 22 (65%) 18 (55%)
Bilateral/generalized 27 (40%) 12 (35%) 15 (45%)
Only cervical 50 (75%)
Unilateral 17 (50%) 14 (42%)
Bilateral 9 (26%) 10 (30%)
Only axillary 6 (9%)
Unilateral 3 (9%) 3 (9%)
Bilateral 0 (−) 0 (−)
Only inguinal 2 (3%)
Unilateral 0 (−) 1 (3%)
Bilateral 0 (−) 1 (3%)
Cervical and axillary 6 (9%)
Unilateral 2 (6%) 0 (−)
Bilateral 1 (3%) 2 (6%)
Cervical bilateral and axilla unilateral 1 (3%) 0 (−)
Generalized 3 (4%) 1 (3%) 2 (6%)
Size of largest lymph nodec .031
≤ 2 cm 9 (13%) 1 (3%) 8 (24%)
> 2–4 cm 25 (37%) 13 (38%) 12 (36%)
> 4 cm 33 (49%) 20 (59%) 13 (39%)
Matted nodes 38 (57%) 24 (71%) 14 (42%) .020
Painful 9 (13%) 7 (21%) 2 (6%) .081
Discharge/fistula 7 (10%) 6 (18%) 1 (3%) .051
Abbreviation: TB tuberculosis
aP value < 0. 01 (0.05/5) considered statistically significant
b Test for different risk for unilateral vs. bilateral/generalized localization in TB and Non-TB group
c Long axis of largest lymph node swelling
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Combination of clinical parameters for assessment of
treatment outcome
Among the patients starting anti-TB treatment, a com-
bination of the following three clinical parameters were
assessed retrospectively; 1) Improvement of reported
symptoms; 2) Weight gain (any weight gain or ≥ 5%
gain); 3) Regression of lymph node swelling or pleural or
peritoneal effusion or other local findings, during and
after treatment compared to baseline. If a weight gain
≥5% was used, all TB cases, except one, had ≥2 parame-
ters after 2 months of treatment, while non-TB cases
fulfilled only 0 or 1 parameter (Fig. 3).
Discussion
In this study, we describe the clinical presentation of
various forms of EPTB and changes in clinical parame-
ters during the course of anti-TB treatment. Our results
show that presenting signs and symptoms alone could
not differentiate TB and non-TB cases among presump-
tive EPTB cases. There was regression in clinical signs in
TB cases during treatment, and we suggest that a com-
bination of 2–3 clinical parameters could predict good
response early (2 months) in the treatment. These find-
ings imply that in low-resource settings where anti-TB
treatment is often started on clinical assumption,
Fig. 1 Time series plot illustrating the regression of lymphadenopathy during anti-TB treatment. The lymph node size (long axis of largest
swelling) is presented at baseline, after 2 months of treatment and at treatment completion according to TB category (confirmed, probable and
possible TB cases) and age. Each patient is represented by an individual line. At baseline, all, except one case, had lymph node enlargement
> 2 cm. At 2 months, there was a trend in regression of lymph node swellings, and at treatment completion, 4 (14%) cases had residual
lymphadenopathy. The patients with residual lymphadenopathy were all confirmed TB cases. Abbreviation: TB, tuberculosis
Fig. 2 Boxplots showing the weight change at 2 months of anti-TB treatment and at treatment completion. Left boxplot: weight change in kg
between treatment onset and 2months of treatment and between treatment onset and end of treatment according to site of TB infection, HIV
status and age. Right boxplot: weight change as percentage change in weight between treatment onset and 2months of treatment and
between treatment onset and end of treatment according to site of TB infection, HIV status and age. Abbreviations: TB, tuberculosis; HIV, human
immunodeficiency virus
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unnecessary over-treatment can be reduced by system-
atic clinical monitoring of responses early during
treatment.
Improvement in symptoms can be assessed by a symp-
toms count ratio [3], or self-rated health using the
EQ-5D 3 level version [8]. Overall clinical improvement
or performance status can be assessed by the health care
worker using standardised systems, like the Karnofsky
performance score [3, 9]. However, clinically relevant
cut-off points for symptoms count ratio, improvement of
self-rated health, performance scores and other clinical
parameters such as weight gain need to be established in
EPTB patients.
Weight gain is an easy, inexpensive parameter for
assessing treatment response. Earlier studies, predomin-
antly among PTB patients, have suggested an association
with weight gain and successful treatment outcome [10],
whereas lesser weight gain or weight loss were associ-
ated with poor outcome [10–12] or relapse [13]. Only a
few studies have evaluated weight gain as a marker of
treatment response in EPTB patients [3, 10, 12]. In our
cohort of TB cases with successful treatment outcome,
≥5% weight gain was recorded in 73 and 83% of the
cases at 2 months and at treatment completion.
Regression of lymphadenopathy could also be a
reliable parameter for assessment of response to treat-
ment, but appearance of newly enlarged nodes, enlarge-
ment of existing nodes, formation of new fistulae and
abscesses during and after treatment [14, 15] can
complicate the evaluation. Paradoxical reactions during
anti-TB treatment [16], are described to occur quite
frequently in TB/HIV co-infected patients [17, 18]. In a
meta-analysis, the frequency was estimated to be 15.7%
among patients treated for active TB and newly
commencing antiretroviral therapy [16, 19]. Further,
paradoxical reactions are reported to be relatively com-
mon in HIV negative EPTB patients [20–25]. Therefore,
a single clinical parameter may not be enough, and a
combination of parameters will be better to differentiate
responders from non-responders.
The failure to treatment response could indicate not
just alternative diagnoses but also poor compliance,
paradoxical reactions or drug resistance in TB cases.
These can be difficult to differentiate using only simple
clinical parameters. Still, such criteria, incorporated
systematically in the follow-up of TB patients, such as in
TB registers or treatment cards, can be valuable and
assist the health care provider in detecting patients who
need clinical reassessment.
Current practice in the TB programme (in
Zanzibar) does not detect EPTB patients with poor
clinical response. The TB register and treatment cards
document treatment completion as the only outcome
for EPTB which is based only on the intake of drugs
without concurrent record of clinical parameters. The
combination of clinical parameters described in this
study could be developed into an assessment tool,
which can be attached to the patients TB treatment
cards. However, the study sample is small, and the
findings need to be validated on a larger number of
patients. This simple tool has the potential to detect
non-responders early at 2 months and standardize
follow-ups. Early detection of non-responders would
save costs, reduce morbidity due to side-effects, and
further minimise the undue delay of alternative
diagnoses.
Fig. 3 Clinical parameters at 2 months of treatment for assessment of treatment outcome. Left figure: Shows the number of patients having each
clinical parameter. 1 – improvement of reported symptoms such as coughing, fever, appetite, fatigue and general condition. 2a – any weight
gain compared to baseline; 2b - ≥5% weight gain compared to baseline; 3 - regression of objective findings. Right figure: Shows the number of
patients having the sum of clinical parameters. Abbreviation: TB, tuberculosis
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The study has some limitations. Single centre study
and the small sample size limits the generalisability of
the results and sub-group analysis. There are few
patients included with presumptive neurological or bone
TB, and none with presumptive genital TB, urinary tract
TB or other forms of abdominal TB besides peritoneal
TB. Therefore, the results may not apply to all patients
presenting with presumptive EPTB in Zanzibar. The
possible TB cases were defined by clinically suspected
EPTB and overall response to treatment. This does not
provide an accurate diagnosis, as some of the patients
may have other infections responding to anti-TB treat-
ment. There was also a limited capacity to perform in-
vestigations to diagnose other infections and for the HIV
patients CD4 counts and viremia were not known. The
lack of standardized questionnaire and clinical registra-
tion during follow-up and standardized measurements
of lymph node size may have influenced the results.
Conclusions
Clinical presentation alone cannot reliably diagnose
EPTB, and empirical anti-TB treatment leads to
over-treatment. A combination of simple clinical param-
eters could be used as an easy tool to assess treatment
responses and thus improve patient management in
low-resource settings. More and larger studies are
needed for further evaluation and validation of these
simple clinical parameters.
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10. APPENDICES 
  
10.1 Appendix A – Study questionnaire and study information and 
consent form  
 




Department:   OPD  IPD 
 Written informed consent  Oral informed consent 
 
PATIENT IDENTIFICATION 
Study Number: _________________ 
Age________Years    
Gender:          Male   Female 
Respondent:   Patient    Parent       Spouse        Child         Other, relative/friend 
Address:  Region__________________ Village_______________ 
 
1. Marital status:         
 Single  Married  Widow/widower  Separated  Divorced  
 Cohabited  Other, please specify____________ 
 
2. Level of education:  
 No formal education                       Not completed primary school 
 Completed primary school  Form I-IV 
 Form IV-VI   Above secondary education 




Muslim  Christian  Other, please mention____________ 
 
PREVIOUS MEDICAL HISTORY 
4. Tobacco use:    Yes  No   ____weeks/months /years 
5. Smoking:          Yes  No   ____weeks/months /years  
6. Alcohol:            Yes  No   ____weeks/months /years  
 
7. Associated Diseases  
COPD:                       Yes  No    
Renal Disease:           Yes  No    
Liver Diseases:         Yes  No    
Diabetes Mellitus:     Yes  No    
Hypertension:            Yes  No    
Other:                         Yes  No    
Describe other: _____________________________ 
                           _____________________________ 
 
8. Medication: Please write the names of the medication 
______________________________________________________________ 
 
PREVIOUS HISTORY OF TUBERCULOSIS 
9. Have you been in contact with a person with known tuberculosis?  
 Yes  No    
 
10. Have you previously been diagnosed with pulmonary tuberculosis?  
 Yes  No    
 
11. Have you previously been diagnosed with extrapulmonary tuberculosis:  
 Yes  No    
If yes, please specify: ______________________________________________ 
 
12. Have you previously been treated for tuberculosis? 
 Yes  No    
 
13. If you have been treated, what was the treatment outcome? 
 Cured 
 Treatment Completed 
 Treatment Interrupted  
 
14. If treated, when was the last time that you completed any TB treatment?  
____________________________ 
 
HEALTH-SEEKING BEHAVIOUR AND DIAGNOSTIC DELAY  
Health seeking behavior for TB patients  
Please remind the patient that this survey is confidential. 
 
15. Please ask if the patient has experienced any of the following symptoms 
 
General Symptoms 
Fever:              Yes  No   ____weeks/months 
What kind of fever do you have? 
 High-grade   Low-grade   
When do you have fever?  
 Morning     Day-time  Evening           Night        all day 
Loss of weight:            Yes  No   ____weeks/months 
Loss of appetite:          Yes  No   ____weeks/months 
Night Sweat:             Yes  No   ____weeks/months 
Fatigue:            Yes  No   ____weeks/months 
Amenorrhea/female:   Yes  No   ____weeks/months 
Body weakness:    Yes  No   ____weeks/months 
Frequent cold:            Yes  No   ____weeks/months 
Neck mass:                   Yes  No   ____weeks/months 
Other:                         Yes  No   ____weeks/months 
Respiratory Symptoms 
Cough:                           Yes  No   ___weeks/months 
Sputum:                       Yes  No   ___weeks/months 
Cough with Sputum:   Yes  No   ___weeks/months 
Cough with blood:      Yes  No   ___weeks/months 
Chest pain:                    Yes  No   ___weeks/months 
Difficult in breathing:      Yes  No   ___weeks/months 
 
Abdominal Symptoms 
Swelling of/in stomach:    Yes  No    ___weeks/months 
Fullness of the stomach:   Yes  No   ___weeks/months 
Vomiting:             Yes  No   ___weeks/months  
Diarrhea:                     Yes  No   ___weeks/months  
Other:                          Yes  No   ___weeks/months 
Describe other: ____________________________________________ 
                           ____________________________________________ 
                    \ 
Neurological Symptoms 
Headache:                    Yes  No   ___weeks/months 
Photophobia:               Yes  No   ___weeks/months 
Vomiting:                     Yes  No   ___weeks/months 
Dizziness:                     Yes  No   ___weeks/months 
Vertigo:                        Yes  No   ___weeks/months 
Weakness/Numbness of extremity:  
                                       Yes  No   ___weeks/months 
Visual disturbance:   Yes  No   ___weeks/months 
Other:                            Yes  No   ___weeks/months 
Describe other: _____________________________ 
                           _____________________________ 
                           _____________________________ 
 
 
16. What were the major symptoms that first made you seek care? 
 Prolong Cough   coughing blood    Breathlessness  
 Chest pain     Fever    Weight loss 
 Fatigue\Weakness   Loss of appetite   Night sweats 
 Bone pain    Lymph node swelling  Diarrhoea    
 abdominal pain   others (specify) _________________ 
 
17. When did you first notice the symptoms? 
_____________________________________________________________________ 
 
18. Did you practice any self-medication before you sought care? 
 Yes       No 
 
19. When did you first seek medical advice for this illness after noticing the symptoms? 
(Ask the respondent to specify how many days/weeks after noticing the symptoms) 
 Today          1-6 days           1-4 weeks      5-8weeks      over 8 weeks  
 
20. How many different places did you go to seek help for the current symptoms? (Ask 




21. How many times have you visited health facilities with the same symptoms before?  
 First visit  Second visit  Third visit 
 > 3 visits  don’t remember 
 
22. Which place did you first seek care for your symptoms? 
 Regional Hospital       District hospital/PHCC     Health center/PHCU 
 Dispensary/private clinic       Private Hospital                  Traditional healer 
 Pharmacy      other, please specify____________________________ 
 
23. Did you get any medicine from there? 
 Yes       No 
24. If yes, what kind of medicine? 
 Antibiotics            Anti-TB          Herbs           others, which_____________ 
25. Were the symptoms relieved after taking medicines? 
 Yes       No 
 
26. What kind of diagnosis did you receive for your illness?  
__________________________________________________ 
 
27. Were any tests done at the first medical service?  
 Yes       No 
 
28. What type of tests? 
 Blood test   Urine test   Sputum   X-ray  
Others, please specify_______________________________ 
 
29. Did you take the results back to the doctor? 
 Yes   No  
 
30. Could you estimate the total cost for the previous visits/investigations related to your 
current illness? 
Admission                        _________________________TZS 
Consultations                   _________________________ TZS 
Medication                       _________________________TZS 
Laboratory tests/X-ray/CT________________________TZS 
Transportation                  _________________________TZS 
 
31. Who referred you here to this health facility? 
 myself    Traditional healers   Religious leaders  
 Pharmacy/drug shop  Village health worker  Government dispensary 
 Government health center  Government hospital  Private dispensary/hospital 
 Charitable/NGO   Member of the family  Other___________________ 
 
32. Have you ever been tested for HIV? 
 Yes   No 
 
33. Self-reported HIV results 
 HIV positive       HIV negative        don’t know      don’t agree to disclose HIV status 
 
34. Before today, had you heard of the illness tuberculosis? 
 Yes   No 
 
35. Do you know any symptoms of tuberculosis? 
 Chronic cough   Spitting blood   Shortness of breath 
 Chest pain   Fever              Weight loss 
 Tiredness   Loss of appetite 
 Others Please specify_____________________________ (Do not probe but ask for more 
symptoms) 
 
36. Do you know which parts of the body that can be affected by tuberculosis? 
____________________________________________________________________ 
 
37. Can tuberculosis spread from person to person? 
 Yes   No   Uncertain 
 
38. Do you drink unboiled milk? 
 Yes   No 
 
39. Do you eat raw meat?  
 Yes   No 
 
40. Did you know that consumption of raw animal products, like uncooked dairy 
products can lead to gastrointestinal tuberculosis as a result of transfer of the disease 
from animals to humans? 
 Yes   No 
 
41. Can tuberculosis be cured with medicines? 
 Yes   No   Uncertain  
 
42. Do you know how long it takes to treat tuberculosis? 
 Yes   No  
If yes, do you know the approximate duration of treatment?  
_____________________ 
 
43. Do people in your community associate tuberculosis with HIV? 
 Yes   No   Uncertain 
If yes, why do they associate it with HIV? _________________________________ 
 
44. Is there anything that would make it easier for people with tuberculosis to get 
treatment, not just in this clinic, but in other health facilities? 
 Yes   No   Uncertain 
If yes, what could be done? ___________________________________________ 
 
45. The moment you realized you may have contracted tuberculosis, did you have any 









47. If you consulted a traditional healer before seeking care at a modern health facility, 






PATIENT AND HOUSEHOLD COSTS, estimate of the patient income level  
 
48. How long does it take you to go to the nearest health facility? 
 Less than 30 minutes       between 30 minutes and one hour         More than one hour 
 
49. How far is this hospital to your home (in Kilometers) _________________ 
 
50. How long (on average) does it take you to this health facility, waiting for your 
consultation and finally returning to your home\workplace?  
________________Hours 
51. How did you get to this health facility? 
 Walked  Bicycle Motorcycle  Private car     Dala Dala 
 
52. If you have to take a Dala Dala, how much (on average) does it cost you to come to 
the clinic? ________________TZS. 
 
53. Do you usually have to make some special arrangements at home before coming to 
the clinic? 
 Yes   No   Uncertain 
If yes, what arrangements?__________________________ 
 
54. What is your main occupation (past twelve months)? 
 Employed by government                Employed private for profit sector 
 Employed by NGO     Self-employed, business with 
employees 
 Self-employed, business no employee       Self-employed (merchant), farmer/ 
fishing 
 Unemployed      Retired    
 Pupil/ student      Disabled/ sick   




55. What is the main income of your house hold? 
 Crop production                         Livestock                           Fishing                
 Hunting/ bee-keeping                 Poultry                               Farm wage               
 Other agricultural activity          Wages (government)         Wages (private)      
 Monetary savings (interest)       Pensions    
 Property (rentals)     Self-employed payments (merchant) 
Other Specify____________________________ 
 
56. In the past 12 months, in what types of activities were you and any members 





57. How much did (NAME) earn (money) for the activities stated on average in the past 
12 months? This should include not only salary or cash income: but also the value of 
goods produced or traded for other goods and services. 
_____________________________________________________________________ 
 
58. Do you have reduced working capacity due to your current illness?  
 Yes, completely stopped working   Yes, working but with reduced capacity 
 Working as normal 
 




60. When did you stop working or working with reduced capacity? 
_____________________________________________________________________ 
 
61. Have any member of your household stopped working or reduced their work 
capacity because of your illness? 
 Yes   No  
If yes, for how long? _______________days    
If yes, how much reduced working capacity? __________________________________  
 
62. Have you/or any member of your household lost any wages or income because of 
your illness? 
 Yes   No   Uncertain 
If yes, how much____________________ 
 
63. Do you own a house? 
 Yes        renting a house  living with relatives /friends  Homeless 
 
64. How many people live in your household: _________________ (number of people) 
      How many: Men: _______Women:_______Elderly:_______ 
Children ( between 0-10):_______ Children (between 11-18):_______ 
 
65. What is the main source of drinking water for members of your household? 
 Piped water   1=Piped into dwelling   2= Piped into yard/plot    3=Public tap    4=Neighbors’ tap      
 Water from open well    
 Water from covered well or borehole 
 Running water 1=spring; 2=river/stream; 3=pond/Lake; 4=Dam 
 Rain water     
 Tanker truck      
 Water vendor      
 Bottled water 
 Others Specify ________________________ 
 
66. What kind of toilet facilities does your household have? 
 Flush toilet                      Pit toilet/latrine 1=traditional pit latrine 2=ventilated pit latrine 
(VIP)  
 No facility/bush/field     other, please specify ______________ 
 
67. Do you share these facilities with other households? 
 Yes    No 
68. Does your household have? 
 Electricity                      Paraffin lamp               Radio     




69. What is the main source of energy for lighting in your household? 
 Main electricity   Solar                               Gas              
 Paraffin-hurricane lamp  Paraffin-Wick lamp     Firewood        
 Candles                         other, please specify _________________________ 
 
70. What is the main material for the walls of your house or house you are living? 
 Grass                                 Poles and mud                    Cement bricks      
 Backed bricks        Timber   Stones        
 Others Specify_________________________ 
 
71. What is the roofing material of your house or house you are living? 
 Grass/leaves/mud     Iron sheets       Tiles       Concrete       Asbestos 
 Others Specify_______________ 
 
72. Does any member of your household own 
 A bicycle       A motorcycle or motor scooter      A car        A bank account 
 
73. How many acres of land for farming/grazing are owned by the household? 
 Arable land_____________acres      Land for grazing__________acres 
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Request for participation in the study: 
Improved diagnosis of tuberculosis by antigen detection from sputum and 
extrapulmonary samples using immunochemistry-based assays 
 
 
This is a request for you to participate in a study on improving the diagnosis of tuberculosis.  
The study will include patients from both Zanzibar and Norway, which would give us the 
opportunity to compare findings and results from the two settings 
 
Tuberculosis most often affects the lungs. However disease may spread anywhere in the body 
which makes the diagnosis very difficult.   
 
Routinely used tests are not able to detect disease in many cases and therefore the disease 
remains undetected leading to the worsening of illness and ultimately death. If tuberculosis is 
diagnosed it is curable.  
 
At the University of Bergen, Norway and Haukeland University Hospital, we have developed 
a new and better test for the detection of tuberculosis. In research settings, this test has been 
shown to be significantly better than the routine tests. We would like to ask you to participate 
in this study, because we want to examine if this new method could improve the routine 
diagnostics of tuberculosis.  
 
This is a laboratory-based test and will be performed on the material collected for the routine 
tests like various fluids, tissue samples, and sputum. All the sample collection and invasive 
procedures will be performed solely for the purpose of diagnosis, and no extra invasive 
procedure will be performed only for the sake of this study. No extra money will be charged 
for the test. 
 
For this research, it is necessary to:  
• ask you questions based on questionnaires 
• obtain information relevant for your disease from your medical record 
• perform our new diagnostic method in your sample material already collected 
 
The objectives of this study are: 
 to implement this test in the routine diagnostic of tuberculosis at Mnazi Mmoja Hospital 
 to study whether the test improves the diagnosis of tuberculosis  
 to study whether it is feasible to implement the test by evaluation of the costs and the 
advantages 
 to compare research findings from Zanzibar and Norway. 
 to further develop new, similar methods for sputum and other samples. 
 
What will happen to the samples and the information about you? 
The samples and data that are registered about you will only be used in accordance with the 
purpose of the study as described above. All the data and samples will be processed without 
name or other directly recognisable type of information. It will not be possible to identify you 
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Voluntary participation 
Participation in the study is voluntary. If you wish to participate, sign the declaration of 
consent on the final page. You can withdraw your consent to participate in the study at any 
time and without stating any particular reason. This will not have any consequences for your 
further treatment.  If you later on wish to withdraw your consent or have questions concerning 
the study, you may contact following person, Melissa Jorstad, phone number 0776 584 962, e-
mail: Melissa.jorstad@gmail.com or Maryam Ali, phone number 0774 040 545 
 
Biobank: 
At Haukeland University Hospital we want to collect blood samples and other biological 
material to be stored in a general research biobank for further research studies. If you give 
your consent that your samples may be stored in a biobank, the samples may later be used for 
further research studies in order to increase the knowledge about tuberculosis and other 
infectious diseases. This information may be beneficial for you as well as for other patients. 
 
Generally, the material and samples that are left after routine examinations or treatment will 
be stored in the biobank. In addition we request for extra blood samples (maximum 50 ml) 
during your follow-up visits. 50 ml corresponds to 1/10 the volume drawn at blood donation. 
You may refuse to give these extra blood samples and in that case only the left-over samples 
from routine examinations will be stored in the biobank.  
 
If you agree to that your samples and de-identified data being released to Haukeland 
University Hospital, Bergen, Norway, you have to sign a separate declaration. The samples 
would then be stored in a biobank at Haukeland University Hospital.You may still participate 
in the study even if you do not consent to your samples and de-identified data being released 
to Haukeland University Hospital, your samples would then be destroyed after this study is 
completed. 
 
If you give your consent, the samples will be frozen at Mnazi Mmoja Hospital and later 
transported, stored and kept indefinitely in a biobank at the Haukeland University Hospital, 
Norway.We follow the laws allowing us to store and perform research on biological material.  
The Biobank is approved by the Regional Committee for Research Ethics in Norway. The 
samples will be used in research only after the specific studies are approved by the Regional 
Committee for Research Ethics in Norway and Zanzibar. 
 
The data will be treated confidentially and stored according to national guidelines for 
sensitive data. If future analyses give results that may have implications for your medical 
health, you will be informed. 
 
Right to access and right to delete your data and samples  
If you agree to participate in the study, you are entitled to have access to what information is 
registered about you. You are further entitled to correct any mistakes in the information we 
have registered. You may withdraw from the study at any time without giving any reason. 
You can also demand that your samples are destroyed and that data concerning you are 
eliminated, unless the data have already been incorporated in analyses or used in scientific 
publications.  
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Information about the study 
Your are entitled to receive information about the outcome/result of the study 
 
 
Contact persons:  Dr. Melissa Davidsen Jørstad, Haukeland University Hospital/Mnazi 
Mmoja Hospital 
   Dr. Msafiri Marijani, Mnazi Mmoja Hospital 
Dr. Maryam Abdalla Ali, Mnazi Mmoja Hospital 
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Consent for participation in the study 
- Adults above 18 years 
 
Project title: 
Improved diagnosis of tuberculosis by antigen detection from sputum 









Dep. of pulmonary medicine 
(Lungeavdelingen) 
It is voluntary to participate in the study. If you would like to participate in the study you have 
to sign the consent form.  If you agree to participate at this time, you may at any time and 
without giving a reason withdraw your consent without your treatment being affected.  If you 
later on wish to withdraw your consent or have questions concerning the study, you may 
contact the following person, Melissa Jorstad, phone number …. or Maryam Ali, phone 
number …. 
 












I agree that my samples and de-identified data may be sent to Haukeland University 
Hospital, Norway, and that the biological material may be stored in a biobank and used 
for further research studies in order to increase knowledge about tuberculosis and other 
infectious diseases. 











To be completed by the representative of the research project 
 










10.2 Appendix B - Standard operating procedures for sample 
collection and processing and immunostaining 
 
Fine needle aspiration cytology 
1) Prepare slides for routine staining and immunocytochemical staining (superfrosted 
slides). Write sample ID on the frosted end of the slide. 
2) Prepare two sterile tubes. Write sample ID on the tubes.  
3) Aspirate material as per routine practice. 
4) Slide preparation 
a. Prepare routine slides. 
b. Prepare 2-4 smears on superfrosted slides.  
i. Air-dry the smears in room temperature. 
ii. Fixate the smears in 96% alcohol for 20 minutes. 
Figure: Preparation of smears from fine needle aspirates. Picture A: Using a syringe expel 
the material in the needle onto two slides (if enough material). Picture B and C: Place another 
slide on top of the slide with the expelled material, apply gentle pressure to spread the 
material, and then pull the slides apart.  
1) Rinse the needle and syringe directly into two sterile tubes (equal volume in each 
tube) using 2 ml sterile normal saline.  
2) Transport the slides to the laboratory. 
3) Material in sterile tubes: 




b. Transport one tube to the TB clinic. The specimen will be sent to PHL-IdC on 
Pemba for mycobacterial culture.  
Effusions and CSF 
1) Divide the specimen equally in three (four) sterile tubes (if not already collected in 
three (four) tubes) 
a. Transport one tube to the TB clinic. The specimen will be sent to PHL-IdC on 
Pemba for mycobacterial culture.  
b. Transport one tube to the TB laboratory at Mnazi Mmoja Hospital for 
GeneXpert® MTB/RIF. 
c. One tube for cytology 
d. One tube for microbiological culture, Gram staining or other special stains.  
2) Prepare slides for routine staining and immunocytochemical staining (superfrosted 
slides). Write sample ID on the frosted end of the slide. 
3) Prepare 5 ml sterile tubes. Write sample ID and date on the tubes.  
4) Centrifuge the sample at 3000 g for 10 minutes. 
5) Transfer the supernatant to 5 ml sterile tubes.  
a. One for estimation of protein and glucose concentrations. 
b. Transfer the remaining supernatant to 5 ml sterile cryotubes for storage. 
6) Use the pellet/sediment to make smears. Use 15-20 µl of the pellet/sediment for each 
smear.  
a. Place the material in the middle of the slide. 
b. Spread the sample material gentle with a pipette tip. 
7) Prepare six slides per patient sample (If limited amount make slides for routine 
staining and reduce the number of slides for immunochemical staining) 
a. Slides for routine staining 
i. The slides for acid fast staining and Giemsa/PAP (or any other staining 
used for morphology) should be fixed according to the routine protocol. 
b. Four slides for immunochemical staining  
i. Air-dry the smear in room temperature. 
Biopsies 
1) In the operating room, divide the fresh surgical biopsy in two halves. 
a. Place one half of the specimen in a sterile container with normal saline. 
 
 
i. Transport the container to the TB clinic. The specimen will be sent to 
PHL-IdC on Pemba for mycobacterial culture.  
b. Place one half of the specimen in a container with formalin for fixation. 
2) Perform conventional paraffin-embedding on the formalin-fixed specimen as per 
routine practice. 
3) Prepare slides for routine staining and immunohistochemical staining (superfrosted 
slides). Write sample ID on the frosted end of the slide. 
4) Prepare six consecutive 5 µm thick sections from the formalin-fixed paraffin-
embedded biopsy. 
a. Slides for routine staining. 
b. Four slides for immunohistochemical staining. 
 
Immunocytochemical staining of smears from FNAC, effusions and CSF 
1) Preparation before the staining protocol. 
a. Prepare working solutions. 
i. Wash buffer: Dilute the concentrated wash buffer (Dako Wash buffer 
10x, S3006, Dako, Glostrup, Denmark) 1:10 with distilled water. 
ii. Primary antibody: Dilute the primary antibody 1:250 in Antibody 
Diluent solution (Dako Antibody Diluent, S0809, Dako, Glostrup, 
Denmark). 
b. Rehydration step: Hydrate the alcohol-fixed slides in decreasing grades of 
alcohol. 
i. 80% alcohol, 4 minutes. 
ii. 70% alcohol, 4 minutes. 
iii. Distilled water, 10 minutes.  
c. Wash step: Using a Pasteur pipette rinse the slides with wash buffer 3 times, 
then apply wash buffer to cover the whole smear, after 1 minutes repeat the 
procedure (Repeat 3 times).  
d. Tap off excess water, and carefully wipe around the smear to remove 
remaining wash buffer. Encircle the region of the smear with the Dako Pen 
(Dako Pen, S2002, Dako, Glostrup, Denmark). 
2) Staining protocol 
a. Step 1: Peroxidase block (EnVision® + System-HRP) 
 
 
i. Apply peroxidase block to cover the whole specimen, incubate in 
humidity chamber for 15 minutes, to inhibit endogenous peroxidase 
activity.  
ii. Wash step: Repeat step 1c. 
b. Step 2: Primary antibody.  
i. Apply diluted primary antibody to cover the whole specimen, incubate 
in humidity chamber for 60 minutes.  
ii. Wash step: Repeat step 1c. 
c. Step 3: Peroxidase labelled polymer (EnVision® + System-HRP). 
i. Apply labelled polymer (horseradish peroxidase labelled polymer 
conjugated with secondary anti-rabbit antibodies) to cover the whole 
specimen, incubate in humidity chamber for 45 minutes.  
ii. Wash step: Repeat step 1c.  
d. Step 4: Substrate-chromogen (EnVision® + System-HRP). 
i. Apply substrate-chromogen solution to cover the whole specimen, 
incubate in humidity chamber for 10 minutes.  
ii. Wash step: Rinse the slides gently with wash buffer using a Pasteur 
pipette, then place in distilled water bath for 10 minutes.  
e. Step 5: Mayer`s hematoxylin counterstain. 
f. Step 6: Mounting. Mount the slides in Immu-Mount (Thermo Fischer 
Scientific).  
Immunohistochemical staining of formalin-fixed, paraffin-embedded tissue 
sections 
1) Preparation before the staining protocol. 
a. Prepare working solutions. 
i. Wash buffer: Dilute the concentrated wash buffer 1:10 with distilled 
water. 
ii. Primary antibody: Dilute the primary antibody 1:250 in Antibody 
Diluent solution. 
iii. Target retrieval solution (Citrate buffer): Dilute Target retrieval 
solution (Dako Target Retrieval Solution (10x), S1699, Dako, Glostrup, 
Denmark) 1:10 in distilled water. Final pH 6.00-6.20.  
b. Deparaffinization and rehydration steps. 
 
 
i. Xylene (to remove the paraffin), 25 minutes. 
ii. 100% alcohol, 4 minutes x 2. 
iii. 95% alcohol, 4 minutes. 
iv. 80% alcohol, 4 minutes. 
v. 70% alcohol, 4 minutes. 
vi. Distilled water, 10 minutes.  
c. Microwave antigen retrieval. 
i. Place the slides in Citrate buffer bath inside the microwave oven. First 
at 800W until the boiling point, then boil at 400-600W for 15 minutes.   
ii. Leave for 20 minutes in room temperature. 
iii. Wash in running distilled water to make the slides cool to room 
temperature.  
d. Wash step: Using a Pasteur pipette rinse the slides with wash buffer 3 times, 
then apply wash buffer to cover the whole smear, after 1 minutes repeat the 
procedure (Repeat 3 times). 
e. Tap off excess water, and carefully wipe around the smear to remove 
remaining wash buffer. Encircle the region of the smear with the Dako Pen. 
2) Staining protocol 
a. Step 1: Peroxidase block (EnVision® + System-HRP) 
i. Apply peroxidase block to cover the whole specimen, incubate in 
humidity chamber for 10 minutes, to inhibit endogenous peroxidase 
activity.  
ii. Wash step: Repeat step 1d. 
b. Step 2: Primary antibody.  
i. Apply diluted primary antibody to cover the whole specimen, incubate 
in humidity chamber for 60 minutes.  
ii. Wash step: Repeat step 1d. 
c. Step 3: Peroxidase labelled polymer (EnVision® + System-HRP). 
i. Apply labelled polymer (horseradish peroxidase labelled polymer 
conjugated with secondary anti-rabbit antibodies) to cover the whole 
specimen, incubate in humidity chamber for 45 minutes.  
ii. Wash step: Repeat step 1d.  
d. Step 4: Substrate-chromogen (EnVision® + System-HRP). 
 
 
i. Apply substrate-chromogen solution to cover the whole specimen, 
incubate in humidity chamber for 10 minutes.  
ii. Wash step: Rinse the slides gently with wash buffer using a Pasteur 
pipette, then place in distilled water bath for 10 minutes.  
e. Step 5: Mayer`s hematoxylin counterstain. 
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